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Abstract 
The main function of human skin is forming of a barrier against physical, chemical, 
and biological stress. Many skin diseases are characterized by weakening of the skin 
barrier leading to transepidermal water loss and aggravation of inflammatory 
processes by enhanced penetration with allergens and pathogens. Atopic dermatitis 
(AD) is an inflammatory skin disease affecting 10-20% of children and 1-3% of 
adults in industrialized countries. Enhanced expression of Interleukin-31 (IL-31) is 
detected in skin samples of AD patients, but its physiological relevance is not known. 
IL-31 was recently discovered as a new member of the IL-6 family of cytokines. IL-
31 signals through a heterodimeric receptor composed of the Oncostatin M receptor 
(OSMR) and the IL-31 receptor alpha (IL-31RA), a complex that stimulates the JAK-
STAT, the RAS/ERK and the PI3K/AKT signal transduction pathways. The available 
data suggest that IL-31 is important for both innate and adaptive immunity in tissues 
that are in close contact with the environment, i.e. skin, airways and lung, and the 
lining of the intestine. Enhanced expression of IL-31 is not only associated with AD, 
but also with allergy and inflammatory bowel disease. In the affected tissues IL-31 
coordinates the interaction of different immune cells, including T-cells, mast cells, 
and eosinophils, with epithelial cells. 
 
I observed that IL-31 interferes with keratinocyte differentiation in 3D organotypic 
skin models. Gene expression analysis revealed a limited set of genes deregulated in 
response to IL-31, including IL20 and IL24. In HaCaT keratinocytes with inducible 
IL-31RA, IL-31 inhibited proliferation upon induction of IL-31RA by inducing a cell 
cycle arrest. As in primary cells, IL-31 treated HaCaT cells elicited a differentiation 
defect in organotypic skin models, associated with reduced epidermal thickness, 
disturbed epidermal constitution, disturbed alignment of the stratum basale and poor 
development of the stratum granulosum. The differentiation defect was associated 
with a profound repression of terminal differentiation markers, including filaggrin, an 
essential factor for skin barrier formation. The highly induced pro-inflammatory 
cytokines IL-20 and IL-24 were responsible for part of the effect on FLG expression 
and thus for terminal differentiation. 
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Several other factors were identified as early IL-31 target genes that are involved in 
stress responses and p38/JNK signaling pathways including JUNB. JUNB is part of 
the AP-1 transcription factor family that controls cell cycle arrest in many different 
cell types. In keratinocytes it is also an essential factor in differentiation. JUN and 
JUNB antagonize each other in controlling the cell cycle by affecting the expression 
of different cell cycle regulators including Cyclin D1, p21, p16 and p53. All of them 
are also involved in regulating differentiation in keratinocytes. I identified changes in 
the expressional pattern of these factors upon IL-31 stimulation that would promote 
an early differentiation state of keratinocytes but inhibit late differentiation processes. 
These studies define IL-31 as an important regulator of keratinocyte differentiation 
and demonstrate a link between the presence of IL-31 in skin, as found in patients 
with AD, and weakening of the skin barrier function. 
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Zusammenfassung 
Die Hauptfunktion humaner Haut ist die Bildung einer Barriere gegen physikalischen, 
chemischen und biologischen Stress. Viele Hautkrankheiten weisen eine Schwächung 
dieser Barrierefunktion auf, die zu einem transepidermalen Wasserverlust und einer 
erhöhten Penetration der Haut mit Allergenen und Pathogenen führt. Dies initiiert und 
verstärkt Entzündungsprozesse in der Haut. Atopische Dermatitis (AD) ist eine 
entzündliche Hauterkrankung die in 10-20% aller Kinder und 1-3% der erwachsenen 
Bevölkerung in den Industrieländern vorkommt. Eine erhöhte Expression von 
Interleukin-31 (IL-31) wurde in Hautbiopsien von AD Patienten festgestellt, die 
physiologische Funktion dieses Zytokin in AD ist bis heute aber unbekannt. IL-31 
wurde kürzlich als neues Mitglied der IL-6 Zytokinfamilie entdeckt. Es bindet einen 
heterodimeren Komplex aus dem Oncostatin M Rezeptor (OSMR) und dem 
Interleukin 31 Rezeptor alpha (IL-31RA). Dieser Komplex aktiviert den JAK-STAT, 
den RAS/ERK und den PI3K/AKT Signaltransduktionsweg. Die vorhandenen Daten 
lassen vermuten, dass IL-31 eine wichtige Rolle in der angeborenen wie auch in der 
erworbenen Immunität in Geweben, welche in direktem Kontakt zur Umgebung 
stehen (wie z.B. die Haut, die Lunge oder der Verdauungstrakt), spielt. Erhöhte IL-31 
Expression ist nicht nur messbar in AD, sondern auch in allergischen Erkrankungen 
sowie chronisch-entzündlichen Darmerkrankungen. In den betroffenen Organen 
koordiniert IL-31 die Interaktion zwischen verschiedenen Zellen des Immunsystems 
wie z.B. T-Zellen, Mast Zellen und Eosinophilen mit epithelialen Zellen. 
 
In meiner Arbeit konnte ich feststellen, dass IL-31 in dreidimensionalen 
organotypischen Hautmodellen in die Keratinozytendifferenzierung störend eingreift. 
Genexpressionsanalysen zeigten, dass nur eine sehr limitierte Anzahl an Genen durch 
IL-31 dereguliert wurde. Zwei dieser Gene waren die Zytokine IL20 und IL24. HaCaT 
Keratinozyten mit einem induzierbaren IL-31RA zeigten eine reduzierte 
Proliferationsrate nach IL-31 Stimulation durch die Induzierung eines 
Zellzyklusarrests. Wie primäre Zellen zeigten auch HaCaT Zellen einen 
Differenzierungsdefekt in organotypischen Modellen charakterisiert durch eine 
Reduzierung der epidermalen Dicke, einer Schwächung der epidermalen Konstitution, 
Störungen in der Formierung der basalen Zellschicht sowie ein schlecht entwickeltes 
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stratum granulosum. Der Differenzierungsdefekt war mit einer tiefgreifenden 
Reduktion in der Expression von terminalen Differenzierungsmarkern wie Filaggrin, 
einem essentiellen Faktor in der Formation der Hautbarriere, verbunden. Die 
induzierten Zytokine IL-20 und L-24 waren für die Reduktion der FLG  Expression 
teilweise verantwortlich und trugen somit zu den Defekten in der terminalen 
Differenzierung bei.  
 
Einige weitere Faktoren wurden als frühe IL-31 Zielgene identifiziert, welche alle in 
Stressantworten und p38/JNK Signaltransduktionswege involviert sind. Eines dieser 
Zielgene war JUNB. JUNB gehört zur AP-1 Familie von Transkriptionsfaktoren, die 
in vielen verschieden Zellen in die Kontrolle des Zellzyklus involviert sind. In 
Keratinozyten kontrollieren sie unter anderem auch viele Aspekte der 
Differenzierung. In der Kontrolle des Zellzyklus wirken JUN und JUNB 
entgegengesetzt durch die Expressionskontrolle verschiedener Zellzyklusregulatoren. 
Dazu gehören Cyclin D1, p21, p16 und p53. Diese Faktoren spielen ebenfalls eine 
Rolle in der Regulation der Keratinozytendifferenzierung. Ich stellte Veränderungen 
in der Expression dieser Faktoren nach IL-31 Stimulation fest, die eine frühes 
Differenzierungsstadium fördern, allerdings späte Differenzierungsprozesse 
inhibieren könnten. Diese Studien definieren IL-31 als einen wichtigen Faktor in der 
Regulation der Keratinozytendifferenzierung und schaffen eine Verbindung zwischen 
erhöhter IL-31 Expression in AD Patienten und der Schwächung der Hautbarriere in 
AD.     
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1 Introduction 
1.1 The human skin 
 
The human skin is the first barrier of the body to protect our organism from harmful 
influences from the “outside”. It forms a barrier for physical, chemical and biological 
stress. The cornified envelope (CE) protects from physical stress and inhibits trans-
epidermal water loss. The inner parts of the epidermis consist of lipids, acids (mainly 
fatty acids), hydrolytic enzymes, antimicrobial peptides and macrophages forming the 
chemical and biological barrier as part of the innate immunity. Other cellular 
components of the immune system reside in the skin to activate the adaptive 
immunity in case of penetration by pathogens. The epidermal barrier is mainly formed 
by differentiating keratinocytes and is divided into different cellular layers: the 
stratum corneum (SC) also called the CE, the stratum granulosum (SG), the stratum 
spinosum (SS) and the stratum basale (SB) (Fig. 1). 
 
The basal layer of the epidermis maintains skin homeostasis by providing 
keratinocytes for terminal differentiation. For this purpose it harbors two types of 
cells; slow cycling epidermal stem cells (SCs), from which emenate all types of 
growing and differentiating keratinocytes and which posses an indefinite renewal 
potential, and transiently amplifying cells (TAC) that are committed to terminal 
differentiation but can still undergo a limited number of cell divisions (Watt, 2001). 
This cellular layer is attached to the basement membrane of the epidermis that is 
characterized by the presence of a small number of keratin filaments and matrix 
adhesion molecules including keratin (K) 5, 14, 15 (Fuchs and Green, 1980; Waseem 
et al., 1999) and α6-, β4-integrin (Margadant et al., 2010). SCs express high levels of 
β1-integrin that is suggested to prohibit differentiation of keratinocytes (Watt and 
Hogan, 2000). As soon as keratinocytes start to differentiate they loose the contact to 
the basement membrane by down-regulating the matrix adhesion molecules α6- and 
β4-integrin and migrate upwards into the SS (Watt, 2002). The expression of K5, K14 
and K15 is down-regulated, they induce the expression of K1 and K10 and develop 
extensive cellular contacts in form of desmosomes (connecting the keratin-filament 
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cytoskeleton) and adherence junctions (connecting the actin cytoskeleton) (Fuchs, 
1990; Waseem et al., 1999; Watt and Hogan, 2000). They transit from a mitotic phase 
into a post mitotic status (Koster et al., 2007). Before transition to the SG, cells in the 
upper part of the SS express involucrin, a late differentiation marker that becomes 
covalently cross-linked to each other as a component of the CE (Eckert et al., 1993).  
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Figure 1. The human Epidermis.                 
The human epidermis is characterized by the presence of different cellular layers with cells in different 
stages of differentiation. Basal keratinocytes are attached to the basal membrane that divides the 
epidermis from the dermis. This basal layer comprises proliferating stem cells as well as transient 
amplifying cells. Detachment of the basal membrane induces early differentiation steps in the stratum 
spinosum. The stratum granulosum contains terminally differentiating cells characterized by lamellar 
and granular bodies containing lipids and proteins important for formation of the cornified and lipid 
envelope that forms the skin barrier in the stratum corneum. Cells that underwent terminal 
differentiation and apoptosis are called corneocytes. The different differentiation steps of keratinocytes 
are characterized by the expression of certain differentiation marker proteins. β4-intergin is exclusively 
present in hemidesmosomes at the basal cell – basal membrane interface. Keratin 14 is expressed in 
basal keratinocytes and downregulated in early differentiating cells. Keratin 10 is induced as soon as 
the cells leave the basal compartment and is repressed again in late terminal differentiation steps. 
Filaggrin and Involucrin are markers of the late stratum granulosum and stratum corneum and are 
major components of the cornified envelope. 
 
Keratinocytes of the SG synthesize keratohyalin granules (Coulombe and Wong, 
2004). The major component of these granules is profilaggrin; a protein consisting of 
10-12 filaggrin repeats that is processed by phosphorylation and proteolysis to mature 
filaggrin monomers and an N-terminal filaggrin S100-protein fragment (Scott and 
Harding, 1981). This N-terminal proteolytic product is proposed to function as a 
transcription factor to stimulate further differentiation events (Pearton et al., 2002). 
The granules also include loricrin, an insoluble protein that becomes cross-linked in 
the cornified envelope (Steven et al., 1990). 
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1.1.1 The Cornified Envelope 
 
Within the granular layer keratinocytes synthesize lipids in lamellar bodies. Keratins, 
loricrin, profilaggrin and other structural proteins are reorganized and bundled 
underneath the plasma membrane. Desmosomes undergo profound changes in their 
morphology and form a homogenous electron-dense plaque called corneodesmosome 
(Simon et al., 2001). In the next steps the lamellar bodies fuse with the membrane to 
secrete their content and form a lipid envelope outside of the cells. The cells undergo 
apoptosis, the plasma membrane gets disintegrated and the calcium influx activates 
transglutaminases and different proteolytic enzymes that irreversibly process and 
cross-link the proteins. Now the cells are referred to corneocytes and form the CE. 
Keratins mediate the mechanical resistance of the epidermis. Differences in the 
mechanical resistance are mediated by differential expression of different keratins. 
Other components of the CE mainly contribute to epidermal elasticity (Candi et al., 
2005; Kalinin et al., 2002). 
 
A large number of genes coding for structural proteins of the CE are located in the 
epidermal differentiation gene cluster (EDC) on chromosome 1q21 (Mischke et al., 
1996). It includes profilaggrin, loricrin, involucrin and trichohyalin as well as several 
proteins of the late cornified envelope (LCE) and the small proline rich (SPR) and 
S100 calcium binding family.  
 
During cornification, profilaggrin is processed to filaggrin monomers that aggregate 
keratin filaments into bundles, which leads to a flattened cell shape that is 
characteristic for corneocytes. In addition these bundles represent 80-90% of the 
whole epidermal protein mass and serve as a scaffold for further development of the 
CE. Filaggrin has a half-life of six hours and is degraded into free amino acids leading 
to a high concentration of up to 100nM hydrophilic amino acids within the CE. This 
contributes to the flexibility and the water retention abilities of the CE (Mack et al., 
1993; Markova et al., 1993; Resing et al., 1993). During the formation of the keratin 
bundles other proteins are synthesized and localized to the plasma membrane 
including involucrin, loricrin, trichohyalin and SPRs. All these proteins become cross-
linked by transglutaminases (TG) that are activated by changes in the calcium 
concentration e.g. after disintegration of the plasma membrane.  
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Involucrin is an early component of the CE that becomes cross-linked and serves as a 
further scaffold for proteins and ipids. It is attached to the plasma membrane and 
becomes replaced during further cornification (Nemes et al., 1999; Simon and Green, 
1988). 
 
Loricrin is a glycine-, serine- and cysteine-rich mainly unstructured protein that 
represents 70-85% of the CE protein mass (Hohl et al., 1991). The N- and C-terminal 
parts of the protein serve as substrates for TGs to cross-link loricrin monomers to 
multimeric structures. The inner part of the protein has no structure and thus mediates 
elasticity of the epidermis. In addition loricrin is cross-linked to other components of 
the CE, e.g. SPRs, to further increase CE stability (Candi et al., 1995; Steven et al., 
1990). 
 
SPRs are small unstructured proteins with a proline-rich flexible centre and glutamine 
and lysine-rich ends that are TG substrates. SPRs cross-link loricrin multimers to 
increase CE stability. The ratio of loricrin to SPRs correlates with the physical 
properties of the skin. For example the SPR to loricrin ratio in the thinner epidermis 
of the trunk is 1:100, while palm or sole epidermises exhibit a ratio of 1:10. The 
content of SPRs in the epidermis alters the physical properties of the CE and thus the 
epidermal structure and barrier function (Candi et al., 1999; Steinert et al., 1998; 
Tarcsa et al., 1998).  
 
The cornified envelope is embedded in a lipid envelope that mainly contributes to the 
skin barrier function in preventing trans-epidermal water loss. This envelope contains 
ceramids, cholesterol, fatty acids and cholesterol esters that form lamellae between 
the corneocytes. These lipids are synthesized as precursors in the granular layer in 
lamellar granules and are extruded into the extracellular space during cornification 
and processed by hydrolases (Bouwstra et al., 2003; Freinkel and Traczyk, 1985; 
Madison, 2003). Although several models have been proposed, the structural 
composition of the lipid envelope and the physical interaction with the CE is not 
understood yet (Forslind, 1994; Norlen, 2001a, b). 
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1.1.2 Signals regulating skin differentiation 
Whereas the changes in skin morphology during epidermal differentiation are well 
described, the molecular mechanisms and signaling events underlying these changes 
are poorly understood and most scientific findings were obtained from mouse models. 
The first event in epithelial differentiation is the transition of cells from the basal layer 
to the spinouse layer. Two factors controlling the transition are p63 and the Notch 
signaling pathway (Koster, 2010; Watt et al., 2008).  
 
p63 is related to p53 (Yang et al., 1998) and primarily expressed in stratified epithelia 
like the epidermis. p63 deficient mice are born with severe abnormalities like a thin 
translucent skin and without any appendages like teeth or hair follicles and mammary 
glands (Mills et al., 1999; Yang et al., 1999). The reason for this is a complete failure 
in epidermal commitment during development (De Rosa et al., 2009; Koster et al., 
2004). 
 
p63 is expressed highest in the basal layer predominantly as it´s isoform ΔNp63α 
(Liefer et al., 2000; Yang et al., 1998). As described, the adult epidermis contains 
several different cell types including SCs and TACs that proliferate or already 
undergo differentiation. The role of p63 is not clear yet but it seems that p63 function 
depends on the cell type, in which it is expressed. p63 can maintain cell proliferation 
by inhibiting the expression of anti-proliferative cell cycle regulators like p21 and 
p16, promoting pro-proliferative factors like ADA and FASN (Lefkimmiatis et al., 
2009; Su et al., 2009; Truong et al., 2006; Westfall et al., 2003). In contrast 
keratinocytes from mice with an inducible epidermis specific ΔNp63α knock out 
exhibit an increased proliferation rate upon ΔNp63α silencing (Koster et al., 2007), 
p63 induces the cyclin-dependent kinase inhibitor p57, which is induced during 
terminal differentiation of keratinocytes (Beretta et al., 2005), and it represses cyclin 
B2 and cdc2 (Testoni and Mantovani, 2006), important factors for cell cycle 
progression. This controversy can be explained by tight differential regulation of p63 
and co-factors that might promote proliferation in early still cycling TACs and 
promote differentiation in late TACs. 
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ΔNp63α is rapidly down regulated to approximately 25% in differentiating suprabasal 
keratinocytes compared to basal layer keratinocytes (King et al., 2006) by microRNA-
203 (Yi et al., 2008) and subjected to proteasomal degradation (Di Costanzo et al., 
2009; Rossi et al., 2006; Vivo et al., 2009). The remaining ΔNp63α still functions as a 
transcription factor regulating further differentiation processes (King et al., 2006). 
 
Notch cell surface receptors and their ligands play a crucial role in cell fate 
determination and epithelial differentiation (Artavanis-Tsakonas et al., 1999). 
Epidermal SCs express the Notch ligand Delta and are proposed to activate Notch 
signaling in neighboring cells and thus commit them to TACs (Lowell et al., 2000). 
After activation, the intracellular domain of Notch gets cleaved and translocates to the 
nucleus where it functions as the transcription factor NCID (Notch intracellular 
domain) (Bray, 2006). In the nucleus it forms a complex with the DNA binding 
protein RBP-Jk (recombination signal binding protein for Igκ J region) and turns it 
from a transcriptional repressor to an activator (Lai, 2002; Mumm and Kopan, 2000). 
Additional binding to co-activators of the mastermind family recruits chromatin-
modifying enzymes like p300 to elevate RBP-Jk dependent gene activation (Ilagan 
and Kopan, 2007). Notch signaling induces cell cycle withdrawal by induction of p21 
expression, activates the expression of the intermediate differentiation markers K1, 
K10 and involucrin and represses terminal differentiation markers (loricrin, filaggrin) 
as well as integrins β1 and β4 that are essential for basal proliferating cells 
(Rangarajan et al., 2001). In addition Notch activity directly inhibits p63 expression 
probably via activation of the NF-kB pathway (Nguyen et al., 2006). This indicates 
that p63 and Notch form a tightly balanced regulatory network that commits cells for 
proliferation or differentiation. Furthermore Notch influences the expression of 
C/EBPs, DNA binding proteins that, in combination with the AP-2 family of 
transcription factors, regulate the commitment to terminal differentiation (Wang et al., 
2008). 
 
An important trigger of terminal differentiation is the internal Ca2+ signaling pathway. 
An increasing extracellular and intracellular Ca2+ gradient is present from the spinous 
cell layer to the CE (Elias et al., 1998). Increased Ca2+ signaling activates kinases of 
the PKC protein family (Lee and Yuspa, 1991) that contribute to the transition of the 
spinouse layer to the granular layer by down-regulating K1 and K10 expression 
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(Dlugosz and Yuspa, 1993) and inducing the expression of loricrin, filaggrin and 
transglutaminases (Dlugosz and Yuspa, 1993, 1994). In addition to PKC several Ca2+ 
sensing proteins have been identified that might contribute to the barrier formation 
including Scarf 1 and 2 (Hwang et al., 2005; Hwang and Morasso, 2003), calmodulin 
like skin protein (CLSP) (Mehul et al., 2000), the calcium sensing receptor (Oda et 
al., 2000), and the calmodulin-like protein (Rogers et al., 2001). At least the calcium 
sensing receptor seems to be directly involved in the regulation of loricrin and 
filaggrin expression (Komuves et al., 2002). During differentiation several Ca2+ 
dependent proteases are expressed that process differentiation markers at the right 
step of differentiation as they get activated at a certain Ca2+ concentration (Candi et 
al., 2005; Ovaere et al., 2009).  
 
Beside the processes of proliferation and differentiation, apoptosis signaling is a 
critical part of epidermal barrier formation although epidermal apoptosis is distinct 
from the common programmed cell death. Corneocytes are not phagocytosed, the 
cytoskeleton does get reorganized instead of broken down, the nuclear destruction is 
different compared to normal apoptosis and many apoptotic caspases are not activated 
during cornification (Lippens et al., 2005; Tschachler, 2005). This leads to the 
assumption that e.g. “apoptotic keratinocyte differentiation program” is a more 
appropriate term to describe the changes occurring in keratinocytes during 
differentiation. In the granular layer cells undergo apoptosis to differentiate to 
corneocytes but the “apoptotic keratinocyte differentiation program” is distributed 
through the whole epidermis. In the spinous layer apoptosis signal-regulating-kinase 1 
(ASK-1) and dual leucine zipper-bearing kinase (DLK) are expressed and induce 
transglutaminase 1, loricrin and involucrin expression (Robitaille et al., 2005; Sayama 
et al., 2001). Basal keratinocytes express Bcl-2, protecting them from apoptosis 
(Hockenbery et al., 1991), while the expression of Bak, the pro-apoptotic inhibitor of 
Bcl-2, increases from the basal layer to the granular layer to promote cell death 
(Krajewski et al., 1996). Furthermore the expression of the p53 inhibitor MDM2 
increases from the basal to the suprabasal cell layers (Ganguli et al., 2000), certain 
death receptors (TNF receptor 1, death receptor 4) and caspase 8 are expressed higher 
in the basal layers, while death receptor 5, Decoy R2, caspase-14 and Bcl-xL are more 
prevalent in the terminally differentiating parts of the epidermis (Nickoloff et al., 
2002). This reflects a very tight regulation of apoptotic pathways, not only controlling 
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cell death in keratinocytes but also regulating differentiation processes. Although 
these factors are known to be important in skin differentiation, it remains to be 
determined how these different pro- and anti-apoptotic factors cooperate in regulating 
the apoptosis related pathways of differentiation. 
 
Several agents have been described to enhance proliferation or differentiation of 
keratinocytes (Eckert et al., 1997). Cholera toxin, phorbol ester, retinoids, viral 
infection or transformation can enhance keratinocyte proliferation and/or reduce their 
differentiation. Vitamin D, Calcium, Hydrocortisone and phorbol ester are potent 
enhancers of differentiation.   
 
Also growth factors and cytokines influence keratinocyte proliferation and 
differentiation. Insulin like growth factor (IGF) 1 and 2, epidermal growth factor 
(EGF) (Krane et al., 1991) and TGF-α (Barrandon and Green, 1987) enhance 
keratinocyte proliferation. Transforming growth factor (TGF)-β1 and 2 suppress 
keratinocyte proliferation and enhance their differentiation (Coffey et al., 1988; 
Massague and Gomis, 2006) as well as Interferon (IFN)-γ (Saunders and Jetten, 
1994). Keratinocyte growth factor (KGF) stimulates both proliferation and 
differentiation (Marchese et al., 1990). Together many agents and cytokines control 
keratinocyte differentiation and formation of an epidermis that provides efficient 
protection. These agents and cytokines interact manifold, forming complex regulatory 
networks that are only poorly understood at present 
  
Many skin diseases like atopic dermatitis are characterized by defects in skin 
differentiation and skin barrier formation. Although in many cases the molecular basis 
of these diseases is not understood it is likely that either the above mentioned 
regulatory molecules and/or essential components of the skin barrier are not 
functioning properly or are defect. In 2004 Interleukin 31 (IL-31) was discovered and 
evidence emerged that it might be involved in the pathogenesis of TH2 cytokine 
mediated skin disorders. However the biological consequences of IL-31 signaling and 
its role in skin differentiation has not been determined yet. 
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1.2 Signaling by IL-31 and functional consequences 
 
1.2.1 Introduction 
 
Cytokines are secreted signaling molecules that enable cells to communicate with 
each other without requiring direct contact. They play important roles in a wide range 
of different cell types, tissues, and organs. Cytokines regulate innate and adaptive 
immunity, stimulate pro- or anti-inflammatory signaling processes, control cell 
differentiation, proliferation, survival and apoptosis. The large family of cytokines 
can be divided into different functional classes. These classifications are somewhat 
artificial because individual cytokines can possess more than one function and thus 
can be part of more than one functional class. Arguably the most simple classification 
is in pro- and anti-inflammatory cytokines with IL-1, IL-6, TNFα, IL-12, IL-18, MIF, 
IL-32, IL-33 being examples of the former and IL-10, IL-13, TGFβ, IL-22, IFNα/β of 
the latter. Relevant for the discussion in this review is that many cytokines can be 
classified dependent on the cell type in which they are expressed and synthesized. For 
example different T helper cell populations, i.e. TH1, TH2, TH17, and TH22 cells, 
synthesize different subsets of cytokines. TH1 cells are characterized by the 
expression of IFNγ, IL-2, IL-12, and IL18; TH2 cells by IL-4, IL-5, IL-13, IL-18, IL-
25, IL-31, and IL-33; TH17 cells by IL-17, IL-17F, IL-6 and TNFα; and TH22 cells by 
IL-22 and IL-14 (Trifari et al., 2009; Wan, 2010; Weaver et al., 2006; Zhu and Paul, 
2010). Moreover cytokines can be classified according to their functions in 
controlling lymphocyte proliferation, hematopoietic differentiation, 
neovascularization, and cellular migration to name just a few (Dinarello, 2007, 2010). 
In this review I summarize the available information on the molecular and biological 
functions of IL-31, a factor that belongs to the IL-6 cytokine family and that was 
originally described to be synthesized by TH2 cells. More recent data provide 
evidence that additional cell types can produce IL-31. Importantly this cytokine has 
been implicated in allergic diseases, including atopic dermatitis. These findings 
suggest that IL-31 is a potentially interesting target for therapeutical approaches.  
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1.2.2 The IL-6 family of cytokines and their receptors 
 
The family of IL-6/gp130 type cytokines includes IL-6, IL-11, IL-27, leukemia 
inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), 
cardiotrophin 1 and 2 (CT-1) and cardiotrophin-like cytokine (CLC) (Fig. 2) 
(Heinrich et al., 2003; Pflanz et al., 2002). The latest addition to this family is IL-31, 
which was discovered in 2004 (Dillon et al., 2004).  
 
Although the members of the IL-6 type cytokine family share very low sequence 
homology, they are structurally highly related. These proteins form anti-parallel four-
helix bundles with a characteristic “up-up-down-down” topology, a structure that is 
relevant for the binding of the cytokine to their respective receptor complexes (a 
model of IL-31 and its receptor is shown in Fig. 3) (Bazan, 1990a; Rozwarski et al., 
1994). IL-6 type cytokines signal through type I cytokine receptors (Fig. 2). These 
share the cytokine binding domain (CBD) with conserved cysteine residues and a 
conserved WSxWS motif in the extracellular domain (indicated for the IL-31RA and 
OSMR in Fig. 3). The cysteines form disulfide bonds to stabilize the tertiary structure 
of the CBD. The WSxWS stabilizes the structure of the CBD and it contributes to the 
formation of the binding crevice. In addition they have a single transmembrane 
domain and an intracellular domain without intrinsic enzymatic activity (Bazan, 
1990b). The receptors form heteromeric complexes that typically contain the 
glycoprotein 130 (gp130), which mediates the binding to members of the Janus 
tyrosine kinase (JAK) subfamily. Thus gp130 is important for activating downstream 
signaling pathways. In addition to gp130 more specific receptor subunits are used, 
including LIFR, OSMR and IL-27RA, which can also stimulate signaling cascades. In 
some instances additional subunits contribute to the binding of ligand exemplified by 
IL-6R, IL-11R or CNTFR. Other cytokines like CLC and IL-27 (or p28) bind soluble 
receptor subunits like CLF, soluble CNTFR or EBI3 prior to binding to their receptor 
complexes. In summary although different IL-6 family cytokines share some of the 
receptor subunits, the composition of the signaling-competent receptor complexes 
varies, providing specificity for individual cytokines. Thus the members of the IL-
6/gp130 type cytokine family can be divided into different groups depending on how 
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the receptor complexes are organized (summarized in Fig. 2) (Elson et al., 2000; 
Heinrich et al., 2003; Pflanz et al., 2002; Plun-Favreau et al., 2001). 
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Figure 2. IL-6 type cytokines and their receptor complexes.            
IL-6/gp130 type cytokines can be divided into different subgroups according to the receptor complex 
they interact with, i.e. heterotrimeric complexes with a glycoprotein 130 (gp130) dimer together with 
non-signaling receptors or accessory proteins that determine specificity (e.g. IL-6R) and heterodimers 
of gp130 with the leukemia inhibitory factor receptor alpha (LIFR), the interleukin 27 receptor alpha 
(IL-27RA), or the oncostatin M receptor (OSMR). The receptor for IL-31 is a heterodimer of the 
interleukin 31 receptor alpha (IL-31RA) and OSMR, without gp130, a set-up which is unique among 
these cytokine receptors. The LIFR/gp130 subgroup can be subdivided according to the presence or 
abscence of CNTFR within the receptor complex. An additional receptor component of CT-1 is 
proposed but not determined yet (displayed as “?“ in the figure). IL-6 and IL-11 bind their specific 
receptor components (IL-6R; IL-11R) prior to binding to gp130. CLC and IL-27 (p28) bind their 
receptor complexes after dimerization with a soluble receptor component (CLF or sCNTFR and EBI3) 
(for details and references see text). Humanin is a 24 aa bioactive peptide with undetermined structure. 
It binds a WSX-1/CNTFR/gp130 trimeric complex (Hashimoto et al., 2009) 
 
JAK kinases are associated constitutively with IL-6 family receptors. Upon ligand 
binding these kinases phosphorylate tyrosine (Tyr, Y) residues of the intracellular 
domain of IL-6/gp130 type receptors. These phosphorylated Tyr motifs serve as 
essential binding sites for proteins that relay receptor activation to downstream 
signaling cascades. One example are signal transducers and activators of transcription 
(STAT) proteins that not only bind to activated receptors but are also phosphorylated 
and activated by JAKs. This results in dimerization of STATs and leads to their 
translocation into the nucleus where they serve as DNA sequence-specific 
transcription factors. Phosphoinositide-3-kinase (PI3K) is another enzyme that can 
associate with specific phosphorylated Tyr residues. Again this results in the 
activation of the catalytic activity of PI3K and the stimulation of the PI3K/AKT 
signaling pathway. JAKs also mediate the binding of additional factors to the 
receptors, including Grb2, SOS, Shc and SHP-2 that allow activation of different 
MAPKinase signaling cascades (Bennett et al., 1994; Salcini et al., 1994). Thus the 
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receptors of IL-6 type cytokines control directly the activities of STAT, MAPKinase, 
and PI3K/AKT signaling pathways (Heinrich et al., 2003).  
1.2.3 The IL-31 receptor alpha 
 
Within the family of IL-6 type cytokines, IL-31 signals through a unique receptor 
complex. While all other members of this family use at least one gp130, as far as 
analyzed, IL-31 signaling does not depend on gp130. The heterodimeric IL-31 
receptor is composed of the IL-31 receptor alpha (IL-31RA) subunit, originally 
described as GLM-R (for gp130-like monocyte receptor) or GPL (for gp130-like 
receptor) and OSMR (Fig. 3) (Diveu, 2003; Ghilardi, 2002). As the alternative names 
suggest, IL-31RA has similarities to gp130. Interestingly the IL31RA gene is located 
on chromosome 5q11.2, 24 kb telomeric to IL6ST, the gene that encodes gp130, with 
the two genes being organized in a head-to-head configuration. The coding regions 
share approximately 28% homology and a somewhat lower homology to the receptor 
of the granulocyte colony-stimulating factor (GCSF-R). These findings support the 
concept that IL-31RA replaces gp130 in the IL-31 receptor complex, the two being 
likely the product of a gene duplication.  
 
The extracellular domain of IL-31RA consists of five fibronectin type III (FN III)-like 
domains (Fig. 3). The first two form the CBD with four conserved cysteins and the 
WSxWS motif. This structural organization is conserved between the IL-31RA and 
other receptors of the family but this structural homology is not represented by their 
primary amino acid sequences. These structural elements are so typical that they 
allow for the classification of type 1 cytokine receptors.  
 
The IL-31RA has a single transmembrane domain. The intracellular domain possesses 
a proline rich motif (box1 motif) that mediates association with kinases of the JAK 
family and thus is essential for propagating the signal (Fig. 3). In addition it contains 
three Tyr residues (Y652, Y683, Y721) that are conserved between human and mouse 
(Diveu, 2003; Ghilardi, 2002). The phosphorylation of these Tyr residues allows for 
the interaction with proteins that promote downstream signaling or that are involved 
in feedback control. The most C-terminal Y721 of the IL-31RA recruits STAT3 to the 
receptor, whereas Y652 is required for STAT5 activation. All three Tyr residues 
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contribute to the activation of STAT1 (Dillon et al., 2004; Diveu, 2003; Dreuw et al., 
2004). However the IL-31RA is unable to recruit SHP-2 or Shc and thus cannot 
activate the MAPKinase cascades, unlike the OSMR (see below) (Fig. 4). 
 
Figure 3. The IL-31/IL-31 receptor 
complex. 
The IL-31 receptor is composed of the IL-
31RA and the OSMR subunits. The 
domain structure of both receptor 
molecules is indicated. Both have a N-
terminal signaling peptide that is cleaved 
off during translocation to the plasma 
membrane. IL-31 is displayed as a 
predicted 3-dimensional model of the 141 
amino acid mature protein calculated by 
the web-based I-Tasser programm (Zhang, 
2008). 4-helical bundle proteins bind their 
receptors through three binding sites 
numbered 1-3. IL-31 binds the IL-31RA 
through binding site two and the OSMR 
through binding site three indicated by 
circular surfaces. Binding site 1 mediates 
the binding to a third cytokine-specific 
receptor component like the IL-6RA, 
which is not present in the IL-31RA 
receptor complex and thus not relevant for 
the binding of this receptor. Amino acids 
demonstrated to be important for binding 
are indicated (in site 2: E44, E106, and 
H110; in site 3: K134, the numbers are 
according to the 164 amino acid immature 
protein). Binding of IL-31 to the two 
receptors appears to be sequential, with 
binding to IL-31RA being first, followed 
by binding to OSMR. The IL-31RA 
mediates, through recruitment of JAKs, phosphorylation of STAT proteins that depends on tyrosine 
residues in the intracellular domain of the receptors (Y652, Y683, Y721). The names of the different 
domains and structures are indicated in the figure.   
 
Of note is the analysis of IL31RA cDNAs obtained from peripheral blood 
mononuclear cells (PBMC), U937 promyelocytes, and GO-G-UVM glioblastoma 
cells. These studies suggest that several splice variants of the IL31RA exist, 
potentially encoding several protein isoforms. Most of these alternative IL-31RA 
proteins are suggested to be membrane bound, but differ in the N-terminal signal 
sequence or in the cytosolic domain. Two protein variants consist only of parts of the 
extracellular domain and thus are predicted to be soluble and may therefore function 
potentially as antagonists (Dillon et al., 2004; Diveu, 2003). This is interesting in 
view of the trans-signaling concept defined for IL-6, suggesting that soluble IL-31RA 
may broaden the range of responsive cells and tissues. However it has to be noted that 
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it is presently unclear whether these different splice variants are indeed expressed and 
to what extent relative to the full-length protein has not been clarified.  
 
The IL-31RA forms a heterodimer with OSMR (Fig. 3) (Dillon et al., 2004; Dreuw et 
al., 2004). The extracellular domain of the OSMR consists of 6 FN III-like domains 
and an immunoglobulin (Ig)-like domain (Fig. 3). The second and third FN III-like 
domain in combination with the Ig-like domain form the CBD on OSMR (Fig. 3). The 
intracellular domain binds JAK1 and JAK2 through its box1 and box2 motifs. 
Recruitment of JAKs results in the phosphorylation of Tyr residues within the 
intracellular domain. Subsequently through these phosphorylation sites STAT3 and 
STAT5 are recruited and phosphorylated by JAKs (Heinrich et al., 2003; Hintzen et 
al., 2008). In addition to STATs, PI3K is recruited, stimulating the PI3K/AKT 
pathway. In contrast to gp130, which binds SHP-2, the OSMR interacts with the 
adaptor protein Shc via Y861-P. Through Shc the RAS/RAF/MEK/ERK pathway is 
activated (Hermanns et al., 2000). The OSMR can also stimulate the p38 and JNK 
pathways (Murakami-Mori et al., 1999; Tong et al., 2004; Wang et al., 2000). These 
two appear to be activated also through Shc, an aspect that is not fully understood 
mechanistically because the p38 signaling seems to interfere with ERK1/2 activation 
(Böing et al., 2006). These findings were derived from studying the OSMR in a 
complex with gp130 and it remains to be analyzed whether the OSMR behaves 
identically when heterodimerized to the IL-31RA.  
 
Together these findings demonstrate that the IL-31 receptor complex is composed of 
the IL-31RA and the OSMR (Fig. 4). This heterodimer recruits JAK1 and JAK2 and 
stimulates STATs, different MAPKinases and PI3K/AKT. These findings were 
obtained by studying modified and/or over-expressed receptor complexes. More 
recently these findings were substantiated in several reports demonstrating that IL-31 
activates these pathways in different primary cells and cell lines through the 
endogenous receptor complex. IL-31 stimulates the ERK, JNK, and p38 MAPKinase 
pathways in human bronchial epithelial cells (Ip et al., 2007), activates STAT1, 
STAT3, ERK1/2 and AKT in colorectal cancer cell lines and in lung epithelial cells 
(Chattopadhyay et al., 2006; Dambacher et al., 2007; Jawa et al., 2008), and STAT3 
in epidermal keratinocytes (Dillon et al., 2004; Heise et al., 2009; Kasraie et al., 
2011). Because the IL-31RA does only activate STAT phosphorylation, the activation 
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of PI3K and MAPKinase pathways must be mediated by the OSMR within this 
complex (Fig. 3). Whether all pathways are activated in all cells that express the IL-31 
receptor or whether tissue specific effects explain some of the differences implied by 
the findings described above remains to be determined by performing more 
systematic studies of the signaling capacity of the IL-31 receptor complex.  
1.2.4 The cytokine IL-31 
 
IL-31 was discovered in a Ba/F3 cell line stably expressing the IL-31RA and the 
OSMR. The proliferation of Ba/F3 cells is highly dependent on cytokine signaling 
and thus it was asked whether known cytokines can promote proliferation of these 
cells when IL-31RA, at that time an orphan receptor, was expressed. Since no known 
cytokine was able to stimulate cells with IL-31RA/OSMR, conditioned media and 
subsequently expression cloning resulted in the identification of IL-31 as a novel 
cytokine that fostered proliferation in Ba/F3-IL-31RA/OSMR cells but not in cells 
expressing IL-31RA together with other gp130 family members (Dillon et al., 2004). 
The human IL31 gene is located on chromosome 12q24.31 and encodes a protein of 
164 amino acids. While the human gene shares only 31% identity with the murine 
gene, the two proteins show 61% homology. The protein is processed through 
cleavage of the N-terminal signal peptide to a 141 amino acid mature protein (Dillon 
et al., 2004).  
Even though the IL-31RA forms a complex with the OSMR, IL-31 binds first to the 
IL-31RA (Le Saux et al., 2010). However, the OSMR is essential for IL-31 signaling 
because in over-expression experiments only a co-expression of the IL-31RA and the 
OSMR led to IL-31-dependent induction of STAT phosphorylation (Diveu et al., 
2004). In addition proliferation of Ba/F3-IL-31RA/OSMR cells was abrogated with 
an antagonistic OSMR antibody. Recent studies provided insight into how IL-31 
binds to its receptor complex. Cytokines of the IL-6 family are composed of 4 α-
helices (named A-D) with three different receptor-binding sites numbered 1-3 
(Boulanger et al., 2003; Hammacher et al., 1998). IL-6 type cytokines belong to the 
family of long chain α-helical bundle cytokines with α-helices of 20-30 amino acids. 
In contrast cytokines like IL-4 or GM-CSF belong to the short chain cytokines with 
20 amino acid α-helices and two small β-sheets. IL-31 possesses two long (A and D 
with 25-28 amino acids) and two short helices (B and C with 10-16 amino acids) 
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without any obvious β-sheets. Therefore IL-31 cannot be simply classified in any of 
these two groups but seems to be a compound of long and short chain cytokines. Site 
directed mutagenesis and co-immunoprecipitation experiments revealed that IL-31 
binds first, through its binding site 2 (composed of residues of the A and C helices), to 
the IL-31RA and subsequently to the OSMR through site 3, which is located at the N-
terminal end of helix D (Fig. 3). The initial binding of IL-31 to the IL-31RA is 
essential for binding to the OSMR, possibly because the binding to the IL-31RA 
induces some conformational change in IL-31, which is relevant for binding to 
OSMR. Glu44, Glu106 and His110 were identified as essential residues of binding 
site 2. Furthermore His131 and Lys134 are critical residues in binding site 3 for 
binding the OSMR, amino acids that are not needed for the binding of IL-31 to the IL-
31RA (Fig. 3) (Le Saux et al., 2010). In this context binding site 1 is not relevant. In 
other cytokines site 1 mediates the initial binding to their non-signaling receptor 
subunits, e.g. to IL-6R or IL-11R in case of IL-6 and IL-11, respectively, a receptor 
component not present in the IL-31 receptor complex.  
1.2.5 IL-31 sources and IL-31RA expressing tissues 
 
First attempts towards understanding the biological functions of IL-31 and its receptor 
were to identify cells and tissues that express IL-31 and/or the IL-31RA. The first 
results indicated that IL-31 is synthesized by activated CD4+ T-helper cells and in 
lower amounts also by activated CD8+ T-cells. Conditions that skew T-cells towards a 
TH1 or TH2 phenotype revealed that TH2 cells express preferentially IL31 mRNA 
(Table 1). Low mRNA expression levels were detected in testis, bone marrow, 
skeletal muscle, kidney, colon, thymus, small intestine and trachea (Dillon et al., 
2004). Recently it has been demonstrated that human mast cells are also a source of 
IL-31 (Ishii et al., 2009; Niyonsaba et al., 2010). Our own analyses revealed that in 
addition to T-cells, monocytes, macrophages, immature and especially mature 
monocyte-derived dendritic cells produce IL-31 in response to UV irradiation and 
H2O2 treatment. Moreover normal human epidermal keratinocytes and dermal 
fibroblast show enhanced IL31 mRNA expression upon H2O2 stimulation (Table 1) 
(Cornelissen et al., 2011).  
While the OSMR is ubiquitously expressed throughout human tissues and organs, the 
IL31RA mRNA is found in specific tissues, including trachea, skeletal muscle, 
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thymus, peripheral blood lymphocytes, placenta, bone marrow, thyroid, testis, brain 
and skin (Dillon et al., 2004). However it has not been clarified yet, whether all these 
tissues also express the IL-31RA protein and which of the postulated isoforms. 
Furthermore several cell lines and primary cells have been shown to express the 
IL31RA mRNA and/or the protein including primary keratinocytes, lung and prostate 
epithelium cells, monocytes and dendritic cells, and different tumor cell lines such as 
osteosarcomas, glioblastomas, melanomas, and myelomonocytic leukemias (Table 1) 
(Chattopadhyay et al., 2006; Dillon et al., 2004; Diveu et al., 2004; Ghilardi, 2002; Ip 
et al., 2007; Jawa et al., 2008). Moreover eosinophils (Cheung et al., 2010), colonic 
subepithelial myofibroblast (Yagi et al., 2007), and several cell lines derived from 
ileal and colon tissue (Dambacher et al., 2007) express the IL-31RA. In the mouse IL-
31RA is expressed in a small subpopulation of neurons of the dorsal root ganglia and 
in small sized sensory neurons of trigeminal ganglia while other neuronal cells do not 
express the receptor. In addition the IL-31RA co-localizes with the OSMR in 
neuronal cells (Bando et al., 2006). The presence of IL-31RA in dorsal root ganglia 
was also measured in humans (Sonkoly et al., 2006). These findings suggest that quite 
a number of tissue and cell types are potentially responsive to IL-31 (summarized in 
Table 1). At present however it is largely unknown whether this is indeed the case.  
Introduction   
 27 
Table 1: Sources of IL-31 and IL-31RA expressing cells 
IL-31 SOURCES REPORTED 
REGULATORY 
STIMULI 
REPORTED BIOLOGICAL 
CONSEQUENCES 
REPRESENTATIVE 
PUBLICATIONS 
PBMCs SEB, UVB, H2O2 Links IL-31 to AD associated penetration 
of lesional skin by S. aureus and to 
inflammatory processes induced by UV 
radiation. 
Sonkoly et al., 2006                 
Cornelissen et al., 
2011 
T-cells (CD4+, CD8+, TH1, TH2, 
CLA+) 
inflammatory stimuli 
like UV radiation, 
allergens, pathogens, 
histamines 
Enhancement of inflammatory processes 
by stimulation of e.g. eosinophils in 
various epithelial diseases. 
Dillon et al., 2004 
Bilsborough et al., 
2006 Sonkoly et al., 
2006   Gutzmer et al., 
2009 Cornelissen et 
al., 2011                   
Monocytes, Macrophages, Dendritic 
cells  
IFNγ, H2O2, UVB Links IL-31to inflammatory processes in 
the skin induced by UV radiation. 
Dillon et al., 2004         
Cornelissen et al., 
2011 
Mast cellls IgE mediated activation,  
human β-defensins, LL-
37 
Links IL-31 to the innate immunity. IL-31 
stimulated MCs from MPN patiens secret 
elevated levels of histamines and 
leukotrienes and reduced levels of 
prostaglandinds - links IL-31 to puritic 
mediators 
Ishii et al., 2009,                       
Wang et al., 2009     
Niyonsaba et al., 2010 
Keratinocytes, Fibroblast H2O2 Links IL-31 to inflammatory processes 
induced by UV radiation in the skin. 
Cornelissen et al., 
2011 
HCT116 Induction of 
differentiation, TNFα, 
IL-1β, IFNγ, LPS 
  Dambacher et al., 
2007 
    
IL-31RA EXPRESSING CELLS       
Primary cells       
Monocytes IFNγ   Ghilardi et al., 2002        
Dillon et al., 2004           
Diveu et al., 2004       
Eosinophils   Potential enhancement of inflammatory 
processes by induced secretion of 
cytokines and chemokines 
Cheung et al., 2010 
Mast cells   Activation of the Fcε-RI leads to IL-31RA 
tyrosine phosphorylation indicating a 
potential role in allergic dissorders 
Yamaoka et al., 2009 
Dendritic cells IL-1α, CD40L   Diveu et al., 2004 
Keratinocytes IFNγ, TLR-2 Enhancement of inflammatory processes 
by direct contact to immune cells in IL-31 
stimulated tissues 
Heise et al., 2009          
Cheung et al., 2010       
Kasraie et al., 2011      
Human dermal microvascular 
endothelial cells 
IFNγ   Feld et al., 2010 
Primary cells of bronchial epithelia TGFβ, Dexamethasone Potential involvement in the pathology of 
allergic disorders 
Chattopadhyay et al., 
2006  Jawa et al., 2008       
Pulmonary macrophages IFNγ Potential involvement in the pathology of 
allergic disorders 
Jawa et al., 2008 
Colonic subepithelial myofibroblasts   Secret cytokines, chemokines and MMPs 
after IL-31 stimulation. Potential 
cooperation of IL-21 and IL-17A in IBD 
Yagi et al., 2007 
Neurons of the dorsal root ganglia   Potential involvement in the sensation of 
disease ralated puritus 
Bando et al., 2006              
Sonkoly et al., 2006 
Cell lines       
A549 TGFβ IL-31 reduces cell proliferation by 
inducing cell cycle inhibitors 
Chattopadhyay et al., 
2006  Jawa et al., 2008          
HBE TGFβ, Dexamethasone   Jawa et al., 2008 
BEAS-2B   IL-31 induces VEGF, EGF, CCL2 
expression which are key regulators in 
bronchial inflammation. Co-culture with 
eosinophils enhances their IL-31 
responsiveness 
Ip et al., 2007 
Cell lines derived from colon epithelia 
(HT-29, SW480, HCT116, CaCo-2) 
  HCT116, SW480 induce IL-8 upon IL-31 
stimulation 
Dambacher et al., 
2007 
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HCT 116 Induction of 
differentiation, TNFα, 
IL-1β, IFNγ, LPS 
IL-31 stimulation inhibits cell proliferation 
and induces migration 
Dambacher et al., 
2007 
GO-G-UVM, U937, THP1, A172 
CCF-S-TTG1. U87MG, A375, A549, 
DU145, MCF-7 
    Ghilardi et al., 2002        
Diveu et al., 2004,               
 
1.2.6 Regulation of IL-31 and IL-31RA  
 
Although a number of studies have described tissues and cells that express IL-31 
and/or its receptor, little is known about how either the ligand or the receptor are 
regulated. The few studies that have been published are summarized below. In general 
these are correlative studies and the molecular mechanisms underlying these 
observations have not been determined yet. 
1.2.6.1 Regulation of the expression of IL-31  
The superantigen staphylococcal enterotoxin B (SEB) of S. aureus is one of the 
stimuli identified, which induces IL31 expression in PBMCs of atopic dermatitis (AD) 
patients (Sonkoly et al., 2006). SEB also induced IL31 expression in in vivo patch 
tests in AD patients, while in the same experimental setup and in PBMCs of psoriasis 
patients no regulation of IL31 was measurable. As pointed out above, IL-31 was 
originally identified as a TH2 cytokine. Thus it is possible that these cells are 
responsible for the SEB effect in PBMCs. Also AD is a TH2-linked skin disorder, 
whereas psoriasis is mainly characterized by the presence of TH1 cells. These 
differences might explain the selective induction of IL31 mRNA but further detailed 
investigations are needed for more definitive conclusions. 
 
Skin biopsies of extrinsic atopic eczema (AE) patients display increased IL31 mRNA 
expression compared to normal skin (Gambichler et al., 2008). A standard therapy for 
these patients is UVA irradiation. After 6 weeks of phototherapy patients show 
decreased IL31 mRNA levels, indicating that IL-31 expression might correlate with 
the AE disease phenotype. Extrinsic AE is driven by an IgE sensitization of the skin, 
which prompts high levels of TH2 cells in the skin. UVA irradiation promotes 
apoptosis of T-cells and this is thought to ameliorate the disease. The reduced number 
of T-cells in UVA irradiated skin could also explain the reduced IL31 mRNA levels 
(Gambichler et al., 2008). Thus IL-31 is a candidate for influencing the severity of AE 
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because the decrease of IL31 mRNA (and other TH2 cytokines) after UVA therapy 
correlates with a decline of the symptoms.  
 
Recently it was reported that CD4+ T-cells express the histamine H4 receptor, which is 
involved in allergic inflammation. This receptor responds to histamines secreted by 
mast cells and basophiles. The expression of the receptor can be up-regulated by 
stimulation of the cells with IL-4, a cytokine produced by TH2 cells. Stimulation with 
the H4 receptor agonist 4-methyl-histamine results in a significant up-regulation of 
IL31 indicating a role of this cytokine in allergic inflammations (Gutzmer et al., 
2009). 
 
Furthermore antimicrobial peptides play an important role in activating mast cells. 
Human β-defensins (hBD) and cathelicidin LL-37 belong to these peptides. They can 
be secreted by monocytes in response to bacteria, LPS or IFNγ (Niyonsaba et al., 
2006). Also keratinocytes express hBDs after stimulation with bacteria or 
inflammatory cytokines. These peptides are important components of innate immunity 
and it has been demonstrated that they also induce IL-31 expression and secretion in 
mast cells. IgE sensitized and subsequently activated mast cells also respond with an 
increase of IL-31 expression. The combined stimulation with hBDs or LL37 and anti-
IgE results in a synergistic induction of IL-31 (Niyonsaba et al., 2010). The 
observation that IFNγ induces IL-31RA expression (see below) and that hBDs 
promote IL-31 production indicates a potential role of IL-31 in innate immunity 
(Duits et al., 2002; Fang et al., 2003). 
1.2.6.2 Regulation of the expression of IL-31 receptor  
The regulation of IL-31RA expression has been studied more extensively. It was 
observed that the receptor is induced in monocytes by the cytokine IFNγ that is 
expressed predominantly by TH1 cells (Dillon et al., 2004; Diveu et al., 2004; Ghilardi 
et al., 2002). Moreover dendritic cells respond to IL-1α and CD40L by stimulating IL-
31RA (Diveu et al., 2004). It was observed that proliferating and early-differentiating 
keratinocytes express the IL-31RA. The expression is rapidly down regulated during 
differentiation. Similar to the observation in monocytes, undifferentiated and early-
differentiated keratinocytes also up-regulate the IL-31RA in response to IFNγ, while 
the pro-inflammatory cytokines IL-1α, IL-6 and TNFα have no effect in 
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keratinocytes. During differentiation keratinocytes down-regulate the IFNγ receptor, 
which might explain the lack of responsiveness to IFNγ in more differentiated cells. 
Taken together the results obtained in keratinocytes combined with the findings that 
IL-31 is high in certain skin diseases suggest that this cytokine might be involved in 
controlling keratinocyte differentiation (Heise et al., 2009).  
 
Further support for a role of IL-31 in skin comes from recent studies demonstrating 
that Pam3Cys, a toll-like receptor 2 (TLR2) ligand, induces IL31RA expression in 
normal skin. Keratinocytes derived from AD patients did not show this effect, 
possibly explained by an impaired TLR2 expression in keratinocytes derived from 
such patients (Kasraie et al., 2011). Recently it has also been reported that human 
dermal microvascular endothelial cells express the IL31RA and its expression can be 
stimulated by IFNγ (Feld et al., 2010). Together these studies identify IFNγ as an 
important regulator of IL31RA expression and therefore IFNγ is most likely a critical 
factor to define the responsiveness of cells to IL-31. Whether all cells that express the 
IFNγ receptor respond by inducing IL-31RA is not known at present.   
 
Human mast cells are also a source of IL-31. They express the high affinity IgE 
receptor Fcε-RI that plays an important role in allergic disorders (Kinet, 1999; 
Siraganian, 2003). Treatment of IgE-sensitized mast cells with anti-human IgE 
antibodies stimulates the receptor, which leads to its aggregation and activation of 
downstream signaling cascades. The comparison of the Tyr phosphoproteome 
between unstimulated and IgE-activated mast cells revealed that IL-31RA is highly 
Tyr phosphorylated (Yamaoka et al., 2009). It is possible that this is the consequence 
of IgE-mediated secretion of IL-31, which then stimulates its receptor in an autocrine 
feedforward loop. Alternatively IL-31RA may be the target of crosstalk signaling. 
Thus mechanistically it is unclear why IL-31RA is Tyr phosphorylated in these cells. 
Also it has not been resolved whether this results in the activation of IL-31RA 
downstream signaling pathways.  
 
Finally the expression of IL-31RA was analyzed in several primary cell types of the 
respiratory system, which was indicated by the potential role of IL-31 in allergic 
reactions (Jawa et al., 2008). The expression of IL-31RA is induced in bronchial 
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epithelial cells and type II pneumocytes in response to TGFβ, whereas IFNγ had no 
effect. In contrast pulmonary macrophages respond to IFNγ but not to TGFβ and 
pulmonary fibroblast do not respond to either of the two cytokines when IL-31RA 
expression was measured. In A549, a transformed type II alveolar epithelial cell line, 
and in HBE, an immortalized human bronchial epithelial cell line, TGFβ induces IL-
31RA, consistent with the findings in primary cells (Jawa et al., 2008).  
 
Dexamethasone (Dex), a cortisol analog, is a potent anti-inflammatory drug. Dex can 
induce the expression of gp130 in different cell types. Dex also induces IL31RA 
mRNA expression in bronchial epithelial and HBE cells and to a lower extent in 
pulmonary cells. Although Dex did not significantly increase IL31RA expression in 
A549 cells, it markedly increased IL31 signaling after Dex pre-treatment, indicating 
that the cells become IL-31 sensitive. Mechanistically it is not entirely clear how Dex 
and IL-31 cooperate in these cells. Taking together these findings suggest that IL-
31RA expression in response to inflammatory mediators varies considerably between 
different cell types. At least in epithelial cells derived from the pulmonary system 
TGFβ replaces IFNγ as a potent IL-31RA regulating factor and induces the sensitivity 
of the cells to IL-31 (Jawa et al., 2008). Figure 4 briefly summarizes what is known 
about the regulation of IL-31 and its receptor and the IL-31 induced signaling 
pathways. Table 1 summarizes IL-31 sources and IL-31RA expressing cells including 
known regulatory stimuli and the biological relevance as far it was further analyzed. 
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Figure 4. IL-31 signaling cascade.  
IL-31 signals through a heterodimeric receptor composed of the IL-31RA and the OSMR. There are 
several stimuli described inducing IL-31RA expression, including IFNγ and TGFβ. IFNγ is mainly 
produced by activated T-cells and activates STAT1 and IRF1, which then translocate into the nucleus 
and regulate the expression of target genes. IFNγ also activates signaling pathways that control mRNA 
stability (not shown). TGFβ is expressed ubiquitously by a wide range of different cells and, when 
interacting with its receptors, induces the translocation of SMAD protein complexes into the nucleus. It 
is also described that toll-like receptor 1/2 (TLR1/2) activates the expression of IL31RA after binding 
of the synthetic ligand Pam3Cys. Under physiological conditions TLR1/2 is activated by components 
of gram+ bacteria, e.g. derived from S. aureus, and induces NF-κB and p38 and JNK MAPKinase 
signaling. Which pathways directly influence the IL31RA expression has not been determined yet. 
Several cell types produce IL-31 and its expression can be induced by different stimuli as indicated. 
Upon binding to its receptor complex, IL-31 activates JAK kinases that subsequently phosphorylate 
and activate STAT1, STAT3, and STAT5. The co-localization with the OSMR enables the complex to 
activate also the PI3K/AKT and different MAPKinase signaling pathways (ERK, p38 and JNK). These 
control downstream effectors of IL-31 signaling and are most likely essential for controlling target 
gene expression.    
 
1.2.7 The biological function of IL-31 in mouse models 
1.2.7.1 IL-31 affects the immune response in the mouse skin  
To address the biology of IL-31, transgenic mouse models over-expressing IL-31 
were developed, in which the cytokine was either expressed under the control of a 
lymphocyte specific or a ubiquitously active promoter (Dillon 2004). In both models, 
the mice developed severe pruritus with alopecia and skin lesions that were 
characterized by hyperkeratosis, acanthosis, inflammatory cell infiltration and an 
increase in mast cells. Overall this phenotype shows similarities with the clinical 
picture of patients suffering from AD. No changes were observed in histological 
samples from lung, intestine, stomach, prostate or brain. A similar phenotype was 
seen in Rag1-deficient animals devoid of lymphocytes that were reconstituted with 
bone marrow of IL-31 transgenic mice (Dillon et al., 2004). This indicates that 
lymphocytes are an important source of IL-31 to develop an AD-like skin phenotype.  
 
Moreover injection of BALB/c or C57BL/6 mice with mouse IL-31 via a 
subcutaneous mini-osmotic pump resulted in the development of severe pruritus with 
patchy regions of alopecia. This phenotype eased 6-9 days after the last IL-31 
injection with a complete reduction of pruritus and alopecia after 40 days. These mice 
did not develop skin lesions indicating that under these experimental conditions 
pruritus was the main consequence of applying IL-31 systemically. Histological 
analysis of enlarged peripheral lymph nodes in IL-31 transgenic mice revealed an 
inverse ratio of B- and T-cells compared with wild type mice (36% B-cells to 63% T-
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cells in IL-31 transgenic and 62% B-cells to 25% T-cells in wild type mice) and the 
portion of activated T-cells and memory T-cells within the T-cell fraction was up-
regulated, specially in the CD4+ fraction of T-cells. Serum levels of IgE and IgG were 
not altered, indicating that no change occurred in the development of cells of the 
myeloid or lymphoid lineage (Dillon et al., 2004). Thus the alterations observed in 
peripheral lymph nodes were probably a consequence of increased inflammatory 
processes triggered by infectious inflammation in the lesional skin. The composition 
of B- and T-cells was unaltered in other organs of the lymphoid system. These 
findings indicate that IL-31 induces pruritus and alopecia independent of IgE, which 
leads to the assumption that this model is more comparable to patients suffering from 
the non-IgE associated form of AD. Of note is that lymphocyte-deficient Reg1-/- mice 
treated with IL-31 injected via a subcutaneous mini-osmotic pump developed a severe 
pruritus with substantially delayed and reduced alopecia indicating that IL-31 
mediated pruritus is lymphocyte-independent whereas the presence of lymphoid cells 
is necessary for the development of alopecia (Dillon et al., 2004). Subcutaneous local 
injection of IL-31 in BALB/c mice induces infiltration of inflammatory cells and 
epidermal thickening, which leads to the assumption that IL-31 has also chemotactic 
functions. Indeed stimulation by IL-31 enhances the expression of several chemokines 
in human keratinocytes including GRO1α, TARC, MIP3β, MDC, MIP-3, MIP-1β and 
I-309 (Dillon et al., 2004). Together these findings demonstrate that IL-31 has a 
number of effects that point to a role in the regulation of immune responses in skin.  
1.2.7.2 IL-31RA is required for IL-31-associated pruritus  
IL-31RA-deficient mice have no obvious phenotype. There are no differences in the 
number of distinct immune cells in different lymphoid organs measureable. Injection 
of mouse IL-31 via subcutaneous mini-osmotic pump into IL-31RA-deficient animals 
did not result in pruritus or alopecia as seen in heterozygous littermate control mice or 
wild-type BALB/c mice, supporting the conclusion obtained from the findings with 
IL-31 transgenic mice that IL-31 is a strong inducer of pruritus and that IL-31RA is 
essential to mediate this effect (Dillon et al., 2004). Thus these findings suggest that 
IL-31 signals exclusively through the IL-31RA/OSMR heterodimeric complex.  
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1.2.7.3 The lack of IL-31 affects hematopoietic progenitor cells  
Although no obvious phenotype is seen in IL-31RA-/- mice, these animals show 
alterations in hematopoietic progenitor cells (HPC) (Broxmeyer et al., 2007). But this 
does not result in any difference in the number of circulating red blood cells (RBC), 
platelets (PLT) or other blood cell types. However a significant reduction of CFU-GM 
(colony-forming unit granulocyte and macrophage), BFU-E (burst-forming unit 
erythroid), and CFU-GEEM (colony-forming unit erythroid, granulocyte, 
macrophage, and megakaryocyte) progenitor cells was measurable in bone marrow 
and spleen of IL-31RA-/- mice compared to control animals. Cells derived from the 
bone marrow of IL-31RA-/- mice are predominantly non-cycling whereas a significant 
fraction (40-50%) from wild type animals are cycling. Stimulation with granulocyte 
macrophage colony-stimulating factor (GM-CSF)/stem cell factor (SCF) (or 
alternatively to SCF fms-like tyrosine kinase ligand (FL)) or IL-3/SCF (or FL) 
induces maturation and proliferation of the “immature subset” of CFU-GMs. In 
contrast stimulation with GM-CSF, SCF or IL-31 alone supports maturation and 
proliferation of the “mature subset” of CFU-GMs (Shaheen and Broxmeyer, 2004). 
Although the total number of CFU-GM per femur that was able to differentiate was 
lower in IL-31RA-/- mice, the number of the “mature subset” of CFU-GMs, which 
proliferates in response to a single cytokine, was not different between wild type and 
IL-31RA-/- mice. In contrast the “immature subset”, which proliferates with a 
combination of cytokines as mentioned above, was significantly under-represented in 
CFU-GM cells derived from IL-31RA-/- mice. This indicates that IL-31 might have a 
positive regulating effect on immature HPCs and that IL-31 influences the 
responsiveness to cytokine stimulation in immature CFU-GM. Although the absence 
of the IL-31RA seems to inhibit cytokine-induced proliferation of HPCs, the 
stimulation of wild type cells with recombinant IL-31 does not promote proliferation, 
neither alone nor in the presence of pro-proliferative cytokines. These findings are 
somewhat difficult to interpret with our current knowledge about IL-31. But it should 
also be remembered that the lack of IL-31RA may free OSMR that becomes available 
for other cytokines and associated signaling mechanisms that may explain some of the 
unexpected results.  
 
Myeloid progenitors need cytokines for survival in cell culture. The combination of 
SDF-1 with CXCL12 is known to enhance survival of these cells. This is true for wild 
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type as well as IL-31RA-/- HPCs, indicating that the death rate of HPCs is not 
enhanced in the absence of IL-31RA. Surprisingly, however, the addition of IL-31 to 
the culture medium of wild type HPCs increases their survival, an effect that is 
abrogated in IL-31RA-/- HPCs (Broxmeyer et al., 2007). Thus the absence of IL-31RA 
leads to a significant reduction in the population of immature HPCs at a very early 
stage but does not affect myeloid differentiation under normal conditions. It leads to 
cell cycle arrest in the bone marrow while IL-31 stimulation of wild type cells 
promotes cell survival. These findings indicate that the lack of IL-31RA reduces the 
number of progenitors and enhance their sensitivity to apoptosis but the final number 
of mature cells is not affected. Obviously these observations are difficult to reconcile 
and are in need of further experimentation.  
 
1.2.7.4 Mouse model for atopic dermatitis  
Nc/Nga mice are a model for AD (Matsuda et al., 1997; Suto et al., 1999). These mice 
develop spontaneous skin lesions, have increased plasma IgE levels, show invasion of 
inflammatory cells into the skin and develop pruritus approximately 8 weeks after 
birth when kept under regular conditions. Under specific pathogen free (SPF) 
conditions they do not develop this phenotype, which is comparable to AD in humans. 
Skin lesions of these mice express higher levels of IL31 and IL4 (Takaoka et al., 
2005). The developing skin lesions lead to an increased scratching behavior that 
correlates with increased IL31 mRNA levels in injured skin compared to NC/Nga 
mice kept under SPF conditions. Treatment with 2,4,6-trinitrochlorbenzene (TNCB) 
induces lesions in the skin and serves as an additional model of allergic contact 
dermatitis. The treatment of NC/Nga mice kept under SPF conditions with TNCB 
induces skin lesions with high plasma IgE levels, infiltration of inflammatory cells, 
and increased IL-4 levels but no increase in the scratching behavior. Because no 
increase in IL31 mRNA expression was observed compared to untreated animals, 
these findings indicated that IL-4 is an important mediator of the inflammatory 
process but does not contribute to pruritus. Instead it appears that IL-31 not only 
contributes to the scratching behavior, it might be the causative factor. It is accepted 
that pruritus is not only a symptom of AD, but it is also a cause for a more severe 
phenotype as it increases indirectly the injury of the skin and thus stimulates the 
inflammatory response as a result of the increased scratching behavior (Takaoka et al., 
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2006). This hypothesis is supported by the observation that scratching behavior of 
NC/Nga mice increased before any signs of dermatitis were detectable. However 
application of anti-IL-31 antibodies in NC/Nga mice reduced scratching behavior but 
had no effect on the development of dermatitis. The treatment with IL-31 neutralizing 
antibodies was started several weeks after birth, thus at a time point when the mice 
had already developed an increased scratching behavior even though there were no 
signs of dermatitis (Grimstad et al., 2009). Whether IL-31 only contributes to pruritus 
under these circumstances or whether it interferes additionally with very early stages 
of dermatitis has to be further investigated.  
 
As mentioned before it has been observed that the IL-31RA and the OSMR are co-
expressed in a subset of neurons of the dorsal root ganglia (Bando et al., 2006), which 
represents the site where the soma of cutaneous sensory neurons are located while 
their sensory fibers protrude directly into the skin. These sensory neurons might be 
implicated in the sensing of itch and are possibly stimulated by IL-31. Another 
hypothesis suggests that IL-31 indirectly induces pruritus by stimulating keratinocytes 
(and/or other cells within the inflamed skin) that subsequently express not only 
inflammatory but also pruritic mediators (Fig. 5). Thus IL-31 may represent a new 
link between the immune and sensory nervous system (Steinhoff et al., 2006). 
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Figure 5. Center stage of IL-31 in skin disorders. 
Disturbances in epidermal barrier formation (as e.g. in AD) allows increased penetration of the 
epidermis by allergens and pathogens. Mast cells and dendritic cells respond to these insults with an 
increased secretion of histamines and IL-31. The secretion of antimicrobial peptides (hBDs and LL-37) 
stimulates mast cells to secret IL-31. Furthermore certain antigens such as the S. aureus superantigen 
SEB stimulate IL-31 expression in TH2 cells. IL-31 activates eosinophils to secret several cytokines 
and chemokines, an effect that is enhanced by direct interaction of eosinophils with keratinocytes. IL-6 
and IL-1β activate TH2 cells leading to the secretion of IL-4 and IL-13 and thus promoting the TH2 
immune response. CCL18 promotes the recruitment of TH2 cells to the site of inflammation, whereas 
CCL2 attracts dendritic cells, and CXCL8/1 allure neutrophils and basophils.  The recruitment of TH2 
cells and dendritic cells further increases the inflammatory response and thus enhances IL-31 levels at 
the site of inflammation. Although eosinophils secret CXCL8 and 1, it has not been reported yet 
whether basophils or neutrophils are important in IL-31 connected inflammations.  NHEKs induce the 
expression of the IL-31RA after stimulation of the TLR1/2 receptor complex by components of gram+ 
bacteria. Pathogens can stimulate TH1 cells to secret IFNγ, which also induces IL-31RA expression on 
NHEKs and thus increasing IL-31 sensitivity. Moreover keratinocytes express cytokines and 
chemokines like CCL2, VEGF and CCL22 after IL-31 stimulation, also attracting inflammatory cells. 
In addition IL-31 might be involved in the development of pruritus in epidermal disorders. Dorsal root 
ganglia express the IL-31RA and their unmyelinated C fibers might be directly stimulated by IL-31 or 
IL-31 induces the expression of pruritic factors by NHEKs with subsequent activation of C fibers 
leading to the sensation of itch. 
1.2.7.5 A role for IL-31 and its receptor in allergic diseases  
Because IL-31 is mainly produced by TH2 cells, a model for antigen-induced airway 
hyper-responsiveness was used that is characterized by the production of the TH2 
cytokines IL-4 and IL-13 (Tomkinson et al., 2001). The expression of IL31RA was 
investigated in an allergy mouse model, whereby ovalbumin (OVA) is applied 
intranasally to BALB/c or C57BL/6 mice and lung tissue and cellular infiltrates are 
collected by bronchoaveolar lavage. Both strains of mice had significantly increased 
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IL31RA mRNA levels in the lung tissue and the infiltrating lymphocytes upon OVA 
application compared to PBS treated mice (Dillon et al., 2004). BALB/c mice are 
known to be more susceptible for TH2 cytokine associated diseases. This correlated 
with higher IL31RA mRNA levels in BALB/c compared to C57BL/6 mice. These data 
reveal a potential role of IL-31 in allergic disorders. 
 
The involvement of IL-31/IL-31RA in inflammatory processes in the lung was also 
confirmed in IL-31RA deficient mice (Perrigoue et al., 2007). In the KO animals the 
composition of immune cells in thymus, spleen, and lymph nodes and in PBMCs was 
unchanged compared to wild-type animals. The intravenous injection of Schistosoma 
mansoni eggs, a model of type 2 inflammation in the lung, leads to the formation of 
IL-4- and IL-13-dependent granulomas in the small blood vessels of the lung (Warren 
et al., 1967; Wynn and Cheever, 1995). IL-31RA knockout mice develope more 
severe inflammation in the lung parenchym surrounding the eggs with increased 
granulocyte infiltration compared to wild type mice. Also KO cells located in the 
lymph nodes secreted more IL-4, IL-13, and IL-5 leading to higher IgE levels in the 
serum. S.mansoni infiltration in the lung is characterized by a TH2 cytokine-dependent 
development of alternatively activated macrophages (AAMs) (Herbert et al., 2004). 
These AAMs were also present in a higher number compared to wild type mice. The 
presence of this macrophage subtype correlates with elevated collagen deposition and 
fibrosis, which is also observed in IL-31RA-/- mice compared to wild type mice. 
Taking this together these mice exhibit a deregulated type 2 inflammation in the lung. 
Furthermore activated naive CD4+ T-cells of IL-31RA-/- mice have an increased 
proliferation rate and expression levels of IL-4 and IL-13 compared to wild type cells. 
In contrast CD4+ T-cell derived TH2 cells show no difference in proliferation or 
cytokine expression indicating that IL-31 can directly influence naïve CD4+ T-cells 
but is not involved in proliferation or cytokine secretion processes in TH2 cells (which 
are the major source of IL-31). This indicates that in this model system IL-31 might 
influence TH2-mediated immune responses in a negative feedback mechanism rather 
than promoting TH2-mediated inflammation (Perrigoue et al., 2007). 
 
In contrast to the above-described association of the IL-31 system with TH2-mediated 
inflammation, no interaction with TH1-mediated immune response was seen. Injection 
of mice with the parasite Leishmania major elicits an immune response that is strictly 
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dependent on the production of IFNγ by TH1 CD4+ T-cells. The absence of the IL-
31RA does neither influence the differentiation to TH1 cells nor alter infection 
symptoms by L. major or interferes with IFNγ production in the lymph nodes 
indicating that IL-31 is not involved in IFNγ-dependent immune responses (Perrigoue 
et al., 2007). 
1.2.7.6 The lack of IL-31RA affects OSM signaling  
It has to be noted that the results obtained from IL-31 transgenic and IL-31RA 
knockout mice are somewhat contradictory. While the IL-31 over-expression induces 
TH2-mediated immune responses with increased TH2 cytokine levels, the IL-31RA 
knockout results in a more severe inflammatory response in a TH2 cytokine-mediated 
inflammation model. The latter findings indicate that an intact IL-31 signaling 
cascade should inhibit TH2 cytokine dependent inflammatory processes. If instead of 
genetically modified mice IL-31 neutralizing monoclonal antibodies are used to 
abrogate the IL-31 signal in antigen-induced immune models, no alterations in the 
expression of TH2 cytokines by T-cells was observed (Bilsborough et al., 2010). Part 
of the observed differences may be due to changes in OSMR-dependent signals 
because the lack of IL-31RA increases the availability of OSMR to form complexes 
with gp130. Indeed the absence of IL-31RA in IL-31RA-/- mice in these studies led to 
an over-representation of gp130/OSMR complexes at the cell surface and an 
increased OSM responsiveness. This switch is most likely independent of IL-31. 
Consequently an elevated expression of IL-6, VEGF, and TIMP-1, whose genes are 
regulated by OSM, was measured in response to OSM in IL-31RA-/- mice. These 
observations lead to the hypothesis that rather enhanced OSM signaling than the 
absence of IL-31 signaling stimulated the TH2 response in the lung of IL-31RA-/- 
mice. This may also relate to the increased expression of VEGF, which is known to 
induce remodeling of the lung epithelium, as seen also in the above mentioned airway 
models, and promote TH2-mediated sensitization in the lung (Chapoval et al., 2009; 
Lee et al., 2004). The hypothesis, albeit attractive, that OSM or VEGF are responsible 
for the IL-31RA-/- phenotype requires further verification. 
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1.2.8 IL-31 in human diseases 
1.2.8.1 Pruritic skin diseases 
In order to evaluate the contribution of IL-31 signaling to different skin disease (Table 
2), it is worth to briefly summarize key observations associated with some of these 
that will be relevant for the subsequent discussion. Atopic dermatitis (AD) is a 
chronic inflammatory skin disease that is characterized by xerosis, pruritus, defects in 
skin barrier formation with trans-epidermal water loss, erythematous lesions, the 
deregulation of inflammatory cytokines, and infiltration of inflammatory cells into the 
skin (Bieber, 2010; Leung and Bieber, 2003). It represents a systemic disease as a 
result of hypersensitivity of the immune system. As such it is a model of allergy and it 
is connected to food allergy, asthma bronchiale, and allergic rhinitis. The spectrum of 
severity of AD is very wide. Two sub-categories of atopic dermatitis can be classified 
(Bardana, 2004): (1) The immunoglobulin E (IgE)-mediated variant (referred to as 
extrinsic form or IgE-associated form of AD) is the most prevalent form of the disease 
(about 70–85% of AD patients). These patients have high serum IgE levels and 
positive skin prick test reactions to common environmental allergens such as food and 
aeroallergens. Target organ challenge with allergens has been shown to precipitate 
worsening of skin lesions, and the extent of IgE sensitization is directly associated 
with the disease severity. (2) The intrinsic form of AD (also referred to as non-IgE-
associated form of AD) is not associated with sensitization to food or aeroallergens 
and total serum IgE is within normal limits. Nevertheless, these patients manifest 
identical skin lesions to the allergic form of the disease. AD is defined as a biphasic 
inflammatory disease with an initial induction of TH2-type cytokines (IL-4, IL-5 and 
IL-13) in the acute phase, e.g. in response to skin penetrating allergens. In the chronic 
course of AD the cytokine expression pattern changes to predominantly TH1-type 
cytokines, including IFNγ, IL-12, IL-5, and GM-CSF. In addition the maintenance of 
chronic AD is characterized by the production of TH1-type cytokines like IL-12 and 
IL-18 as well as some remodeling-associated cytokines like IL-11, IL-17 and TGFβ 
(Bieber, 2010). 
 
Allergic contact dermatitis (ACD) is a complex syndrome representing 
immunological responses to cutaneous exposure to protein-reactive chemicals, most 
frequently caused by low molecular weight electrophilic chemicals or metal ions. 
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ACD represents a common inflammatory skin disease, that is T cell-mediated, with a 
cumulative prevalence of 15–20% in the general population of western countries (Ott 
et al., 2010). Activation of DCs by contact allergens is a prerequisite for the induction 
of the pathogenic skin-specific T cell response. DC activation proceeds via a broad 
variety of innate immune receptors, including pattern recognition receptors, Toll-like 
receptors (TLRs), and NOD-like receptors (Weber et al., 2010). The onset of the 
disease is mostly due to the rapid recruitment of chemical-specific CD8+ T cells, 
which induce apoptosis of keratinocytes. Additionally, CD4+ TH1 and TH17 cells 
contribute to the extension of the inflammatory reaction by releasing pro-
inflammatory cytokines that activate keratinocytes and other resident skin cells. ACD 
is a chronic disease, which lasts, in most cases, for the entire life of the affected 
individual (Cavani and De Luca, 2010).  
 
Prurigo nodularis is a chronic condition characterized by a papulonodular pruriginous 
eruption of unknown aetiology. A variety of systemic conditions have been reported 
to be associated with prurigo nodularis but the underlying mechanisms are unknown. 
Nerve growth factor has been implicated in the pathogenesis of prurigo nodularis. 
Calcitonin gene-related peptide and Substance P immunoreactive nerves are markedly 
increased in prurigo nodularis when compared to normal skin. These neuropeptides 
may mediate the cutaneous neurogenic inflammation and pruritus in prurigo nodularis 
(Lee and Shumack, 2005). 
 
The observations made in IL-31 transgenic mice indicated a potential role of IL-31 in 
AD. The expression of IL4 and IL13, the major cytokines expressed by TH2 cells in 
TH2 mediated inflammation, and IFNγ, which is mainly expressed by TH1 cells, in 
skin biopsies of 33 AD patients was analyzed. Serum IgE levels and IL-31 expression 
were measured in these patients. As expected the TH2 cytokines IL4 and IL13 and 
serum IgE levels were high in AD patients compared to healthy donors. This was in 
contrast to IFNγ that is only expressed in chronic AD. Interestingly the expression of 
IL31 mRNA was induced and correlated with the increased IL4 and IL13 expression. 
A comparison of the expression levels of these factors with the severity of AD of 
single patients revealed neither a correlation with IL31, IL4 or IL13 expression nor 
with serum IgE levels. Nevertheless these findings suggested that overall IL31 
expression correlated with an acute AD phenotype (Neis et al., 2006). 
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Biopsies of psoriasis patients, a TH1 cytokine-mediated skin disease, did not show 
increased IL4 and IL13 levels but elevated IFNγ expression as expected. The IL31 
expression was even lower compared to normal skin. Also biopsies from atopic 
contact dermatitis (ACD) patients were analyzed, a disease that is proposed to be TH1-
mediated, but also shows aspects of TH2-mediated diseases with a pathogenesis 
comparable to AD. Biopsies of 56 patients with acute ACD were analyzed and IL31 
mRNA expression was up regulated in 43%, IL4 in 89% and IL-13 in 86% compared 
to healthy skin. Surprisingly IFNγ was induced only in a minority of patients (27%) 
(Neis et al., 2006). This indicates that also ACD, despite it being described as a TH1 
cytokine-mediated disease, probably has an acute phase with a TH2 contribution 
including IL-31. This is consistent with the skin samples analyzed in this study that 
were taken during the acute phase of ACD. Evidence for an involvement of TH2 cells 
and TH2 cytokines in the development of contact hypersensitivity has been reported 
previously (Niiyama et al., 2010; Yokozeki et al., 2000). 
 
These data were confirmed by another study comparing skin biopsies of healthy 
patients with biopsies of psoriasis, non-lesional AD, lesional AD and prurigo 
nodularis patients (Sonkoly et al., 2006). This study revealed that lesional AD and to a 
minor extend non-lesional AD as well as prurigo nodularis skin expresses increased 
IL31 mRNA levels, while psoriasis samples were comparable to healthy skin. AD and 
prurigo nodularis (as well as ACD) are skin diseases often associated with severe 
pruritus while psoriasis rarely causes an itch sensation. This indicates a connection of 
IL-31 with pruritic skin diseases in humans and thus is similar to the observations 
made in the mouse. Genome-wide gene expression analysis in different human tissues 
revealed that IL31RA is highly expressed in dorsal root ganglia also in humans. Since 
the sensation of itch is mediated by unmyelinated C fibers of primary sensory neurons 
and the cell bodies of these neurons reside in the dorsal root ganglia, these 
observations led to the hypothesis that IL-31 is directly involved in modulating the 
signaling of sensory neurons in pruritic skin and may contribute to the itch sensation 
(Sonkoly et al., 2006). It is currently argued that IL-31 may induce pruritus through 
the induction of an as yet unknown keratinocyte-derived mediator, which 
subsequently activates unmyelinated C fibers in the skin. This suggests that IL-31 
represents possibly a new link between the immune and the nervous system (Steinhoff 
et al., 2006). Alternatively IL-31RA may be present also in the C fibers and thus IL-
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31 may directly stimulate these sensory neurons in the skin. Together these findings 
provide interesting models of how IL-31 may contribute to pruritus that can now be 
evaluated.  
 
A recent clinical study compared the severity of AD in a group of 50 children with 
their IL-31 serum levels. The severity of AD was assessed according to different 
scoring systems and correlated to IL-31 levels (Ezzat et al., 2011). It was observed 
that serum IL-31 directly correlates with the severity of AD. The IL-31 levels 
decreased during quiescent phases of the disease but remained elevated if the previous 
burst of the disease was accompanied by high IL-31 serum levels. In contrast to IL-
31, serum IgE levels, total LDH or absolute eosinophil counts in the blood, which 
were proposed to be indicators for the severity of AD, did not correlate (Ezzat et al., 
2011). 
  
Exposure of non-lesional skin of AD patients, who have a known house dust mite 
allergy, with house dust mite allergen induces skin lesions mimicking AD. In these 
lesions compared to non-treated biopsies, increased IL31 mRNA expression was 
detected in some but not all patients. This supports the idea that IL-31 might be one 
important factor in allergen-induced AD. Skin of AD patients is often colonized with 
S. aureus, which is a known trigger factor for atopic skin inflammation. Exposure of 
skin of AD patients to S. aureus superantigen (SEB) in a patch test enhanced IL31 
mRNA expression and PBMCs derived from these patients show a significantly 
higher IL31 mRNA expression compared to PBMCs of healthy donors after exposure 
to SEB. This indicates that AD patients respond to the exposure to allergens with 
increased IL-31 expression, while healthy individuals do not (Sonkoly et al., 2006).  
 
Furthermore it has been demonstrated that circulating T-cells expressing the skin-
homing receptor cutaneous lymphocyte antigen (CLA) induce IL31 mRNA after 
activation by anti-CD3 and anti-CD28 antibodies in AD patients and healthy donors 
with a trend to higher expression by T-cells derived from AD patients. These T-cells 
accumulate at inflamed cutaneous sites, because CLA mediates binding to E-selectin 
(Teraki et al., 2000). These cells express also higher amounts of IL-4 and IL-13 in AD 
patients and respond to allergens more intensely. The number of circulating CLA 
positive T-cells is increased in AD patients. Thus these cells have been suggested to 
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be a major contributor to the pathology of AD (Bilsborough et al., 2006). Since they 
accumulate at inflammatory sites of AD patients (the majority of T-cells at these sites 
are CLA+), this subtype of T-cells is most likely responsible for increased IL-31 
expression in lesional skin of AD patients. In addition the IL31RA expression of 
keratinocytes in biopsies of lesional skin of AD patients is significantly higher 
compared to biopsies of healthy donors. Furthermore macrophages expressing the IL-
31RA infiltrate inflammatory sites in AD patients. This suggests that IL-31 expressing 
T-cells accumulate at lesional skin sites of AD patients and interact with target cells 
with high IL-31RA. In contrast CLA+ T-cells from psoriasis patients only express 
minimal IL31 mRNA. These data provide further evidences for the involvement of 
IL-31 in pruritic skin disorders. 
 
A common therapy for AD patients is UVA1 phototherapy at a wave length of 340-
400nm. It has been demonstrated that IL5, IL13 and IL31 mRNA levels in UVA1 
treated skin were significantly down-regulated compared to untreated skin. UVA1 
stimulates apoptosis in T-cell. The reduction in mRNA levels supports the suggestion 
that T-cells are the major source of IL-31 in atopic skin (Gambichler et al., 2008). 
  
One report suggested that the expression of IL-31 is affected by single nucleotide 
polymorphisms (Schulz et al., 2007). Homozygocity of one of the haplotypes 
identified correlates with increased IL31 expression in activated PBMCs. Interestingly 
this haplotype is also strongly associated with the non-atopic form of dermatitis 
indicating that an altered IL-31 expression may be important in the pathogenesis of 
these patients. However, so far no additional evidence has been published to suggest 
that these three haplotypes differ in IL-31 expression. 
 
Eosinophils are one type of inflammatory cells that infiltrate lesional skin of AD 
patients. Interestingly these cells express the IL-31RA (Cheung et al., 2010). In an in 
vitro co-culture system with keratinocytes, which also express the IL-31RA, it has 
been demonstrated that IL-31 delays the apoptosis of eosinophils and stimulates the 
secretion of pro-inflammatory cytokines and chemokines (IL-6, IL1β, CXCL1, 
CXCL8, CCL2, and CCL18) by eosinophils but not keratinocytes (Cheung et al., 
2010). IL-6 and IL-1β are known to activate TH cells and induce a TH2-mediated 
immune response (Lacy and Moqbel, 2000). Thus IL-31 stimulation might contribute 
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to the inflammatory response by inducing the expression of these cytokines. The 
induction of the above mentioned chemokines might promote the infiltration of 
immune cells into lesional AD skin. CCL2 and CCL18 are AD associated chemokines 
(Homey et al., 2006). CCL18 is a highly expressed chemokine in AD skin and 
stimulates the recruitment of CLA+ T-cells to the site of inflammation (Günther et al., 
2005). CCL2 recruits dendritic cells while CXCL8 and CXCL1 induce infiltration of 
neutrophils and basophiles (Conti and DiGioacchino, 2001; McColl and Clark-Lewis, 
1999; Rossi and Zlotnik, 2000). Taken together these results suggest that IL-31 might 
amplify the inflammatory responses in AD by initiating the expression of 
inflammatory cytokines and chemo-attracting chemokines. Although keratinocytes do 
not induce the expression of these above-mentioned inflammatory factors, they 
nevertheless might contribute to the secretion of these factors by eosinophils. The 
recruitment of inflammatory cells to the site of inflammation is a critical aspect of 
AD. Inflammatory cells are attracted by chemokines and maintained at the site of 
inflammation by adhesion molecules. Keratinocytes express the adhesion molecule 
ICAM-1, while eosinophils are positive for the integrin LFA-1, which is composed of 
CD11a/CD18. ICAM-1 interacts with LFA-1 and thus eosinophils are likely to be 
retained at the site of inflammation by direct interaction with keratinocytes (Larson 
and Springer, 1990; Nickoloff et al., 1990). In addition co-culturing of keratinocytes 
and eosinophils stimulates the expression of these adhesion molecules and thus 
enhances the possibility for efficient retention of eosinophils in the tissue.  
 
Moreover the direct contact of these cells might contribute to the secretion of 
cytokines. Indeed the direct interaction of eosinophils and keratinocytes seems 
important for the production of cytokines and chemokines in response to IL-31. If the 
two cell types are separated in a trans-well chamber, the IL-31 effect was notedly 
reduced, indicating that the direct physical contact of these two cell types enhances 
the IL-31 stimulating effect on eosinophils (Cheung et al., 2010). The mechanistic 
base for this cooperative effect remains to be established.  
 
An important aspect of AD is a defect in skin barrier formation and function, which 
results in the increased penetration of the skin with allergens and microbes. The skin 
produces a number of antimicrobial peptides and proteins as part of the innate 
immune system. Two of them are the human β-defensins (hBDs) and cathelicidin LL-
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37 (Niyonsaba et al., 2006). Important cells mediating inflammatory and allergic 
responses in the skin are mast cells that are also recruited to the site of inflammation. 
Mast cells induce IL31 mRNA expression upon treatment with hBDs and LL-37. Pre-
sensitization of cells with IgE and co-stimulation of the cells with hBDs or LL-37 and 
anti-IgE antibodies synergistically increases the expression of IL31 (Niyonsaba et al., 
2010). This indicates an involvement of IL-31 in the innate immune response, an 
aspect that might be particularly relevant in AD patients, involving a feed-forward 
loop with innate immune cells and cytokines affecting the skin barrier further 
enhancing the effects of allergens. I suggest that IL-31 contributes to this vicious 
cycle. 
 
As mentioned above, stimulation of lesional skin of AD patients with SEB induces 
IL-31 expression in various cell types. In addition keratinocytes seem to be able to 
enhance IL-31-mediated expression of inflammatory factors and therefore stimulate 
the inflammatory response in AD. Keratinocytes express the TLR-2, which is an 
important mediator of the innate immune response to gram-positive bacteria, 
including S. aureus (Takeuchi et al., 2001). Stimulation of human primary 
keratinocytes with the synthetic TLR-2/TLR-1 heterodimeric ligand Pam3Cys induces 
IL-31RA and OSMRβ expression, an effect that is even more potent for IL-31RA 
than the previously described TH1-linked cytokine IFNγ (Morr et al., 2002). In 
addition the TH2 cytokine IL-4 did not up-regulate IL-31RA in keratinocytes 
indicating a link of IL-31RA expression to TH1 type cytokines in contrast to IL-31 
that is linked with TH2-type cytokines. After pre-stimulation of keratinocytes with 
Pam3Cys or IFNγ, the expression of CCL2, VEGF, and CCL22 was induced in 
keratinocytes in contrast to unstimulated cells (Kasraie et al., 2011). This 
demonstrates that keratinocytes can indeed directly contribute to changes in cytokine 
composition in AD skin, at least after pre-stimulation with IFNγ (i.e. as a consequence 
of activation of TH1 cells) or activation of TLR-2 by S. aureus superantigens. 
 
In addition chronic spontaneous urticaria (CU) is a skin disorder characterized by the 
development of highly pruritic relapses lasting for 24 hours up to periods of weeks or 
even years (Zuberbier et al., 2009). These patients show elevated serum IL-31 levels 
indicating a role of IL-31 in this pruritic disease (Raap et al., 2010).  
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Table 2: IL-31 related diseases 
1.2.8.2 IL-31 in the lung 
IL-31 is not only important in the skin; it also seems to play a role in the lung 
epithelium (Table 2). Primary type II pneumocytes, primary bronchial epithelial cells, 
as well as A549 cells express the IL-31RA and respond to IL-31 by activating STAT3 
and its target genes (Chattopadhyay et al., 2006). In addition ERK, JNK and AKT 
phosphorylation is induced in A549 cells. IL-31 stimulation efficiently suppresses 
proliferation in lung epithelial cells by altering the expression of cell cycle regulators. 
While the cyclin-dependent kinase (CDK) inhibitor p27KIP1 is induced, cyclin B1, 
CDC2, and CDK6 are repressed (Chattopadhyay et al., 2006). Furthermore the 
IL31RA is expressed in a wide range of lung cells including primary bronchial 
epithelial cells, pulmonary macrophages and primary type II pneumocytes. Also HBE 
and A549 cells, cell lines derived from bronchial epithelial cells, express the IL31RA 
(Jawa et al., 2008). The broad expression spectrum of IL-31 and its receptor in lung 
epithelial cells supports the assumption that IL-31 is involved in inflammatory 
diseases associated with the airways, including allergic asthma.  
 
PUBLISHED IL-31 RELATED 
SKIN DISEASES 
OBSERVATIONS INDICATING THE INVOLVEMENT OF IL-31 
IN THESE DISEASES REFERENCE 
Pruritic skin diseases     
Atopic Dermatitis                              
Non-atopic Dermatitis                    
Atopic Contact Dermatitis 
IL-31 mRNA expression correlates with IL-4 and IL-13 in biopsies of 
AD and ACD patients. IL-31 serum level correlate with AD severity in 
children. An IL-31 haplotype is associated with non-AD. IL-31 
stimulates the secretion of inflammatory cytokines and chemokines in 
eosinophils that are in contact with keratinocytes. 
Neis et al., 2006       
Sonkoly et al., 2006      
Ezzat et al., 2011 
Bilsborough et al., 2006 
Schulz et al., 2007     
Cheung et al., 2010 
Prurigo Nodularis   Skin biosies of patients show increased IL-31 level. Sonkoly et al., 2006 
Chronic Spontaneous Urticaria Patiens have elevated IL-31 serum level. Raap et al., 2010 
Diseases of the repiratory system     
Allergic Asthma 
Patiens show increased IL-31 expression in PBMCs. Lung epithelial 
cells and cell lines respond to IL-31 and secret inflammatory cytokines 
important in inflammatory deseases of the lung. Allergic mouse models 
exhibit an upregulation of IL-31 and IL-31RA in the lung tissue. 
Lei et al., 2008 
Chattopadhyay et al., 
2006 Ip et al., 2007               
Dillon et al., 2004  
Perrigoue et al., 2007 
Inflammatory Bowel Dieseases     
Crohn´s Disease                       
Ulcerative Colitis 
Upregulation of IL31RA, IL31 and OSMR mRNA in biopsies of 
inflammed tissues. Like IL-17, an important mediator in IBD, IL-31 
induces the expression of cytokines, chemokines and MMPs in colonic 
subepithelial myofibroblasts. 
Dambacher et al., 2007  
Yagi et al., 2007  
Philadelphia chromosome-negative 
myeloproliferative neoplasms 
Mast cells derived from MPN patients show an incresed IL-31 secretion 
upon activation. Patients have elevated IL-31 plasma level. Wang et al., 2009 
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Allergic asthma is a chronic inflammatory disease that is, similar to AD, characterized 
by the presence of TH2 cytokines (IL-4 and IL-13), increased serum IgE levels, 
bronchial infiltration of immune cells, reversible bronchial obstruction, mucus 
hypersecretion and bronchial hyper reactivity (Chiappara et al., 2001). Thus some of 
these phenomenological alterations are comparable to those seen in the skin of AD 
patients. These findings resulted in the suggestion that IL-31 is also involved in 
inflammatory processes associated with allergic asthma. In BEAS-2B cells, a 
transformed bronchial epithelium cell line, CCL2, VEGF and EGF expression is 
induced upon IL-31 stimulation. In contrast the TH2 cytokines IL-4 and IL-13 are 
unable to induce VEGF or EGF. The expression of the chemokine CCL2 is, however, 
induced by IL-4 and IL-13 and these two cytokines function cooperatively with IL-31. 
As described above eosinophils, which are prominent immune cells to infiltrate the 
bronchial tissue in allergic asthma, express EGF, CCL2, IL-6 and IL-8 after IL-31 
stimulation, an effect that is significantly enhanced in co-cultures with bronchial 
epithelial cells. CCL2, VEGF and EGF are proposed to be key regulators of bronchial 
inflammation and remodeling of the lung tissue, frequently associated with lung 
fibrosis and loss of function, in bronchial asthma (Amishima et al., 1998; Ferrara and 
Davis-Smyth, 1997). Furthermore CCL2 and VEGF are highly involved in recruiting 
immune cells to inflammatory sites in the lung (Romagnani, 2002; Zittermann and 
Issekutz, 2006). In conclusion IL-31 might contribute to inflammation by inducing the 
expression of inflammatory cytokines in the lung and, similar to keratinocytes, 
enhance the inflammatory response of eosinophils at the site of inflammation (Ip et 
al., 2007). 
 
In addition to the effects seen in lung tissue, serum levels of IL-31 and mRNA 
expression in PBMCs of allergic asthma patients are significantly up-regulated 
compared to non-allergic asthma patients and healthy individuals (Lei et al., 2008). 
These findings provide further support for a functional role of IL-31 in promoting 
and/or sustaining allergic asthma.  
The assumption that IL-31 is important in allergic reactions in the skin and the 
respiratory system is further corroborated by the finding that CD4+ T-cells, especially 
TH2 cells, express the histamine H4 receptor, which is up-regulated upon IL-4 
treatment. Subsequent stimulation with a histamine agonist (see above) results in the 
activation of IL31 mRNA expression in these T cells. This links IL-31 directly to 
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histamines that are secreted by mast cells and basophils in allergic reactions (Gutzmer 
et al., 2009). The finding that mast cells and eosinophils express IL-31 and IL-31RA, 
respectively, provides a connection of skin and lung epithelia with critical cells of the 
innate immune system through IL-31, indicating a direct involvement of IL-31 in 
innate immunity at sites of the body, where the initial confrontation with allergens and 
pathogens occurs.  
1.2.8.3 IL-31 in inflammatory bowel disease 
Since IL-31 is present in the epithelia of skin and lung, an obvious thought is that IL-
31 is present also in other epithelia that are in close contact with the environment. 
Indeed, it has been reported that IL-31 is expressed in the small intestine and colon 
(Dillon et al., 2004). Inflammatory bowel disease (IBD) comprises a group of 
inflammatory disorders of the colon and the small intestine, with the major types 
being Crohn´s disease (CD) and ulcerative colitis (UC) (Mizoguchi and Mizoguchi, 
2010). The etiology is largely unknown but a common view is that the mucosal 
immune system aberrantly responds to allergens and microbes in the gastrointestinal 
lumen, especially in patients with a genetic pre-disposition. For example mutations in 
the NOD2 gene, a cytosolic pattern recognition receptor that senses peptidoglycans 
from gram+ and gram- bacteria, are associated with CD. It is suggested that an 
impaired NOD2 function promotes epithelial barrier dysfunctions with increased 
bacterial invasion and inflammation in the intestine (Lecat et al., 2010). This leads to 
infiltration of inflammatory cells including T-cells that express IL-17 and IL-22, two 
important mediators in IBD. The chronic inflammation results in mucosal damage by 
abnormal killing of bacteria of the normal microbial flora in the gut, disruption of the 
epithelial barrier, and the formation of epithelial ulcerations. Patients with IBD have 
an increased risk to develop colon cancer (Mizoguchi and Mizoguchi, 2008, 2010; 
Sartor and Muehlbauer, 2007). 
 
It has been demonstrated that several human cell lines derived from the small intestine 
and the colon epithelia, including HT-29, SW480, HCT116 and CaCo-2, express IL-
31RA and OSMR, and in low amounts IL31 mRNA (Table 1) (Dambacher et al., 
2007). Furthermore in HCT116 and SW480 the phosphorylation of STAT1, STAT3, 
ERK1/2 and AKT is induced in response to IL-31 stimulation, which results in the 
activation of downstream target genes, including IL8. IL-31 stimulation inhibits cell 
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proliferation of HCT116 cells, comparable to the effects in lung epithelial cells, and 
increases cell migration. Induction of differentiation in HCT116 cells, using sodium 
butyrate, increases the expression of IL31RA, OSMR, and IL31. The stimulation of 
HCT116 cells with the inflammatory cytokines TNFα, IL-1β, and IFNγ, and treatment 
with LPS induces the expression of all three genes (Dambacher et al., 2007). Whether 
this is relevant for tumor cell physiology remains to be addressed. Moreover in CD 
and UC patients IL31RA, OSMR, and IL31 mRNA is upregulated in inflamed but not 
in unaffected skin biopsies (Dambacher et al., 2007). While CD is proposed to be a 
TH1/TH17 cytokine-mediated disorder, UC is more linked to TH2 cytokines. The 
finding that IL-31 and IL-31RA are up-regulated in both forms of IBD suggests that 
although IL-31 is a TH2 cytokine, it is not restricted to TH2-mediated diseases. 
 
Human colonic subepithelial myofibroblasts (SEMFs) respond to IL-31 stimulation 
by secretion of pro-inflammatory cytokines, chemokines and matrix 
metalloproteinase’s (MMPs) that contribute to tissue destruction. SEMFs are located 
directly under the basement membrane of the intestinal mucosa and play a role in 
wound healing and inflammation. In microarray analyses, IL-31 was found to induce 
efficiently the chemokines CXCL8 (IL-8), CXCL1 (GRO-α), CCL7 (MCP-3), CXCL3, 
CCL13 and CCL15, the pro-inflammatory cytokines IL6, IL16 and IL32, as well as 
MMP-1, MMP-3, MMP-25 and MMP-7 in SEMFs. In addition the secretion of some 
of these proteins, including IL-6, IL-8, GRO-α, MCP-3, MMP-1 and MMP-3, was 
demonstrated. IL-17A has been identified as an important mediator for IBD also 
inducing IL-6, IL-8 and MMP-3 secretion (Andoh et al., 2008; Harrington et al., 
2005). The effects of IL-17A were comparable to those seen with IL-31 and 
application of both cytokines resulted in additive effects on mRNA expression of 
these factors (Yagi et al., 2007). These results indicate that TH2 T-cell secreted IL-31, 
together with IL-17, might contribute to the pathology of IBD by inducing the 
expression of the above-mentioned factors in SEMFs. It is tempting to speculate that 
IL-31 and IL-17 might cooperate in regulating inflammatory processes in the 
intestine, but possibly also in other tissues including skin.  
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1.2.8.4 Involvement of IL-31 in Philadelphia chromosome-negative 
myeloproliferative neoplasms (Ph-MPN) 
MPN are characterized by excessive proliferation of cells of one or more 
differentiated myeloid lineages. Polycythemia vera (PV), essential thrombocythemia 
(ET) and primary myelofibrosis (PMF) belong to the Ph-MPN (Finazzi and Barbui, 
2008; Mesa, 2002; Tefferi et al., 2009). An important aspect of Ph-MPN is the 
development of pruritus in roughly 50% of all patients (Diehn and Tefferi, 2001; 
Gerlini et al., 2002). Mast cells appear to be important for Ph-MPN-associated 
pruritus, possibly because they produce IL-31. It was observed that mast cells derived 
from SCF/IL-6-stimulated CD34+ cells of MPN patients secrete significantly more 
pruritic factors than corresponding mast cells from healthy donors in response to IgE 
sensitization and anti-IgE activation (Wang et al., 2009). Moreover the secretion of 
histamines, prostaglandins and leukotrienes was significantly higher in patient-
derived mast cells upon stimulation. Important for the discussion here, this was also 
true for IL-31 and, furthermore, IL-31 serum levels in MPN patients and secretion of 
IL-31 by CD3+ T-cells from MPN patients after phytohemaglutinin activation were 
also elevated. The perception of pruritus in MPN patients correlates with the number 
of mast cells generated from bone marrow of these patients in culture, a decreased 
mast cell apoptosis rate and an increased IL-31 plasma level. In addition, as 
mentioned above the overall prostaglandin release of mast cells derived from MPN 
patients is higher compared to control cells, but mast cells derived from MPN patients 
that suffer from pruritus release significantly less prostaglandins than patients without 
pruritus (Ishii et al., 2009). This further increases the itch sensation as prostaglandins 
are proposed to play a role in inhibiting pruritus (Arai et al., 2004; Sugimoto et al., 
2005; Sugimoto et al., 2007). In summary activated mast cells secrete IL-31 in 
combination with other pruritic factors in MPN. Furthermore mast cells derived from 
MPN patients proliferate faster and show a lower apoptosis rate. Importantly they 
accumulate in the skin of PV patients with pruritus. In combination with the proposed 
role of IL-31 in pruritic skin diseases, it is attractive to suggest that this cytokine 
contributes to MPN associated pruritus.  
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1.2.9 Conclusions 
 
Although the literature on IL-31 function is not very extensive yet, the available 
findings suggest that this cytokine regulates aspects of innate as well as adaptive 
immunity in tissues that are exposed to the environment. In this setting IL-31 is 
associated with a number of diseases, including atopic dermatitis, inflammatory bowl 
diseases, and allergic asthma (summarized in Table 2). Common to these diseases is 
the deregulation of cells of the innate immune system, including mast cells and 
eosinophils, and of the adaptive immune system. For the latter TH2 helper T cells 
appear to be particularly relevant but contributions by other T cell subpopulations, 
e.g. TH1 and TH17 cells, may also turn out to be relevant. These cells together with the 
epithelial cells in the skin, intestine, and lung form a network of interactions, both 
through cytokines and direct cell-cell contacts, in which IL-31 appears to play an 
important role. Clearly furthermore detailed molecular studies will be required to 
firmly establish the role of IL-31 in the normal physiology of these organs and in 
different disease states.  
 
The molecular studies have established that IL-31 signals through a heterodimeric 
receptor composed of the IL-31RA and OSMR. This complex can stimulate different 
signaling pathways through receptor-associated JAK kinases. This results in the 
activation of STATs, MAPKinases, and PI3K/AKT, factors that control many aspects 
of cell physiology. Although these signaling pathways are well studied, their relative 
contributions to different IL-31 phenotypes have not been established yet.  
 
One of the conclusions that can be drawn from the work in mice is that IL-31 plays a 
key function in pruritus. This is supported by work using IL-31 transgenic and IL-
31RA-/- mouse models and by experiments, in which IL-31 was subcutaneously 
injected into the skin. In all these situations TH2 cells are activated and secrete a 
cocktail of cytokines that includes IL-31. Moreover the stimulation of mast cells 
through antigens and allergens results in the release of IL-31 in combination with 
other factors. It appears that IL-31 then stimulates other immune cells, which results 
in further cytokine production and provokes the release of pruritic factors from 
keratinocytes. It is thought that the latter somehow affects sensory neurons and thus 
induces itch sensation. Although these experiments cannot be directly compared to the 
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human situation, several lines of evidence suggest that IL-31 is also a pro-pruritic 
factor in humans. This is of interest because pruritus is a severe symptom of many 
skin diseases. Thus interfering with IL-31-mediated itch sensation could be 
therapeutically relevant and substantially improve substantially the condition of 
patients with AD or some forms of MPN.  
 
IL-31 has additional consequences in skin, lung, and intestinal epithelia. In this 
respect an important finding is that keratinocytes express the IL-31 receptor and 
therefore are responsive to this cytokine. From the interaction of different immune 
cells with keratinocytes in the skin, it seems likely that IL-31 contributes to skin 
diseases (Fig. 5). In this tissue IL-31 may control not only the presence and activity of 
different immune cells but also affect the proliferation and differentiation of 
keratinocytes and by this contribute to the function of the skin as a protective organ. 
For example IL-31 might affect skin barrier function, thereby controlling the exposure 
to antigens and allergens but also microorganisms. This again provides opportunities 
for specific molecular intervention, e.g. in AD.  
 
Because several cell types in lung and intestine carry the IL-31 receptor, it is likely 
that also in these tissues IL-31 has specific effects. However the molecular 
consequences are less well studied. Nevertheless, also in these tissues barrier function 
might be controlled by IL-31, in analogy to the skin.  
 
In conclusion the information available suggests that human IL-31 is an important 
factor in innate immunity and inflammation that enhances immune responses in 
epithelial tissues. How important IL-31 in epithelial inflammations is remains an open 
question. But the evidence that is being accumulated indicates that IL-31 contributes 
to the severity of TH2-mediated diseases, including AD, allergic asthma and 
inflammatory bowel diseases. Most likely IL-31 is able to amplify the expression of 
pro-inflammatory cytokines and chemokines and thus increases the recruitment of 
inflammatory cells to the site of inflammation. Although IL-31 is probably not 
directly involved in TH1-mediated diseases, the fact that IL-31RA can be regulated by 
cytokines of TH1 cells provides support for the hypothesis that IL-31 links TH2- and 
TH1-mediated immune responses. Preliminary evidence also suggests that IL-31 
controls the proliferation and differentiation of cells of non-hematopoietic origin, 
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lending support to the concept that this cytokine plays an integrative role in the proper 
formation of epithelia.  
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2 Results 
2.1 The biological effect of IL-31 treatment: IL-31 interferes with 
keratinocyte differentiation in an organotypic skin model 
 
To understand the role of IL-31 for keratinocyte proliferation and differentiation, 
recombinant human (rh) IL-31 was applied to organotypic human 3D models of skin 
differentiation. These reconstructs were generated from primary normal human 
epidermal keratinocytes (NHEK) and primary dermal fibroblasts (see Materials and 
Methods). IL-31 treatment resulted in a disturbed epidermal differentiation, 
characterized by a thin epidermal layer with hypogranulosis and an abolished 
alignment of keratinocytes in the stratum basale (Fig. 6A). The proliferation of 
keratinocytes was impaired as measured by the reduced staining for Ki67. In addition 
reduced expression of epidermal differentiation markers, including filaggrin and 
keratin (K) 10 was observed in the upper epidermal layer. These findings were 
confirmed by measuring the FLG, KRT10, INV and ITGB4 mRNA levels of the 3D 
models (Fig. 6B). FLG and KRT10 expression was considerably delayed and reduced 
during differentiation in response to rhIL-31. The expression of involucrin was also 
reduced (Fig. 6A), but this was only apparent at day 2 of the model at the mRNA 
level (Fig. 6B). Moreover the expression of β4-integrin and K14 was disorganized 
(Fig. 6A). β4-integrin expression seems not to be restricted to the basal cell layer, but 
rather is distributed throughout the whole model and at least at day 2 a 25-fold 
increased ITGB4 mRNA expression compared to non-treated cells was observed (Fig. 
6B). 
 
These results implicated that IL-31 modulates fundamental aspects of keratinocyte 
proliferation and differentiation. Therefore NHEKs were stimulated for 1h with rhIL-
31 and gene expression was measured using Affymetrix gene arrays. One could 
observe changes in the expression of a rather limited set of genes (Fig. 6C). The most 
highly regulated gene was SOCS3, a direct target of the JAK-STAT3 pathway 
activated by the IL-31RA/OSMR receptor complex as described above. In addition 
the expression of several cytokines and transcriptional regulators was enhanced. Of 
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particular interest were the genes that encode IL-20 and IL-24. They are located in the 
IL10 gene cluster containing two further cytokine genes, IL10 and IL19, flanked by 
genes encoding the mitogenic activated protein kinase activated kinase 2 
(MAPKAPK2), an upstream kinase of the MAP-kinase signaling pathway (Zu et al., 
1994), the fas apoptotic inhibitory molecule 3 (FAIM3), an Fc receptor for 
immunoglobulin (Ig) M (Shima et al., 2010), and the (PIGR), an Fc receptor that 
facilitates the secretion of IgA and IgM (Kaetzel, 2005) (summarized in Fig. 6D). 
We observed that IL20 and IL24 gene expression was robustly activated within one 
hour of rhIL-31 application (Fig. 6E). In contrast the neighboring genes were either 
not expressed (IL10, IL19, FAIM3 and PIGR) or their expression was not affected by 
rhIL-31 treatment (MAPKAPK2). Similarly the expression of IL31RA and OSMR was 
not regulated by rhIL-31. These findings validate the IL-31-dependent regulation of 
IL20 and IL24 and suggest that these two cytokines are involved in the downstream 
effects of IL-31. Indeed both IL-20 and IL-24 have been suggested to affect 
keratinocyte differentiation, although some of the reports are controversial (Sabat, 
2010). 
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Figure 6. IL-31 disturbs differentiation of primary NHEKs in organotypic skin equivalents.     
A. NHEKs and fibroblasts were grown as 3D organotypic skin equivalents and stimulated with or 
without rhIL-31 (100ng/ml; every second day) as indicated after lifting the cells to the air – liquid 
interphase. The skin equivalents were harvested and histological sections were stained for the indicated 
markers at day 8 (1 of 6 models).  
B. Organotypic skin equivalents grown in parallel to the one in panel A (the same primary cells were 
used) were harvested at day 2, 5, 8, and 14 and the expression of FLG, KRT10, INV and ITGB4 
determined by RT-qPCR. Displayed are relative expression levels compared to the non-stimulated day 
2 sample (normalized to HPRT expression). One representative experiment of 3 is shown.  
C. NHEKs were stimulated with rhIL-31 for 1 h; mRNA was isolated and analyzed on Affymetrix 
Exon arrays. Displayed are genes that are regulated more than two fold compared to a non-stimulated 
control in two independent experiments.  
D. Schematic representation of the IL10 gene cluster located on chromosome 1 that spans a region of 
about 140 kb. The IL19 gene is transcribed from two different promoters. The indicated genes flank the 
cluster and the chromosomal orientation is marked.  
E. NHEKs from three different donors were isolated and stimulated with rhIL-31 (100ng/ml) for the 
indicated time periods (h). The expression of IL20 and IL24 was analyzed in comparison to other genes 
in the IL10 gene cluster, flanking genes, and IL31RA and OSMR by RT-qPCR. 
Results   
 
 58 
2.2 Development of model systems: 
2.2.1 HaCaT cells treated with IFN-γ 
Primary keratinocytes often show donor dependent variability, which was noted by 
studying the response to rhIL-31 in many different batches of primary NHEKs. 
Therefore I wanted to establish a donor-independent reproducible cellular system for 
subsequent studies. HaCaT cells are spontaneously immortalized primary 
keratinocytes that are still capable to differentiate in organotypic skin models 
(Boukamp et al., 1988). HaCaT keratinocytes constitutively express the OSMR (Fig. 
7B) but not the IL-31RA receptor chain and are therefore not capable of responding to 
IL-31. The expression of the IL-31RA in HaCaT cells can be induced by IFN-γ (Heise 
et al., 2009) with expression first measureable by 2-3 hours (Fig. 7A, B and C), which 
enables the cells to respond to rhIL-31 and to induce target genes, including IL20 and 
IL24 (Fig. 7D). Similar to NHEKs IL10, IL19, FAIM3 and PIGR are not expressed 
and MAPKAPK2 and OSMR are not affected by rhIL-31 stimulation (summarized in 
Fig. 7E). IFN-γ controls many cellular processes and induces cell cycle arrest, making 
it difficult to investigate IL-31 specific functions during differentiation. To overcome 
this limitation I generated stable cell clones expressing IL-31RA under a tetracycline 
controllable promoter. 
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Figure 7. HaCaT cells express IL-31RA in response to IFNγ and subsequently respond to IL-31 
A. HaCaT cells were stimulated with IFNγ (20ng/ml) for the indicated time points (h). Then IL31RA 
expression was analyzed by RT-qPCR. Displayed are relative expression levels compared to non-
stimulated cells, normalized to HPRT expression of one representative experiment.  
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B. HaCaT cells were stimulated with IFNγ (20ng/ml) for 24 h. Then IL31RA and OSMR expression 
was analyzed by RT-qPCR. Displayed are relative expression levels (IL31RA) and Ct-values (OSMR) 
comparing non-stimulated with stimulated cells, normalized to HPRT expression (mean values and 
standard deviations of three biological replicates).  
C. The expression of IL-31RA at the cell surface was evaluated in cells treated as described in panel A 
using FACS.  
D. HaCaT cells either pre-treated or not with IFNγ for 24h, were stimulated with rhIL-31 (100ng/ml) 
for the indicated time periods (h). The expression of IL20 and IL24 was analyzed by RT-qPCR. 
Displayed are relative expression levels compared to non-stimulated cells, normalized to HPRT 
expression of one representative experiment (of a total of 3).  
E. Summary of relative expression values of the two IL-31RA receptor components IL31RA and 
OSMR, the three IL10-cluster flanking genes MAPKAPK2, PIGR and FAIM3 and the IL10-cluster 
members IL10 and IL19 in untreated (-) and 24h IFNγ/1,5h IL-31 treated HaCaT cells. The displayed 
genes are either highly (++) or not (-) expressed.    
 
 
2.2.2 HaCaT-pRTS IL31RA cell lines with inducible IL31RA expression  
The human IL31RA cDNA was obtained from Imagenes cloned into the pENTR221 
Gateway® (Invitrogen) entry vector, which allows easy sub-cloning into gateway 
compatible vectors via recombination. For expression of the IL-31RA in HaCaT cells 
I chose the pRTS vector (Bornkamm et al., 2005) (relevant features summarized in 
Fig. 8A). This vector persists as a replication-competent episomal vector within the 
nucleus of the target cell. It harbors an ampicillin resistance for prokaryotic and a 
hygromycin resistance for eukaryotic selection. The bi-directional tetracycline 
controllable promoter (Ptetbi-1) can drive the expression of a gene of interest in one 
direction and the expression of another protein or shRNA in the opposite direction. 
For the stimulated expression of the gene of interest, doxycycline (dox), a semi-
synthetic derivate of tetracycline, is used. The bi-directional promoter is blocked by 
the binding of a repressor (rtTA-M2) in dox-free conditions. Addition of dox leads to 
the release of the repressor from the promoter and binding of a dox dependent 
activator protein (tTSKRAB). Both repressor and activator are optimized for the 
binding of dox and binding to the tetracycline responsive element (TRE) within the 
tetracycline controllable promoter to obtain high specificity. This combination of 
activator and repressor is meant to mediate a very tight regulation of expression. The 
repressor and activator are expressed in a single mRNA connected by an internal 
ribosomal entry site (IRES) and its expression is controlled by the mouse heavy chain 
intron enhancer (Eµ) in combination with the chicken β-actin promoter (Fig. 8B).  
 
The cDNA of pENTR221-IL31RA was fully sequenced before amplification of the 
IL31RA cDNA via PCR and subsequent insertion of the amplicon into an EcoRV 
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digested pSFIexpress vector generating pSFI-IL31RA-HA. pSFI serves as a sub-
cloning vector adding a haemaglutinin (HA)-tag to the C-terminus of the protein and 
embedding the HA-tagged cDNA into SfiI restriction sites for cloning it into pRTS. 
The IL31RA-HA cDNA was fully sequenced and pSFI-IL31RA-HA and pRTS were 
SfiI digested. The resulting IL31RA-HA fragment was ligated into the linearized 
pRTS generating pRTS-IL31RA-HA. pRTS harbors a gene expressing the green 
fluorescence protein (GFP) at the opposite side of the bi-directional promoter which 
was removed by digestion with BglII and SwaI. After converting the resulting sticky 
DNA ends to blunt ends via incubation with the Klenow fragment of polymerase II, 
the plasmid was religated to generate pRTS-IL31RA-HAΔGFP. This step was 
performed to avoid side effects on cellular behavior and experimental procedures by 
the expression of GFP that includes the detection of other fluorescently labeled 
proteins. 
 
The dox-dependent expression of IL31RA mRNA was evaluated by RT-qPCR in 
transiently transfected HEK293 cells (Fig. 8B). The expression of the protein was 
confirmed in lysates of transfected and dox induced HEK293 cells using different 
combinations of primary and secondary antibodies to ensure a specific detection of 
IL-31RA (Fig. 8C). 
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Figure 8. pRTS-IL-31RA-HAΔGFP induces IL-31RA expression after doxycycline induction in 
HEK293 cells.             
A. Scheme of relevant pRTS IL-31RA-HAΔGFP features. The vector contains genes providing 
ampicilline resistance (bla) as bacterial selection marker and hygromycine (hyg) resistance for 
eukaryotic selection. The IL31RA gene, with a C-terminal added HA-tag (IL31RA-HA), is under the 
control of a bi-directional tetracycline dependent promoter (Ptetbi-1). The tet-activator (rtTA2-M2) and 
tet-repressor (tTSKRAB) are expresses from a single mRNA with an internal ribosomal entry site 
(IRES) and constitutively expressed under the control of the mouse heavy chain intron enhancer (Eµ) 
and the chicken ß-actin promoter (CAGp). The vector exists as an episomal replication-competent 
vector in the target cells. Under doxycycline free conditions the tet-repressor binds to the bi-directional 
promoter to inhibit expression. Addition of dox leads to the replacement of the repressor by the 
activator and subsequent expression of IL31RA.  
B. HEK293 cells were mock or pRTS IL-31RA-HAΔGFP transfected and stimulated with dox 
(1µg/ml) for 16h. The IL31RA expression was analyzed by RT-qPCR. Displayed are relative 
expression levels (IL31RA) comparing mock transfected with non-stimulated and dox stimulated cells 
normalized to HPRT expression (one representative experiments of three).  
C. HEK293 cells were treated as described in B. The IL-31RA-HA expression was analyzed in western 
blot using different combinations of primary (either a goat derived biotinylated IL-31RA specific 
antibody or a rat derived anti-HA antibody) and secondary antibodies coupled to horseradish 
peroxidase (HRP) as indicated. 
 
To generate a stable pRTS-IL31RA containing cell line, HaCaT cells were seeded in 
10cm dishes and transfected with Superfect (Qiagen) according to the manufacturers 
recommendations. Transfected cells were selected by addition of 400ng/ml 
hygromycine and seeded at low density to select individual cell clones that were 
called HaCaT-pRTS-IL31RA. Well-growing individual clones were stimulated with 
dox for 16h and IL31RA expression was measured by RT-qPCR (Fig. 9A). All 
selected clones induced IL31RA expression, which was also confirmed at the protein 
level (Fig. 9B). For further characterization clone K2 and K15 were selected. Clone 
K15 induced IL-31RA protein expression in a concentration-dependent manner (Fig. 
9C). After 16h of dox pre-treatment and 30min rhIL-31 (100ng/ml) stimulation, 
STAT3 phosphorylation could be detected, indicating that the receptor is active (Fig. 
9D). Furthermore the receptor was expressed at the cell surface as evaluated by 
fluorescence microscopy and indirect confocal immunofluorescence microscopy of 
paraformaldehyde fixed but not permeabilized cells to prevent the binding of the 
primary antibodies to intracellular IL-31RA (Fig. 9E). Clone K15 induced IL31RA 
expression upon dox treatment (Fig. 9F) and subsequent stimulation with IL-31 for 1 
hour led to the expression of the IL-31 target genes IL20 and IL24 (Fig. 9G). Similar 
results were obtained with clone K2 (data not shown). 
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Figure 9. HaCaT-pRTS-IL-31RA cells induce IL31RA expression and respond to IL-31.     
A. HaCaT cells were transfected with pRTS IL-31RA-HAΔGFP and individual clones selected with 
hygromycine. The clones were stimulated with or without dox (1µg/ml) for 16h and the expression of 
IL31RA mRNA was analyzed by RT-qPCR compared to the non-stimulated control and normalized to 
HPRT expression.  
B. IL-31RA protein expression was analyzed in lysates of cells treated with or without dox (1µg/ml, 16 
hrs) by western blotting. Tubuline served as loading control.  
C. Clone K15 was stimulated with the indicated concentrations of dox for 16h and IL-31RA protein 
expression was analyzed by western blotting. Tubuline served as loading control.  
D. The phosphorylation of STAT3 was analyzed by western blotting in lysates of clone K15 that were 
16h stimulated with dox and 30min with rhIL-31 (100ng/ml).  
E. IL-31RA protein expression was evaluated in clone K15 cells treated with or without dox for 16h 
and visualized using fluorescence microscopy (panels on the left) and indirect confocal 
immunofluoresence microscopy (panels on the right). Comparable findings were obtained with clone 
K2.  
F and G. Clone K15 cells were  pre-treated with dox for 16h and stimulated with rhIL-31 for 1h. 
IL31RA (F) and IL20/IL24 (G) expression was analyzed by RT-qPCR. Displayed are the mean values 
and standard deviation of three biological replicates using HPRT for normalization. 
 
 
2.2.3 IL-31 disturbs proliferation of HaCaT-pRTS-IL31RA cells in monolayer 
cultures and differentiation in organotypic skin equivalents 
As IL-31 affected the formation of the epidermis in organotypic skin equivalents of 
NHEKs, now the question was addressed whether this is also true for HaCaT-pRTS-
IL31RA cells. In a monolayer culture dox and rhIL-31 co-stimulation significantly 
reduced the proliferation rate of clone K2 and clone K15 (Fig. 10A), which is 
consistent with the reduced Ki67 staining observed in the NHEK model (Fig. 6A). In 
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addition the induction of IL-31RA by dox alone was already sufficient to reduce the 
proliferation rate of these two clones by 50% compared to the dox/rhIL-31 co-
stimulation. Furthermore rhIL-31 treatment alone slightly reduced the proliferation 
rate of the cells (Fig. 10A). This indicates that HaCaT-pRTS-IL31RA cells probably 
exhibit some basal IL-31RA expression without dox induction and that the high 
overexpression of IL-31RA after dox pre-treatment may cause auto-activation of the 
receptor. Nevertheless in organotypic skin equivalents dox/rhIL-31 stimulation 
resulted in similar defects in formation of the epidermal structure in both clone K2 
and clone K15 compared to primary cells (Fig. 10B). The haematoxylin-eosin staining 
revealed no (clone K15) or only minor differences (clone K2) in the dox or rhIL-31 
alone treated model, compared to the non-stimulated control. In addition the clone 
K15 model was also stained for phosphorylated STAT3 to visualize IL-31 dependent 
signaling activation (Fig. 10B; red staining). The dox/rhIL-31 treated model shows 
increased STAT3 activation compared to the controls demonstrating the functionality 
of the induced IL-31RA in organotypic skin equivalents. 
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Figure 10. IL-31 disturbs proliferation and differentiation of HaCaT-pRTS-IL-31RA in 
organotypic skin equivalents.             
A. The proliferation rate of HaCaT-pRTS-IL-31RA clone K15 or clone K2 was measured by counting 
cells incubated in the presence or absence of dox and rhIL-31. The cultures were re-stimulated with 
dox and rhIL-31 daily. At the indicated time points the cell number of the differently treated cultures 
was determined. Displayed are mean values with standard deviation of three biological replicates.  
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B. HaCaT-pRTS-IL-31RA clone K15 or clone K2 and fibroblasts were grown as 3D organotypic skin 
equivalents and stimulated with or without dox (1µg/ml) and/or rhIL-31 (100ng/ml) every second day 
as indicated after lifting the cells to the air – liquid interphase. The skin equivalents were harvested and 
histological sections were haematoxylin-eosin stained (HE) (clone K2) and stained for phosphorylated 
STAT3 as indicated (clone K15) at day 7. 
 
2.2.4 Individual HaCaT-pRTS-IL31RA clones are not stable 
As demonstrated in Fig. 10A, rhIL-31 or dox treatment alone is sufficient to cause a 
reduced HaCaT-pRTS-IL31RA proliferation rate. To evaluate if also the expression 
of IL-31 target genes can be induced without induction of IL31RA, individual clones 
were stimulated with either dox or rhIL31 or with a combination of both followed by 
measuring IL20 and IL24 expression using qRT-PCR. All tested HaCaT-pRTS-
IL31RA clones induced IL20 and IL24 expression after rhIL-31 stimulation without 
initial induction of the IL-31RA by dox pre-treatment (Fig. 11A). In contrast to the 
proliferation rate measured in Fig. 10B, dox treatment alone was not enough to induce 
IL20 or IL24 expression. This indicates that HaCaT-pRTS-IL31RA cells exhibit a 
basal IL31RA expression without the presence of dox that is sufficient to induce IL-31 
signaling, leading to target gene expression. However pre-treatment of dox with 
subsequent IL-31 stimulation further increased the induction of IL20 and IL24 
expression in all clones (Fig. 11A). To evaluate whether HaCaT-pRTS-IL31RA cells 
in later passages still express the IL-31RA and induce IL-31 signaling to a similar 
degree, clone K15 cells in passage 24 (after isolation) were pretreated with dox for 
16h and stimulated with rhIL-31 for 30min. The expression of the IL-31RA and the 
induction of STAT3 phosphorylation were visualized by fluorescence microscopy 
(Fig. 11B).  
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Figure 11. Individual HaCaT-pRTS IL-31RA clones are not stable        
A. The expression of IL20 and IL24 was analyzed by RT-qPCR in response to dox (1µg/ml for 16h), 
rhIL-31 (100ng/ml for 1h) or a combination of the two. Displayed are relative expression values 
compared to non-treated cells HPRT expression was used for normalization.  
B. IL-31RA protein expression and STAT3 phosphorylation was evaluated in clone K15 cells treated 
with or without dox (1µg/ml, 16h)/rhIL-31 (100ng/ml), 30min) and visualized using fluorescence 
microscopy. The DNA was stained with Hoechst 33258.  
C. L-31RA protein expression was evaluated in clone K15 cells treated with or without dox for 16h and 
visualized using FACS.  
D. Clone K15 cells were seeded in very low density and individual sub clones were selected and 
analyzed for IL-31RA protein expression after dox stimulation for 16h visualized using fluorescence 
microscopy. 
 
The immunofluorescence images showed a very heterogeneous distribution of IL-
31RA with no, low or highly expressing cells. In addition the induction of STAT3 
phosphorylation did not correlate with the IL-31RA expression (Fig. 11B). 
Furthermore FACS analysis of the IL-31RA expression revealed that after dox 
treatment of K15 cells two populations existed; one expressing low to medium the 
other high amounts of IL-31RA (Fig. 11C). To solve this problem clone K15 cells 
were seeded at very low density to isolate single cell subclones. Several subclones 
were tested for IL-31RA expression after dox induction by immunofluorescence 
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microscopy. All subclones still demonstrated a heterogeneous expression of the IL-
31RA (Fig. 11D). 
 
2.3 HaCaT-pSLIK-IL31RA cell lines with inducible IL31RA 
expression  
 
Because HaCaT-pRTS-IL31RA seem to silence parts of the pRTS vector over time, 
leading to differences in their dox responsiveness and expression of IL31RA, it was 
decided to clone a new monoclonal dox inducible cell line, using the pSLIK vector 
system (Shin et al., 2006). This vector is delivered into the cells by lentiviral infection 
and its dox controllable expression cassette integrates into the target cell genome via 
its long terminal repeats (LTR). The IL-31RA expression is controlled by a 
tetracycline responsive element (TRE) that binds the TRE- and dox-binding optimized 
activator rtTA3. The rtTA3 gene is expressed from one mRNA together with a 
neomycine (Neo) selection marker connected by an internal ribosomal entry site 
(IRES). This mRNA is constitutively expressed under the control of an ubiquitin-C-
promoter. Binding of dox to the rtTA3 protein leads to association with the TRE and 
activation of IL31RA expression. The rtTA3-IRES-Neo expression cassette is directly 
located behind the IL31RA thus transactivation by rtTA3 also enhances the expression 
of the transactivator and the selection marker. In addition the vector has an HIV 
derived DNA-Flap region supporting the integration into the host genome with its 3 
dimensional structure, and the 3´ SIN (self-inactivating) LTR lacks elements 
necessary for reverse transcription and thus inhibits viral replication. Furthermore a 
WRE (woodchuck regulatory element) between the neomycin resistance gene and the 
3´SIN LTR promotes mRNA export and protein expression. Fig. 12A summarizes the 
pSLIK-IL31RA cassette that integrates into the target cell genome. 
 
The vector was cloned using pSFI-IL31RA-HA. To keep the HA-tag, the IL-31RA 
cDNA including the HA-tag was PCR-amplified and sub-cloned into the pSLIK entry 
vector pEN_TGmirc3 (Shin et al., 2006) into Klenow-fragment blunted NcoI/XbaI 
restriction sites generating pEN-IL31RA-HA. The integrated PCR fragment was fully 
sequenced. Sub-cloning into pEN_TGmirc3 adds the TRE in front of the IL31RA-HA 
and embeds the gene within attL sites for recombination. Using the Gateway® LR 
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Clonase® enzyme mix (Invitrogen) according to the manufactures recommendations, 
the TRE-IL31RA-HA cassette was integrated into the pSLIKNeo vector via in vitro 
recombination between attL and attR sites creating pSLIK-IL31RA-HA. 
 
Lentiviral pSLIK-IL31RA-HA particles were generated by transient transfection of 
HEK293T cells together with the appropriate helper plasmids (Materials and 
Methods). HaCaT cells were infected and selected by adding 800ng/ml Geneticin 
(G418), whose activity is also inhibited by the Neo selection marker, and seeded in 
low density to select single cell clones that were called HaCaT-pSLIK-IL31RA.  
 
The resulting clones expressed IL31RA mRNA (Fig. 12B) and protein (Fig. 12C) 
upon addition of dox except clone 7 that was G418 resistant but did not induce 
IL31RA expression, which was not further investigated. IL-31RA was expressed at the 
cell surface (Fig. 12F) and was functional because stimulation with rhIL-31 resulted 
in the phosphorylation of STAT3 (Fig. 12G), an immediate downstream target of 
receptor-bound JAK kinases. The HaCaT-pSLIK-IL31RA clones responded also with 
induction of IL20 and IL24 mRNA expression (Fig 12D). Clones K12 and K14 were 
selected for the subsequent experiments. In these two clones the induction of the IL20 
and IL24 genes was observed exclusively when the IL-31RA was induced and the 
cells were stimulated by rhIL-31. In contrast to HaCaT-pRTS-IL31RA cells, only the 
combination of the two treatments induced IL20 and IL24, while neither of the two 
treatments alone was sufficient (Fig. 12E). 
2.3.1 IL-31 inhibits proliferation in HaCaT-pSLIK-IL31RA cells 
Now the question was addressed how the established HaCaT-pSLIK-IL31RA clones 
reacted to rhIL-31 stimulation. Treatment of these cells with rhIL-31 resulted in a 
reduced proliferation, whereas the induction of the IL-31RA or the treatment with IL-
31 alone had no effect (Fig. 13A). FACS analyses revealed that within 48h the 
number of cells in S/G2 phase of the cell cycle was significantly reduced with a 
parallel increase in G1 phase cells (Fig. 13B). Since no signs of apoptosis were 
observed by staining the cells for Annexin V (Fig. 13C), by evaluating the cells 
morphologically, and by measuring sub-G1 cells (data not shown), the proliferation 
effect is most likely due to reduced cell cycle progression, consistent with the reduced 
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Ki67 staining observed in the 3D NHEK model (Fig. 6A) and the proliferation rate 
observed in HaCaT-pRTS-IL31RA cells (Fig 10B). 
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Figure 12. HaCaT-pSLIK-IL-31RA cells induce IL31RA expression and respond to IL-31.            
A. Scheme of the pSLIK-IL31RA-HA vector that integrates into the genome of the target cell via its 
long terminal repeats (5´LTR and 3´SIN LTR) after lentiviral infection. The 3´SIN (self inactivating) 
LTR furthermore inhibits viral replication because it lacks important enhancer elements. The FLAP 
region promotes the import of the viral genome into the nucleus. The IL-31RA-HA gene is under the 
control of a tet-responsive element (TRE) that induces target gene expression after binding of dox to 
the dox and TRE binding optimized tet-transactivator (rtTa3). The genes encoding the tet-transactivator 
and the neomycine resistance (neo) are located on one mRNA connected by an internal ribosomal entry 
site (IRES). Their expression is controlled by an ubiquitin-C promoter (Ubi-c). The WRE (woodchuck 
regulatory element) promotes mRNA export into the cytosol and enhances protein expression. 
Transactivation by the rtTA also enhances the expression of the rtTa3-IRES-Neo cassette.  
B. HaCaT cells were infected with pSLIK-IL31RA-HA and individual clones were selected with G418 
(800ng/ml). The clones were stimulated with or without dox (1µg/ml) for 16h, the expression of 
IL31RA mRNA was analyzed by RT-qPCR and normalized to HPRT expression.  
C. IL-31RA protein expression was analyzed in lysates of cells treated with or without dox (1µg/ml, 
16h) by western blotting. Tubulin served as loading control.  
D. IL-31RA protein expression was evaluated in clone K14 cells treated with or without dox (1µg/ml) 
for 16h and visualized using fluorescence microscopy (panels on the left) indirect confocal 
immunofluoresence microscopy (panels in the middle) and FACS (panel on the right). Comparable 
findings were obtained with at least 5 clones.  
E. Clone K14 cells were treated with or without dox (1µg/ml, 16h), stimulated with rhIL-31 for 45min, 
fixed and subsequently stained for IL-31RA (Alex-Fluor488, green) and phospho-STAT3 (Alexa-
Fluor555, red). The DNA was stained with Hoechst 33258. Comparable findings were obtained with at 
least 5 clones.  
F. The expression of IL20 and IL24 was analyzed by RT-qPCR in response to 16h dox/1h rhIL-31 
stimulation. The IL20 expression in individual clones is displayed as Ct-values because the basal 
expression values for IL20 in the different clones was either not detectable or very low. The IL24 
expression is shown as relative expression compared to cells without dox and rhIL-31 treatment. HPRT 
expression was used for normalization.  
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G. The expression of IL20 and IL24 was analyzed by RT-qPCR in two individual clones in response to 
dox (16 hrs), rhIL-31 (1h) or co-treatment. Displayed are the mean values and standard deviation of 
three biological replicates using HPRT for normalization.  
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Figure 13. IL-31 inhibits proliferation in HaCaT-pSLIK-IL31RA cells.       
A. The proliferation rate of HaCaT-pSLIK-IL31RA clone K14 cells was measured by counting cells 
incubated in the presence or absence of dox (1µg/ml) and rhIL-31 (100ng/ml). The cultures were re-
stimulated with dox and rhIL-31 daily. At the indicated time points (days) the cell number of the 
differently treated cultures was determined. Displayed are mean values with standard deviation of three 
biological replicates. Similar findings were obtained with clone K12.  
B. Cell cycle distribution of HaCaT-pSLIK-IL31RA clone K14 cells was determined in response to 
dox/rhIL-31 treatment after 48h. The percentage of cells in G1-, S- and G2-phase was determined by 
FACS. Displayed are mean values with standard deviation of three biological replicates. Statistical 
significance was determined by the two-sided Student’s t-test (**p<0,01). Comparable results were 
obtained with clone K12 cells.  
C. HaCaT-pSLIK-IL31RA cells were stimulated with or without dox (1µg/ml) and rhIL-31 (100ng/ml) 
as indicated. The cells were then stained for AnnexinV and analyzed by FACS. Displayed are mean 
values with standard deviation of three experiments. The differences were not statistically significant.  
 
2.3.2 IL-31 interferes with HaCaT-pSLIK-IL31RA cell differentiation in the 
organotypic 3D skin model 
To evaluate whether IL-31 compromised differentiation of HaCaT cells, these clones 
were utilized in the organotypic 3D skin model and the consequences of IL-31 
signaling were determined. Representative micrographs depict the effect of 
continuous rhIL-31 treatment (at day 7 and day 14) on 3D reconstructs of HaCaT-
pSLIK-IL31RA cell clones (Fig. 14A). Similar to the findings with primary cells, 
IL31-treament significantly disturbed epidermal differentiation. This is specific for 
IL-31 signaling, because neither dox nor rhIL-31 alone resulted in changes in the 
differentiation compared to the control. This disturbance became evident by a thin and 
disordered epidermal layer and is further supported by immunohistology, which 
showed abolished expression of epidermal differentiation markers in the upper 
epidermal layer including filaggrin, involucrin, and K10 as well as an increased 
distribution of β4-integrin through the whole epidermal layer (Fig. 14B).  
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The IL-31 effects were equivalent to the ones seen in the organotypic 3D skin model 
using NHEK cells. Therefore the HaCaT-pSLIK-IL31RA cell clones were used as a 
model system to further study the effects of IL-31 exposure in a defined cellular 
genetic background. 
2.4 Quantitative and morphological evaluation of the IL-31 effect on 
differentiation 
 
For a semi-quantitative estimation of IL-31-induced disordered differentiation, an 
expert dematopathologist (PD Dr. med Jörg Wenzel, Klinik und Poliklinik für 
Dermatologie und Allergologie, Universitätsklinikum Bonn) was asked to examine 
blinded the different haematoxylin-eosin-stained slides from three independent 
experiments. He defined a scoring method for semi-quantitative analysis of the 
epidermal constitution (Wenzel et al., 2005). 
 
The epidermal thickness of each reconstruct was measured (Fig. 14C) and the 
specimens were scored according to the epidermal constitution, alignment of the 
stratum basale, and development of the stratum granulosum on a scale from 0 
(completely disturbed) to 3 (normally differentiated, i.e. equivalent to healthy human 
skin) as described previously (Fig. 14D) (Wenzel et al., 2005).  
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Figure 14. IL-31 interferes with HaCaT-pSLIK-IL31RA cell differentiation.       
A. Clone K14 (panel on the left) and clone K12 (panel on the right) cells and primary dermal 
fibroblasts were grown as organotypic skin equivalents in the presence or absence of dox (1µg/ml) 
and/or rhIL-31 (100ng/ml). Dox and rhIL-31 were added every second day. The skin equivalents were 
harvested after 7 and 14 days and histological sections were stained with haematoxylin-eosin.  
B. Clone K14 cells and primary dermal fibroblasts were grown as organotypic skin equivalents in the 
presence or absence of dox and rhIL-31 (100ng/ml). Dox and rhIL-31 were added every second day. 
The skin equivalents were harvested after 7 days and analyzed histologically (HE, haematoxylin-eosin) 
or stained for the indicated marker proteins. These results are from the same experiment as shown in 
panel A. C. and D. Haematoxylin-eosin-stained histological sections were examined blinded. The 
epidermal thickness of each epidermal reconstruct was measured (C) and the specimens were scored 
semi-quantitatively on a scale from 0 (completely disturbed) to 3 ("normally differentiated" = similar to 
healthy human skin) regarding the epidermal constitution, the alignment of the stratum basale, and the 
development of the stratum granulosum (D) as described in a previous study (Wenzel et al., 2005). 
Displayed are mean values of three biological replicates. Statistical significance was determined by the 
Mann-Withney U test (*p<0,05). 
 
 
In addition most striking was the reduction of both proliferation (Ki67) and the 
expression of late differentiation markers (filaggrin, involucrin, and keratin 10), 
which are strong indications for inappropriate differentiation. Most prominent was the 
effect on filaggrin expression, as seen also in the primary cell model (Fig. 6A). The 
FLG, INV and KRT10 expression was strongly reduced when the 3D model was 
analyzed upon permanent rhIL-31 treatment at day 7 (Fig. 15B). The expression of 
β4-integrin was also disorganized and no longer confined to the basal layer although 
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changes on mRNA levels were not observed (Fig. 15B). rhIL-31 pulse experiments 
were also performed and it was evident that 2h were not sufficient to observe a 
phenotype in the 3D model (data not shown) but 8h and 24h treatment resulted in a 
partial phenotype after developing the model for 7 days (Fig. 15A), suggesting that an 
initial, relatively short IL-31 stimulus is sufficient to deregulate late differentiation 
processes. FLG was a particularly sensitive marker because a reduction of expression 
already after an IL-31 pulse of 2 hrs could be observed, while KRT10 expression was 
less sensitive and INV expression even showed a slight increase rather than a decrease 
after IL-31 pulse stimulation (Fig. 15B). Furthermore ITGB4 expression was also not 
altered after IL-31 pulse stimulation. This supports the hypothesis that IL-31 induces 
a series of molecular events that culminate in defective differentiation. 
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Figure 15. IL-31 interferes with HaCaT-pSLIK-IL31RA cell differentiation.                    
A. Clone K14 and clone K12 (data not shown) cells and primary dermal fibroblasts were grown as 
organotypic skin equivalents in the presence or absence of dox. rhIL-31 (100ng/ml) was added for the 
indicated times and the skin equivalents were harvested after 7 days and processed as described in Fig. 
14  
B. Parts of the organotypic skin equivalents displayed in panel A were used for total mRNA isolation 
and the expression of FLG, KRT10, INV and ITGB4 was determined by RT-qPCR. Displayed are 
relative expression levels compared to the non-stimulated sample (normalized to HPRT expression). 
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2.5 Evaluation of signaling pathways downstream of IL-31 
 
2.5.1 IL-20 and IL-24 mediate part of the IL-31 effect on keratinocyte 
differentiation 
Candidates for mediating the above discussed IL-31 effects are IL-20 and IL-24, 
which are induced rapidly in response to IL-31 (Fig. 16A). In addition an enhanced 
expression of both genes was also measured upon prolonged stimulation of HaCaT-
pSLIK-IL31RA cells with IL-31 (Fig. 16B). IL-31 pulse stimulation was sufficient to 
cause a slight increase in IL20 and IL24 expression also in 7 day old organotypic skin 
equivalents and that is significantly further increased upon permanent IL-31 
stimulation (Fig. 16C). The specificity of induction of these two genes was further 
elucidated by using kinase inhibitors. The inhibition of JAK kinases completely 
blocked the expression of IL20 and IL24, consistent with a key role of these kinases in 
IL-31RA/OSMR-dependent signal transduction (Fig. 16D). In addition the p38 and 
ERK kinases but neither JNK nor PI3K kinases were critical to induce the two 
cytokine genes (Fig. 16D). Thus HaCaT cells stably expressing an inducible IL-31RA 
receptor subunit and NHEK cells respond comparably to IL-31 signaling when IL20 
and IL24 expression is measured requiring the activation of distinct signaling 
pathways. To evaluate if the receptor heterodimers of these two cytokines, i.e. IL-
20Rα/IL-20Rβ and IL-22Rα/IL-20Rβ that are both recognized by IL-20 and IL-24 
(Parrish-Novak et al., 2002), are expressed, their surface expression was determined 
using specific antibodies and FACS. All three receptor subunits were found at the cell 
surface of HaCaT-pSLIK-IL31RA cells (Fig. 16E). Therefore I tested whether rhIL-
20 and rhIL-24 affected keratinocyte differentiation. While rhIL-20 and rhIL-24 alone 
gave variable and small effects, the combination of the two cytokines resulted in 
reduced differentiation (Fig. 16F). This was associated with reduced FLG and, to a 
lesser extent, INV expression while KRT10 and ITGB4 were not affected in the model 
displayed in Fig. 16F (Fig. 16G). By analyzing the expression of FLG and KRT10 in 
two different IL20/IL24 stimulated models from clone K12 and clone K14 the 
reduction in expression of these two differentiation markers was rather small (Fig. 
16H). Moreover reduced FLG and KRT10 were seen early during differentiation of 
3D equivalents of primary NHEK (Fig. 16H), while at later time points the expression 
of the two genes recovered (data not shown). The treatment with rhIL-20 and rhIL-24 
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was clearly less efficient than rhIL-31, suggesting that other genes regulated by IL-31 
are involved additionally in controlling keratinocyte proliferation and differentiation. 
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Figure 16. IL-20 and IL-24 impair differentiation of HaCaT-pSLIK-IL31RA cells in organotypic 
3D co-cultures                         
A. and B. HaCaT-pSLIK-IL31RA clone K14 cells were 16h pre-treated with dox (1µg/ml) and rhIL-31 
(100ng/ml) stimulated for the indicated time periods and the expression of IL20 and IL24 was analyzed 
by RT-qPCR. Displayed are relative expression levels comparing non-stimulated to stimulated cells, 
normalized to HPRT expression (IL20). For IL24 Ct-values are given, because no signals were 
detectable from unstimulated controls (mean values and standard deviations of three biological 
replicates).  
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C. Parts of the organotypic skin equivalents displayed in Fig. 15A were used for total mRNA isolation 
and the expression of IL20 and IL24 was determined by RT-qPCR. Displayed are relative expression 
levels compared to the non-stimulated sample (normalized to HPRT expression).  
D. The expression of IL20 and IL24 was analyzed by RT-qPCR in clone K14 cells in response to dox 
(16h), rhIL-31 (1h) or co-treatment. In addition the indicated kinase inhibitors (JAK inh. I, 100nM; 
JNK inh. II, 20µM; SB202190, selective for p38 MAP kinases (20µM); U0126, selective for ERK 
kinases (20µM); Wortmannin, selective for PI3-Kinases (500nM)) were added 1h prior to stimulation 
with rhIL-31. Mean values and standard deviations of 3 independent experiments are displayed. 
Statistical significance was evaluated using the two-sided Student’s t-test (**p< 0,01; n.d.: not 
detectable).  
E. HaCaT-pSLIK-IL31RA clone K14 cells were fixed with 3,8% paraformaldehyde and incubated with 
antibodies specific for IL-20Rα, IL-20Rβ and IL-22Rα and a secondary antibodies coupled to Alexa-
Fluor 488. Cells incubated with the secondary antibodies alone served as a control. The cell surface 
expression was analyzed by flow cytometry. Displayed is one representative experiments of three.  
F. HaCaT-pSLIK-IL31RA clone K14 cells and fibroblasts were grown in an organotypic skin 
equivalent in the presence or absence of rhIL-20 (20ng/ml) and rhIL-24 (20ng/ml). The equivalents 
were harvested at day 7 and stained for differentiation markers as indicated. One representative 
experiment of three is shown.  
G and H. Total RNA was isolated from the organotypic skin equivalents displayed in panel F (G. and 
H.) and from comparable samples of clone K12 and of 3D equivalents of primary NHEKs that were 
grown in the presence or absence of rhIL-20 (20ng/ml) and rhIL-24 (20ng/ml) (H). The expression of 
FLG, INV, ITGB4 and KRT10 was analyzed by RT-qPCR at the time points indicated. Displayed are 
relative expression levels compared to the non-stimulated control (normalized to HPRT expression). 
Displayed are the findings from two experiments with triplicate measurements. 
 
2.5.2 Additional targets of IL-31 
As demonstrated in Fig. 6C, beside IL20 and IL24 several other factors that are 
involved in stress response, cell cycle progression and p38/JNK signaling pathways 
are induced upon IL-31 stimulation in NHEKs. IRF1, DUSP1, JUNB, EGR1 and 
GADD45β were further verified as IL-31 target genes. All genes were rapidly induced 
after IL-31 stimulation in HaCaT-pSLIK-IL31RA clone K12 and K14 cells (Fig. 17A 
and 18A). Both clones showed similar expression patterns with slight differences in 
the expression peaks and later during the time course in silencing of gene expression. 
The specificity of induction was further elucidated by using kinase inhibitors. The 
inhibition of JAK kinases completely blocked the expression of all investigated genes, 
which is consistent with the observations made for IL20 and IL24 expression (Fig. 
17C and 18C). In addition MAPKinase pathway specific inhibitors show differences 
in abrogating the expression of certain IL-31 target genes. The induction of IRF1 
expression, a negative regulator of cell proliferation and a classical target of STAT1 
signaling (Romeo et al., 2002), was significantly repressed only by the inhibitor of 
JAK kinases indicating that the most critical IRF1 activating pathway was indeed 
STAT signaling in HaCaT-pSLIK-IL31RA cells. The same is true for GADD45β, a 
factor involved in stress response especially in myeloid cells (Hoffman and 
Liebermann, 2009). DUSP1, a p38-specific phosphatase that gets activated by p38 
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signaling (Owens and Keyse, 2007), was significantly repressed by p38 and ERK 
pathway specific inhibitors. EGR1, a transcription factor that is involved in the 
regulation of several cellular processes including the suppression of transformation, 
cell growth and apoptosis (Baron et al., 2006; Khachigian and Collins, 1998; Liu et 
al., 1998), was specifically repressed by the ERK specific inhibitor and at least in 
clone K12 cells also by the p38 specific inhibitor (Fig. 17C). Finally JUNB was 
repressed in both clones by JAK inhibition and at least clone 12 showed a significant 
decrease in JUNB expression after inhibition of the ERK and p38 pathways (Fig. 17C 
and 13C). Taking these results together JAK/STAT, p38 and ERK signaling play a 
critical role in early activation of the investigated IL-31 target genes while JNK and 
PI3K signaling do not seem to be relevant.  
2.5.3 JUNB target gene expression is affected by IL-31 signaling 
Prolonged stimulation of IL-31 revealed that especially JUNB expression is constantly 
increased during IL-31 stimulation in both clonesat the mRNA (Fig. 17B and 18B) 
and the protein level (Fig. 19C and 20B). JUNB belongs to the AP-1 family of 
transcription factors that forms heterodimers with other JUN or FOS proteins 
(Shaulian and Karin, 2001, 2002). Another transcription factor of the AP-1 family is 
JUN whose function is antagonized by JUNB (Shaulian and Karin, 2001). In a large 
variety of cells JUNB and JUN are involved in the control of cell cycle progression by 
directly or indirectly altering the expression of cell cycle regulators (summarized in 
Fig. 19A right side of the panel). JUNB directly induces p16 expression, an inhibitor 
of cyclin D1/CDK complexes, and inhibits cyclin D1 expression, an essential cyclin 
for G1-S transition (Bakiri et al., 2000; Shaulian and Karin, 2001). In addition it 
inhibits JUN function probably by forming heterodimers with JUN or by competing 
for JUN binding sites or heterodimerization partners for JUN like FOS (Shaulian and 
Karin, 2002). In contrast to JUNB, JUN inhibits p16 expression and induces cyclin 
D1 expression and thus promotes cell cycle progression (Shaulian and Karin, 2001). 
In addition JUN is directly involved in the expressional control of p21, a cyclin 
dependent kinase inhibitor important to repress cell cycle progression (Dotto, 2000), 
and p53, a transcription factor that promotes cell cycle exit e.g. by activating p21 
expression and furthermore can induce apoptosis (Vogelstein et al., 2000; Vousden, 
2000). By antagonizing JUN function JUNB influences probably also the expression 
of p21 and p53. In differentiating keratinocytes JUNB and JUN act as regulators of 
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differentiation (summarized in Fig 19A left side of the panel). JUNB promotes early 
differentiation and inhibits terminal differentiation while JUN seems to promote 
terminal differentiation processes (Angel et al., 2001) but the mechanisms underlying 
these effects are not fully understood. p21 is a JUN target gene that is probably 
involved in controlling early differentiation but needs to be repressed to enable the 
cells to enter terminal differentiation processes (Di Cunto et al., 1998). Cyclin D1 
needs to be repressed in differentiation for the cells to be able to exit the cell cycle in 
early differentiation and p53 (among other proteins involved in apoptosis pathways 
like Bak, MDM2, and Bcl-2) is important for controlling apoptotic pathways that are 
involved in terminal differentiation as described above. 
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Figure 17. IRF1, DUSP1, JUNB, EGR1 and GADD45β are targets of IL-31 in HaCaT-pSLIK-
IL31RA clone K12 cells                      
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A. and B. HaCaT pSLIK-IL31RA clone K12 cells were pre-treated with dox (1µg/ml) for 16h and 
stimulated with rhIL-31 (100ng/ml) for the indicated time periods. The expression of IRF1, DUSP1, 
JUNB, EGR1 and GADD45β was analyzed by RT-qPCR. Displayed are relative expression levels 
comparing non-stimulated to stimulated cells, normalized to HPRT expression (mean values and 
standard deviations of three biological replicates).  
C. The expression of IRF1, DUSP1, JUNB, EGR1 and GADD45β was analyzed by RT-qPCR in clone 
K12 cells in response to dox (16h), rhIL-31 (1h) or both together. In addition the indicated kinase 
inhibitors (JAK inh. I; 100nM; JNK inh. II, 20µM; SB202190, selective for p38 MAP kinases (20µM); 
U0126, selective for ERK kinases (20µM); Wortmannin, selective for PI3-Kinases (500nM)) were 
added 1h prior to stimulation with rhIL-31. Mean values and standard deviations of 3 independent 
experiments are displayed. Statistical significance was evaluated using the two-sided Student’s t-test. 
(**p< 0,01; n.d.: not detectable)  
 
 
We analyzed the expression of the JUN/JUNB target genes CDKN1A (p21), CDKN2A 
(p16), CCND1 (cyclin D1) and TP53 (p53) in HaCaT-pSLIK-IL31RA clone K12 and 
K14 cells stimulated with rhIL-31 for up to 72h. The expression of CDKN1A was 
increasing constantly on both the mRNA (Fig. 19B and 20A) and protein level (Fig. 
19C and 20B). TP53 and CCND1 expression was repressed by IL-31 at the mRNA 
level (Fig. 19B and 20A), which was also confirmed at the protein level for p53 (Fig. 
19C and 20B). CDKN2A expression was reduced by IL-31 signaling (Fig. 19B and 
20A), an observation that could not be confirmed when the protein was analyzed (Fig. 
19C and 20B). In addition the mRNA obtained from organotypic skin equivalents of 
NHEKs, displayed in Fig. 6A and 6B, was analyzed for the expression of JUN/JUNB 
target genes. While 2, 5, 8 and 14 day old models showed no significant differences in 
CDKN2A and TP53 expression in the presence or absence of rhIL-31, JUNB and 
CDKN1A expression was significantly stimulated at day 2 (Fig. 19D). At later time 
points JUNB expression constantly increased but did not show differences between 
the IL-31 stimulated and non-stimulated control. In contrast the CDKN1A expression 
levels stayed significantly higher at day 8 and day 14 of the model compared to the 
non-stimulated control. Taking together these results suggest that IL-31 induces 
JUNB expression, which subsequently alters the expression of p21, p53, cyclin D1 
and p16 in HaCaT-pSLIK-IL31RA cells. These proteins, probably together with 
additional factors, appear to promote an early-differentiated state of the cells and 
moreover seem to inhibit terminal differentiation. In organotypic models of NHEKs 
the early induction of JUNB expression might cause a constant increase of p21 
expression during the whole differentiation process. It is possible that this deregulated 
p21 expression contributes to the IL-31 phenotype, consistent with the findings that 
pulse stimulation with IL-31 is sufficient to cause a differentiation phenotype (Fig. 
15). 
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Figure 18. IRF1, DUSP1, JUNB, EGR1 and GADD45β are targets of IL-31 in HaCaT-pSLIK-
IL31RA clone K14 cells                   
A. and B. HaCaT pSLIK-IL31RA clone K14 cells were pre-treated with dox (1µg/ml) for 16h and 
stimulated with rhIL-31 (100ng/ml) for the indicated time periods. The expression of IRF1, DUSP1, 
JUNB, EGR1 and GADD45β was analyzed by RT-qPCR. Displayed are relative expression levels 
comparing non-stimulated to stimulated cells, normalized to HPRT expression (mean values and 
standard deviations of three biological replicates).  
C. The expression of IRF1, DUSP1, JUNB, EGR1 and GADD45β was analyzed by RT-qPCR in clone 
K14 cells in response to dox (16h), rhIL-31 (1h) or both together. In addition the indicated kinase 
inhibitors (JAK inh. I; 100nM; JNK inh. II, 20µM; SB202190, selective for p38 MAP kinases (20µM); 
U0126, selective for ERK kinases (20µM); Wortmannin, selective for PI3-Kinases (500nM)) were 
added 1h prior to stimulation with rhIL-31. Mean values and standard deviations of 3 independent 
experiments are displayed. Statistical significance was evaluated using the two-sided Student’s t-test. 
(**p< 0,01; n.d.: not detectable)  
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Figure 19. JUNB target gene expression is affected by IL-31 signaling in HaCaT pSLIK-IL31RA 
clone K14 cells                     
A. Scheme of the JUN-JUNB network controlling cell cycle progression (blue site) and skin 
differentiation (purple site). JUN and JUNB antagonize each other in their function in cell cycle 
progression leading to alterations in p16, CyclinD1, p21 and p53 expression. JUN and JUNB belong to 
the AP-1 family of transcription factors that form heterodimers and bind DNA. JUN can form dimers 
with FOS, which then promote cell cycle progression. JUNB forms dimers with FOS, FRA-1 and also 
with JUN, which then antagonizes the pro-proliferative functions of JUN. In skin differentiation both 
proteins have additional functions that are not well characterized. While JUNB promotes early 
differentiation and inhibits late differentiation, JUN is described as a promoter of late differentiation by 
direct activation of differentiation related genes or indirectly by controlling p21 and p53 expression. In 
addition apoptosis related factors like MDM2, Bak and Bcl-2 or matrix proteins like β1-integrin are 
important mediators in the transition from early to late differentiation, that might be controlled by JUN 
and JUNB.  
B. HaCaT-pSLIK-IL31RA clone K14 cells were pre-treated with dox (1µg/ml) for 16h and stimulated 
with rhIL-31 (100ng/ml) for the indicated time periods. The expression of CDKN1A, CDKN2A, TP53 
and CCND1 was analyzed by RT-qPCR. Displayed are relative expression levels comparing non-
stimulated to stimulated cells, normalized to HPRT expression (mean values and standard deviations of 
three biological replicates).  
C. JUNB, p21, p53 and p16 protein expression was analyzed in lysates of cells treated with dox 
(1µg/ml) and rhIL-31 (100ng/ml) for 0, 24, 48 or 72h by western blotting. Tubulin served as loading 
control.  
D. Total mRNA obtained from organotypic skin equivalents described in Fig. 6B was analyzed for 
JUNB, CDKN1A, CDKN2A and TP53 expression by RT-qPCR. Displayed are relative expression 
levels compared to the non-stimulated day2 sample normalized to HPRT expression. 
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Figure 20. JUNB target gene expression is affected by IL-31 signaling in HaCaT-pSLIK-IL31RA 
clone K12 cells                     
A. HaCaT-pSLIK-IL31RA clone K12 cells were pre-treated with dox (1µg/ml) for 16h and stimulated 
with IL-31 (100ng/ml) for the indicated time periods. The expression of CDKN1A, CDKN2A, TP53 and 
CCND1 was analyzed by RT-qPCR. Displayed are relative expression levels comparing non-stimulated 
to stimulated cells, normalized to HPRT expression (mean values and standard deviations of three 
biological replicates).  
B. JUNB, p21, p53 and p16 protein expression was analyzed in lysates of clone K12 cells treated with 
dox (1µg/ml) and rhIL-31 (100ng/ml) for 0, 24, 48 or 72h by western blotting. Tubulin served as 
loading control. 
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3 Discussion 
3.1 Involvement of IL-31 in the inflammatory processes of atopic 
dermatitis 
 
AD is characterized by the deregulation of a number of cytokines that are postulated 
to participate in the disease progression (Carmi-Levy et al., 2011) One of the TH2 
effector cytokines implicated in AD is IL-31, in addition to a number of other 
cytokines including IL-4 and IL-13. IL-31 is also produced by monocytes, dendritic 
cells and mast cells (Ishii et al., 2009; Niyonsaba et al., 2010). UV and reactive 
oxygen species strongly enhance the expression of IL-31 in at least some of these 
cells that have the capacity to infiltrate human skin or are resident skin cells 
(Cornelissen et al., 2011). From these observations an important role of IL-31 in AD 
pathology has been postulated. While several cell types in the skin are capable to 
synthesize IL-31, as described in the introduction, the target cells and the 
physiological consequences on these cells are less well described. Keratinocytes 
express the IL-31RA and OSMR receptor subunits, the expression of the former can 
be further stimulated with pro-inflammatory cytokines including IFNγ (Fig. 7A, B and 
C) (Heise et al., 2009) suggesting that keratinocytes are responsive to IL-31. Another 
relevant cell type found in lesions of AD patients are eosinophils, which express the 
IL-31 receptor (Cheung et al., 2010). IL-31 stimulates the secretion of a number of 
different pro-inflammatory cytokines and chemokines by eosinophils. Together these 
findings suggest that IL-31 has broad pro-inflammatory effects in the skin and thus 
IL-31 is a valid candidate to contribute to the development of AD pathology. 
 
Human mast cells play an important role in allergic disorders and are an additional 
source of IL-31 (Abraham and St John, 2010; Yamaoka et al., 2009). Mast cells are 
localized in tissues that are in contact with the environment such as the skin, where 
mast cells play an important role in pathogen surveillance and innate immunity. 
Recent findings suggest that anti-IgE treatment and stimulation with antimicrobial 
peptides such as human β-defensins (hBD) and cathelicidin LL-37 induce IL-31 
expression and secretion in mast cells (Niyonsaba et al., 2010). These peptides, 
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important components of innate immunity, are secreted from monocytes and 
keratinocytes upon stimulation by bacteria and pro-inflammatory cytokines (Abraham 
and St John, 2010). Moreover CD4+ T-cells, especially TH2 cells, express the 
histamine H4 receptor, which is upregulated upon IL-4 treatment. Stimulation with a 
histamine agonist results in the activation of IL31 mRNA expression in these T cells 
(Gutzmer et al., 2009). Together these findings further support a role of IL-31 in AD. 
A possible scenario is that the reduced skin barrier formation observed in AD patients 
allows the activation of monocytes and mast cells during infection and by allergens 
stimulating IL-31 production. Increasing amounts of this cytokine will then further 
impair proper differentiation of keratinocytes, thereby worsening the skin lesions. In 
addition the findings summarized above provide a direct link of histamine secretion 
and IL-31 function in allergic reactions. 
 
Another important aspect of AD is the development of pruritus. Enhanced expression 
of IL-31RA was discovered in cells of the human and murine dorsal root ganglia and 
in murine primary afferent fibers of the spinal cord and dermis that are proposed to be 
involved in the sensation of itch (Bando et al., 2006; Sonkoly et al., 2006). These 
cells, comparable to most cells, express the OSMR. A putative functional role of IL-
31 in induction of pruritus in patients with AD was suggested. These findings are 
supported by studies in an atopic dermatitis-like murine model (NC/Nga mice) 
revealing an association between high IL-31 mRNA expression and itch-associated 
scratching behavior (Takaoka et al., 2006). Although a direct correlation of itch 
sensation and IL-31 in AD patients is missing, Ishii et al. demonstrated a correlation 
of pruritus with IL-31 serum level and the number of mast cells in patients suffering 
from Philadelphia chromosome-negative myeloproliferative neoplasms (Ishii et al., 
2009). Moreover significantly enhanced expression of IL-31 was detected in skin and 
serum samples of patients with AD (Neis et al., 2006) correlating with the severity of 
AD (Ezzat et al., 2011).  
 
Finally it is worth noting that genetic predispositions associated with the IL31 locus 
appear to influence the pathogenesis of AD. Three different haplotypes of single 
nucleotide polymorphisms (SNP) in the IL31 gene and promoter were identified 
(Schulz et al., 2007). One of these is significantly associated with non-IgE-mediated 
AD. PBMCs of healthy individuals of this risk-haplotype responded with a stronger 
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induction of IL31 expression in response to CD3/CD28-mediated stimulation 
compared to the other haplotypes. This study provides additional evidence for a 
determining role of IL-31 in AD.  
 
A critical role of IL-31 in skin was also seen in a mouse model, in which IL-31 was 
overexpressed. These mice developed severe pruritus with alopecia and skin lesions 
that were characterized by hyperkeratosis, acanthosis, inflammatory cell infiltration 
and an increase in mast cells (Dillon et al., 2004). These studies also highlight the role 
of infiltrating monocytes and mast cells, consistent with the findings in human cells.  
 
3.2 IL-31 regulates epidermal differentiation 
 
3.2.1 The anti-proliferative function of IL-31 
Beside its potential role in inflammatory processes it was observed in the studies 
presented here that IL-31 inhibited proliferation and deregulated differentiation in 
both primary NHEKs and in two different HaCaT cell clones conditionally expressing 
the IL-31RA receptor subunit (Figs. 6, 10, 13, 14 and 15). The effect of IL-31 on 
proliferation are consistent with the observations that this cytokine interferes with the 
proliferation of lung epithelial cells and of the colon carcinoma cell line HCT116 
(Chattopadhyay et al., 2007; Dambacher et al., 2007). In lung epithelial cells IL-31 
represses different cell cycle regulators, including cyclin B1 and CDK1, and 
stimulates the expression of p27, a negative regulator of cyclin/CDK complexes 
relevant for the transition from G1 into S phase and progression through S phase of 
cells. These findings are somewhat unexpected since IL-31 stimulates in different cell 
types several signaling pathways, i.e. the RAS/ERK, the PI3K/AKT, and the 
JAK/STAT pathway, all of which are rather pro-proliferative (Dillon et al., 2004; 
Diveu et al., 2004; Dreuw et al., 2004; Ip et al., 2007; Kasraie et al., 2011). At present 
it is not clear whether the combination of pathways or as yet not described signaling 
pathways are key to understand the anti-proliferative phenotype of IL-31. 
Furthermore an IL-31 effect on cell cycle progression is only reported for a very 
limited number of cell types indicating a cell type specific effect of IL-31. It is also 
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not excluded that downstream effectors of IL-31 signaling function as inhibitors of 
proliferation. In fact my studies revealed an effect of IL-31 on the expression of 
JUNB, Cyclin D1, p21 and p53 that have all been described to affect cell 
proliferation. The impact of IL-31 on these genes and their involvement in 
keratinocyte proliferation and differentiation is discussed further below. 
3.2.2 IL-31 stabilizes β4-integrin in keratinocyte differentiation 
My findings suggest that IL-31 interferes with the proper differentiation of 
keratinocytes. Marker proteins for various differentiation steps of the epidermis 
(described in the introduction) were investigated. IL-31 interferes with the expression 
of the late differentiation markers filaggrin and to a lesser extent involucrin. Also the 
marker of the spinouse layer, K10 is reduced and β4-integrin, which needs to be 
down-regulated during differentiation to enable the cells to detach from the basal 
membrane, seems to be distributed throughout the whole cellular layer. Differences in 
β4-integrin mRNA level could only be observed early in the NHEK 3D models (Fig. 
6B, day2) but no differences were present at day 7 of the HaCaT-pSLIK-IL31RA 
models (Fig. 15B). The missing differences on mRNA expression in the 3D models 
are probably due to the presence of cells in many different stages of differentiation 
within the models and/or the result of translational or post-translational regulation of 
β4-integrin expression by IL-31. Nevertheless the difference in β4-integrin expression 
is clearly visible in the immunofluorescence stainings of the 3D models (Figs. 6A, 
14B and 15A). 
 
β4-integrin is located in the basal cellular layer and forms a heterodimeric complex 
with α6-integrin. It is essential for the attachment of cells in the basal layer to the 
basal membrane because mutations or depletion of β4-integrin leads to severe 
blistering of the skin in mice and humans associated with a high mortality rate in both 
(Ashton et al., 2001; Murgia et al., 1998; Nakano, 2004). It is exclusively located at 
hemidesmosomes where it binds laminin-5 (also called laminin-332) at the cell 
surface and hereby connecting the extracellular matrix to the intracellular 
cytoskeleton and stabilizing the interaction of the cells with the basal membrane. It 
connects the intermediate filaments in the cytosol through the cytoskeleton linker 
protein plectin (Margadant et al., 2010). The lack of β4-integrin also destabilizes α6-
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integrin and leads to a failure in forming hemidesmosomes (Dowling et al., 1996; van 
der Neut et al., 1996). Beside its essential role in keratinocyte adhesion other 
functions of β4-integrin, including the regulation of the cell cycle and later 
differentiation steps are rather controversial because most mouse models with β4- or 
α6-integrin depletion or expression of modified proteins demonstrate no or only minor 
differences in epidermal differentiation (Margadant et al., 2010).  
 
Nevertheless an extensive crosstalk of β4-integrin with growth factor dependent 
signaling pathways has been reported in tumors and cancer cell lines. The current 
opinion is that in normal epithelia β4-integrin, located in hemidesmosomes of cells in 
the basal layer, does not come in contact with proteins exhibiting signaling capacity. 
Detachment of cells from the basal membrane leads to disappearance of the 
hemidesmosomes and thus re-distribution of β4-integrin over the whole cell surface if 
it is not down-regulated. This leads to the association with receptor tyrosine kinases, 
which frequently seems to happen in tumor development also with other types of 
integrins (Guo and Giancotti, 2004).  
 
The cytoplasmic tail of β4-integrin is phosphorylated following stimulation with 
hepatocyte growth factor (HGF), macrophage-stimulating protein (MSP) or epidermal 
growth factor (EGF) in different carcinoma models and might form a complex with 
the corresponding receptors to amplify and/or alter their signaling capacity 
(Margadant et al., 2010; Wilhelmsen et al., 2006). The biological consequences of β4-
integrin, not associated with hemidesmosomes, range from tumor promotion to 
inhibition and seem to depend on the tumor type and genetic background of the 
tumor. For example in the presence of functional p53 α6β4-integrin stimulates 
apoptosis by stimulating caspase-3-dependent AKT/PKB kinase cleavage, while it 
promotes survival AKT/PKB signaling dependent on a p53 negative background 
(Bachelder et al., 1999; Clarke et al., 1995). Human keratinocytes lacking α6β4-
integrin are resistant to transformation mediated by oncogenic RAS or blocking of 
NF-κB signaling (Dajee et al., 2003), indicating its influence on both signaling 
pathways. Furthermore tumor growth in isolated p53 and Smad4 deficient mouse 
tumor-initiating cells (mTICs) is inhibited by α6β4-integrin, which depends on its 
ability to bind intracellular plectin (Raymond et al., 2007), a linker-protein to the 
cytoskeleton that is able to activate signaling pathways, like PKC and RHO family 
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GTPases. In contrast addition of oncogenic RAS into these cells changes the tumor 
inhibiting function of α6β4-integrin to a tumor promoting function, which is probably 
due to further enhanced RAS signaling (Raymond et al., 2007). One central molecule 
in β4-integrin mediated signaling seems to be the PI3-Kinase. In breast carcinoma cell 
lines α6β4-integrin cooperates with ErbB2, a receptor of the EGFR family, in 
activating PI3-K signaling and enhancing tumor progression (Mercurio et al., 2001). 
These and more examples demonstrate that β4-integrin can have broad effects on 
internal signaling pathways (Oldak et al., 2006). 
 
Hemidesmosome free β4-integrin could significantly change signaling pathways 
activated by growth factors that are essential for a proper keratinocyte differentiation. 
In organotypic cultures the presence of fibroblasts as feeder cells is needed. They 
secret e.g. EGF that promotes the proliferative state of the basal epidermal layer, 
which is essential for the development of organotypic cultures and the epidermis in 
vivo (Kern et al., 2011; Pastore et al., 2008). Broad effects of β4-integrin on different 
cell types are reported but the role of IL-31 induced stabilization of β4-integrin in the 
examined organotypic co-cultures remains an open question. In addition a 
physiological role for β4-integrin in non-transformed cells, tissues and organs in vivo, 
beside its essential function in attaching cells to a basal membrane, has not been 
reported. If IL-31 mediated stabilization of β4-integrin has physiological 
consequences has to be clarified in the future. 
3.2.3 Inhibition of terminal differentiation markers by IL-31 
The studies presented here demonstrate that K10, involucrin and filaggrin expression 
is negatively affected by IL-31 signaling. The morphological changes in keratinocyte 
differentiation and the expressional changes of differentiation markers are well 
described in the literature (as summarized in the introduction). Although the 
molecular changes in signaling events occurring during differentiation are less well 
understood, several secreted factors and signaling pathways are identified, e.g. leading 
to the activation of important transcription factors, that positively or negatively 
influence the differentiation process. However missing are direct links of signaling 
events to the molecular changes at e.g. promoters of differentiation markers leading to 
changes in gene transcription. A large number of terminal differentiation markers 
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including involucrin and filaggrin are located in an approximately 2 MB large gene 
cluster (termed the Epidermal Differentiation Cluster (EDC)) on chromosome 1q21 
(Hoffjan and Stemmler, 2007). This cluster includes more than 50 genes all being 
regulated exclusively during epidermal differentiation. A similar genomic 
organization is true for keratins. Type 1 keratins are located in two clusters on 
chromosome 17 (17p11-12 and 17q11-13), type II keratins including K10 are located 
in a single cluster on chromosome 12 (12q11-13) (Bowden, 2005). These 
observations allow the hypothesis that epigenetic remodeling of chromatin might be 
the most important factor and that IL-31 might interfere with epigenetic mechanisms 
that normally lead to the expression of K10, involucrin and filaggrin during 
differentiation. But this hypothesis has not been verified yet. 
 
Nevertheless IL-31 is able to activate signaling pathways and transcription factors that 
might influence differentiation marker expression after chromatin remodeling 
including MAPkinases, JAK/STAT signaling and the PI3-K/AKT pathway.  
 
There is very little information available about the direct transcriptional regulation of 
K10 beside the observation that keratin 10 expression seems to be regulated by a 
p63/Notch-dependent mechanism. At the transition from the basal cell layer to the 
spinous layer the expression of the basal keratins K5 and K14 is switched off and 
K1/K10 expression is induced. This switch is regulated by p63/Notch. p63 promotes 
K5/K14 expression and inhibits the induction of differentiation, which is counteracted 
by Notch signaling that promotes K1/K10 expression (Koster, 2010; Lefort and Dotto, 
2004; Watt et al., 2008). If or how IL-31 might influence p63/Notch signaling has not 
been determined but is one central future question since my results indicate that IL-31 
might interfere with early differentiation steps that are mainly controlled by 
p63/Notch and their downstream signaling cascades. 
 
The regulation of involucrin is described a bit more extensively. The involucrin 
promoter harbors a distal- (DRR) and a proximal-regulatory region (PRR) that are 
essential for optimal promoter activity. Both elements have well defined AP-1 binding 
sites, recruiting JUNB, JUND and Fra-1 in a keratinocyte specific manner (Welter et 
al., 1995), which is essential for promoter activation (Crish et al., 2002). Separated 
from these AP-1 sites, an additional SP-1 site is present in the DRR that contributes to 
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promoter activity (Banks et al., 1998). Addition of extracellular calcium activates the 
INV promoter dependent on the action of PKC (Deucher et al., 2002; Ng et al., 2000). 
The PRR contains an additional C/EBP binding site that also contributes to promoter 
activation while the intensity of activation seems to depend on the composition of 
C/EBP proteins in the cell (Agarwal et al., 1999). p38 is the main MAPkinase that 
controls involucrin expression by regulating AP-1, SP-1 and C/EBP factors (Agarwal 
et al., 1999; Banks et al., 1998; Efimova et al., 1998). In addition efficient activation 
of involucrin expression requires repression of ERK1/2 (Efimova et al., 2003; 
Efimova et al., 2002). How IL-31 might directly affect involucrin expression or 
eventually indirectly by activating the expression of certain transcription factors like 
JUNB, remains to be determined. 
 
Filaggrin is one of the most important proteins in formation of the skin barrier. Loss-
of-function mutations in FLG cause ichthyosis vulgaris (Sandilands et al., 2007; 
Weidinger et al., 2007). Filaggrin is essential for the formation of the stratum 
corneum and for skin barrier function (Mildner et al., 2010; Sandilands et al., 2009). 
Considering that FLG mutations are frequent in the general Western population, the 
enhanced expression of IL-31 with the here-described consequence on filaggrin 
suggests that IL-31 has the capacity to aggravate AD pathology and to further weaken 
skin barrier function. The IL-31 pulse experiments that was performed suggest that 
FLG is not a direct target of IL-31-induced signaling pathways (Fig. 15). Although 
the FLG promoter has not been studied in great detail, the AP-1 family of 
transcriptional regulators, POU-domain transcription factors, and p63 have been 
implicated in controlling FLG expression (Candi et al., 2006; Jang et al., 2000; Jang et 
al., 1996). Moreover AP-1 factors have been demonstrated to regulate different 
aspects of skin differentiation (Angel et al., 2001). Recently several signaling 
pathways have been proposed to be implicated in FLG regulation. Ca2+ signaling in 
the transition from the spinous to the granular cell layer induces filaggrin expression 
via PKC signaling, the Ca2+ sensing receptor and Dlx3 (Koster and Roop, 2007). A 
recent publication demonstrated that TNF-α expression in psoriasis patients correlates 
with reduced filaggrin and loricrin expression and an activation of the JUN N-
terminal kinase-dependent pathway (Kim et al., 2011). Another recent publication 
revealed a potential role of NFκ-B signaling on filaggrin expression in HaCaT 
keratinocytes. Overexpression of S100A8 and A9 (both parts of the EDC) increases 
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NFκ-B activation leading to increased expression of involucrin and filaggrin (Voss et 
al., 2011). NFκ-B and components of the NFκ-B system have been demonstrated to 
be important mediators in epidermal homeostasis especially in the regulation of the 
“apoptotic keratinocyte differentiation program” (Lippens et al., 2005). IL-31 can 
activate the expression of AP-1 transcription factors (JUNB and FOS) but 
implications of IL-31 in other pathways that have been demonstrated to regulate 
filaggrin expression have not been published. Since IL-31 activates typical receptor 
tyrosine kinase pathways and FLG is not an early target of IL-31 stimulation and only 
expressed in late differentiation it is most likely an indirect IL-31 target gene.  
 
Taking together these results suggests that IL-31 stimulation promotes early 
differentiation steps but inhibits the transition of cells towards terminal 
differentiation. This leads to weakening of the skin barrier, a typical symptom of AD, 
giving IL-31 the potential to aggravate AD pathology. This hypothesis is supported by 
the findings that the basal differentiation marker β4-integrin is not restricted to the 
basal cellular layer and the expression of the early differentiation marker of the 
stratum spinosum, keratin 10 as well as the expression of the terminal markers 
involucrin and filaggrin are all affected by IL-31. In addition basal cells exit the cell 
cycle and accumulate in G1 phase indicating an induction of differentiation. 
Furthermore the IL-31 induced phenotype is most likely indirect but IL-31 induces a 
persistent IL-31 specific differentiation process already after short stimulation times 
demonstrated by IL-31 pulse stimulation. The IL-31 phenotype in organotypic models 
of NHEKs is present predominantly in early stages of the models (day 2 and day 5). 
Older models seem to recover since no or only minor differences were present. This is 
probably due to the down-regulation of the IL-31RA rapidly after initiation of 
differentiation as demonstrated by Heise et al. 2009. The HaCaT cell clones stably 
express the IL-31RA after dox induction and thus do not loose their IL-31 
responsiveness. 
 
3.3 IL-20 and IL-24 in IL-31 mediated defects in skin differentiation 
 
In order to identify factors that are involved in the IL-31 phenotype the potential of 
IL-20 and IL-24 to influence keratinocyte differentiation was investigated. Both are 
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early IL-31 target genes (Figs. 6C, 6E and 16A) and their mRNA expression 
constantly increases over time in IL-31 stimulated HaCaT-IL-31RA clones (Fig. 
16B). In 3D models IL20 and IL24 expression is already affected after an IL-31 pulse 
stimulation (Fig. 16C). IL-20 and IL-24 do affect the expression of the late 
differentiation markers filaggrin and involucrin in NHEK and HaCaT 3D models 
while keratin 10 was not affected (Fig. 16F-H). 
 
IL-20 has been discussed to be one of the key players by the pathology of psoriasis. 
Overexpression of IL-20 in transgenic mice is neonatal lethal caused by a psoriasis-
like skin phenotype including hyperkeratosis, thickened epidermis and aberrant 
epidermal differentiation. This includes the overexpression of basal epidermal layer 
markers in suprabasal keratinocytes (K5 and K14) and the weakening of the barrier 
formation although the expression of filaggrin and loricrin are not altered. Taken 
together this leads to the assumption that IL-20 mainly affects the differentiation of 
early-differentiated cell layers (Blumberg et al., 2001). Keratinocytes from psoriatic 
lesions demonstrate an increased expression of IL-20 and IL-20 receptor components 
accompanied by an elevated STAT3 activation, a major signaling pathway activated 
by IL-20 (Blumberg et al., 2001; Wei et al., 2005). Moreover easing psoriasis 
symptoms by successful therapy correlates with a reduced cutaneous IL-20 level 
(Ogilvie et al., 2006; Otkjaer et al., 2005). But in contrast to AD, psoriasis is thought 
to be a disease mediated by TH1 type cytokines with increased expression of IL-2, IL-
6, IL-8, IL-12, INF-γ and TNF-α (Asadullah et al., 1999) and thus until today IL-20 
was not proposed to play a role in TH2 mediated skin diseases. This is supported by 
the findings that other TH1 mediated diseases like rheumatoid arthritis (Hsu et al., 
2006) and atherosclerosis (Hsieh et al., 2006) also exhibit elevated IL-20 levels. Main 
sources of IL-20 are monocytes, keratinocytes and endothelial cells while other cells 
of the immune system do not express IL-20 (Chen et al., 2006; Kunz et al., 2006; 
Wolk et al., 2002). The mechanisms how IL-20 might influence skin differentiation in 
psoriasis are largely unknown. It has been demonstrated that mice expressing a 
constitutively active STAT3-variant develop a psoriasis-like phenotype (Sano et al., 
2005) but if this is also the main signaling pathway activated by IL-20 leading to this 
phenotype remains open. Neither resting nor activated immune cell populations 
express the IL-20 receptor chains and thus are not able to respond to IL-20 (Kunz et 
al., 2006; Wolk et al., 2002; Wolk et al., 2004; Wolk et al., 2005). The current opinion 
Discussion   
 
 92 
is that the pro-inflammatory potential of IL-20 is mainly directed against 
keratinocytes and thus it was hypothesized that IL-31-induced IL-20 expression 
contributes to the IL-31 phenotype, although the pathology of psoriasis is clearly 
distinct from the AD like-phenotype that was observed in my studies. Recent studies 
demonstrated that maturated dendritic cells, derived by TNF-α/IL-1β stimulation of 
monocytes, induce IL-20 expression giving a potential link to innate immunity (Wolk 
et al., 2008). In addition IL-20 stimulated keratinocytes increased the sensitivity of the 
cells to Toll-like receptor 2 and 3 ligands leading to increased IL-8 expression. 
Furthermore IL-20 induced human β defensin-2 expression supporting a role for IL-
20 in innate immunity. These observations are in agreement with the potential role of 
IL-31 in innate immunity as described in the introduction. 
 
How IL-31 exactly regulates IL20 expression remains to be determined. IL-1β 
induced IL-20 expression in keratinocytes depends on the p38 MAPkinase pathway 
and NFκ-B signaling (Otkjaer et al., 2007). The authors proposed a model indicating a 
transactivation of NFκ-B signaling by p38 activated MSK-1 leading to IL20 
expression. Figure 11D demonstrates the importance of p38 MAPkinase signaling for 
IL-31 stimulated IL20 expression. However the activation of NFκ-B by IL-31 has not 
been tested but will be an aspect for future studies.  
 
IL-24 was originally identified as a tumor suppressor (melanoma differentiation 
associated gene 7: MDA-7). Adenoviral overexpression in various tumor cells leads to 
the inhibition of tumor growth (Dash et al., 2010; Jiang et al., 1995). Surprisingly the 
physiological und patho-physiological function of IL-24 is largely unknown. Recent 
studies describe very similar functions in psoriasis and psoriatic skin compared to IL-
20. An IL-24 transgenic mouse develops a similar psoriasis-like skin (He and Liang, 
2010), psoriasis lesions (Kunz et al., 2006; Romer et al., 2003) and rheumatoid 
arthritis, comparable to the phenotype seen in humans (Kragstrup et al., 2008), 
attended by elevated IL-24 levels. Main sources of IL-24 are monocytes, T-cells 
(Wolk et al., 2002) and keratinocytes (Kunz et al., 2006; Tohyama et al., 2009). 
Furthermore IL-4 is able to induce IL-24 expression in keratinocytes (Kunz et al., 
2006) and IL-24 signals through the same receptor complexes as IL-20 (Sabat, 2010), 
supporting the assumption of similar target cells and functions. As mentioned, besides 
its role in skin diseases, IL-24 (together with its family members IL-19 and IL-20) is 
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also thought to be involved in immune-mediated diseases like rheumatoid arthritis. It 
may induce the production of IL-6 and some other chemokines and aggravate the 
inflammatory process by attracting neutrophilic granulocytes (Hsu et al., 2006; 
Sakurai et al., 2008). Although little is known about IL-24 function the available 
information indicates a similar role as IL-20 in inflammatory skin diseases and thus 
IL-31 induced IL-24 expression might cooperate with IL-31 and IL-20 in altering 
keratinocyte differentiation. Indeed IL-20 and IL-24 have a similar influence on 
keratinocyte differentiation like IL-31 but to a much weaker extent (Figs. 11F and G). 
One report comparing the expression of IL-20 and IL-24 in psoriatic and AD lesions 
demonstrates that both skin diseases have similarly increased cytokine levels (Kunz et 
al., 2006) although both diseases have a quite different pathology concerning the 
defects in the skin differentiation and the involved inflammatory cytokines. This 
indicates that probably the inflammatory environment independently of the disease 
itself leads to induction of IL-20 and IL-24 in the skin and thus stimulates functions in 
the inflammatory process that are distinct from their role in epidermal differentiation. 
Since IL-20 and IL-24 expression has only minor effects on keratinocyte 
differentiation compared to IL-31, the IL-31 mediated expression of IL-20 and IL-24 
might have another function distinct from epidermal differentiation and thus the IL-31 
induced defects in skin barrier formation are directly mediated most likely by IL-31 
induced signaling pathways and expressional changes of IL-31 target genes that are 
not secreted.  
 
While IL-20 and IL-24, as direct targets of IL-31, contribute to the IL-31 
differentiation phenotype, the array data indicate that different AP-1 family members, 
i.e. FOS and JUNB, as well as genes that code for components of MAPKinase 
signaling pathway are also targets of IL-31. This suggests that these genes will also 
contribute to altered differentiation of keratinocytes and disregulated filaggrin 
expression and differentiation. 
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3.4 JUNB in keratinocyte differentiation and involvement in the IL-
31 phenotype 
 
3.4.1 The JUN-JUNB network in cell cycle arrest and epidermal differentiation 
We identified JUNB as an early target gene of IL-31 signaling in keratinocytes that is 
induced on the mRNA (Fig. 6C, Fig. 17 and Fig. 18) and protein level (Fig. 19C, Fig. 
20B). JUNB belongs to the group of JUN proteins (like JUN and JUND) that are part 
of the AP-1 family of transcription factors. Further members of this family are FOS 
(FOS, FOSB, FRA-1, FRA-2), ATF (ATFa, ATF2, ATF3), JDF (JDF-1 and JDF-2) 
and MAF (c-MAF, MAFB, MAFA, MAFG/F/K, NRL) proteins (Shaulian, 2010). All 
AP-1 proteins form homo- or heterodimers and function as transcription factors by 
binding to DNA via their basic region-leucine zipper motif (Angel and Karin, 1991; 
Karin, 1995). JUN proteins, dimerized with FOS proteins, bind DNA elements known 
as TREs (phorpol 12-O-tetradeconate-13-acetate (TPA) response element) (Angel et 
al., 1987) to regulate gene expression. ATF homodimers or JUN/ATF heterodimers 
bind cAMP responsive elements (CREs) (Ryseck and Bravo, 1991). AP-1 
transcription factors regulate various cellular processes including cell growth, cell 
cycle progression, apoptosis and transformation. JUN gets activated by growth 
factors, pro-inflammatory cytokines and UV irradiation (Karin, 1995). Growth factors 
induce the activation of the ERK MAPkinase pathway leading to FOS gene 
expression and heterodimerization with JUN. This leads to a further increase in JUN 
transcription (Angel et al., 1988). Cytokine and UV mediated activation of AP-1 
factors mainly depends on the activation of the JNK and p38 MAP kinase pathways 
(Karin, 1995). A large number of reports demonstrate that JUN proteins are involved 
in cell cycle progression and transformation in a wide range of different cell types 
(Hess et al., 2004; Shaulian, 2010; Shaulian and Karin, 2001, 2002).  
 
JUN is the most extensively studied member of the AP-1 family and in general 
promotes cell cycle progression especially in situations of cellular stress. In this 
context one target gene of JUN is Cyclin D1 (CCND1) that binds CDK4 and promotes 
G1-S phase transition (Sherr, 1996). This is consistent with the findings that JUN is 
essential for G1-S transition (Schreiber et al., 1999; Smith and Prochownik, 1992). 
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But Cyclin D1 contributes only partially to the cell cycle-promoting effects of JUN 
(Wisdom et al., 1999). Activated JUN directly represses p53 expression (Schreiber et 
al., 1999; Shaulian et al., 2000), a negative regulator of cell proliferation (Vogelstein 
et al., 2000; Vousden, 2000), which subsequently also represses the expression of the 
p53 target gene p21. p21 belongs to the family of cyclin-dependent kinase inhibitors 
that inhibit the activity of Cyclin/CDK complexes (Dotto, 2000) and thus results in 
cell cycle arrest. In fact in UV dependent cell cycle arrest the repression of p21 seems 
to be the most important function of JUN induction to allow reentering into the cell 
cycle (Shaulian et al., 2000). In addition p16, another member of the CDK inhibitor 
family, is repressed by JUN at least in transient transfection experiments (Passegue 
and Wagner, 2000).  
 
JUNB directly antagonizes JUN functions (Passegué et al., 2002). It represses Cyclin 
D1 expression (Bakiri et al., 2000) and induces p16 expression (Passegue and 
Wagner, 2000), while its absence leads to down-regulation of p16 and increased JUN 
levels (Passegue et al., 2001). Notably replacement of JUN in JUN deficient MEFs by 
a JUNB transgene abrogates anti-proliferative effects of JUNB and rescues a 
deregulated Cyclin D1, p53 and p21 expression (Passegué et al., 2002). This indicates 
that anti-proliferative effects of JUNB depend on the presence of JUN probably by 
forming a growth inhibitory JUN/JUNB heterodimer. Nevertheless JUNB exhibits a 
much weaker dimerization affinity with other AP-1 family members and a much 
weaker DNA binding activity due to changes in the amino acid sequence within the 
bZIP region compared to JUN (Deng and Karin, 1993; Mechta-Grigoriou et al., 
2001). These findings allow to postulate that JUN and JUNB differ considerably in 
the target genes they regulate and in their capacity to control expression. In fact JUNB 
activates efficiently only those target genes which harbor multiple AP-1 binding sites 
but can block effectively the expression of JUN target genes with only one AP-1 
binding site by either competing with JUN for binding sites or maybe forming 
repressive JUN/JUNB heterodimers (Zenz and Wagner, 2006).  
 
Beside the general role of JUN proteins in cell cycle progression, they play an 
important role in keratinocyte differentiation and wound healing. Studies in mouse 
and human epidermis revealed a differential expression of AP-1 proteins throughout 
differentiated skin (Angel et al., 2001). While JUNB is highly expressed in the 
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basement membrane and the early to mid-differentiated keratinocytes of the stratum 
spinosum and the stratum granulosum, JUN is hardly detectable in basal and early 
differentiating keratinocytes while it is highly expressed in the stratum granulosum 
(Angel et al., 2001). In addition also other members of the AP-1 family are expressed 
dependent on the differentiation state indicating that certain sets of AP-1 factors are 
associated with the differentiation status of keratinocytes (Angel et al., 2001; Eckert 
and Welter, 1996). The differing expression pattern of JUN family members indicates 
that the JUN-JUNB antagonizing function on cell proliferation might be less 
important in differentiating keratinocytes and that JUN proteins contribute also 
directly to keratinocyte differentiation. Several AP-1 target genes encoding critical 
markers in epidermal differentiation have been identified. A large number of keratins 
(including K5, K6, K8, K14, K18 and K19) and transglutaminases are potential AP-1 
target genes (Eckert and Welter, 1996; Hu and Gudas, 1994; Navarro et al., 1995). 
K14 and K18 expression depend on their AP-1 binding sites (Rhodes and Oshima, 
1998; Sinha et al., 2000), high basal profilaggrin expression in late differentiated 
keratinocytes depends on JUN/FOS dimers (Jang et al., 1996), involucrin 
transcription is regulated by AP-1 and SP-1 (Lopez-Bayghen et al., 1996) and JUND, 
Fra-1 and Fra-2, which are regulated by intracellular calcium concentration, bind 
calcium response elements in the involucrin promoter (Ng et al., 2000). Furthermore 
JUNB, JUND and Fra-1 seem to be responsible for involucrin regulation by phorbol 
ester (Welter et al., 1995). Furthermore co-transfection experiments indicate that 
JUNB/FOS dimers are involved in the differentiation-specific expression of loricrin 
(DiSepio et al., 1999) and AP-1 and ETS proteins regulate K14 expression (Sinha et 
al., 2000). Recently it was reported that JUNB/Fra-1 dimers bind the ß4-integrin 
promoter and activate its transcription (Oldak et al., 2010). Finally several 
differentiation-induced pathways including the MAP kinase and PKC pathway are 
involved in modulating AP-1 activity (Angel et al., 2001). 
 
3.4.2 JUN-JUNB target genes in IL-31 stimulation affected epidermal 
differentiation 
AP-1 dimers are directly involved in the transcription of differentiation-related genes 
like filaggrin or involucrin but they also regulate the expression of other genes that are 
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involved in regulating differentiation. Initiation of keratinocyte differentiation 
depends on a cell cycle arrest in the G1 phase (Hauser et al., 2004; Martinez et al., 
1999). Downregulation of Cyclin D1 is associated with a G1 arrest in the cell cycle. 
Keratinocyte cell lines undergoing differentiation by detachment from the surface 
depend on the down-regulation of Cyclin D1 for permanent cell cycle exit (Nishi et 
al., 2009). Non-melanoma skin cancers (like keratoacanthomas or squamous cell 
carcinomas) are associated with Cyclin D1 overexpression preventing a cell cycle exit 
(Burnworth et al., 2006). In the epidermis Cyclin D1 is preferentially expressed in the 
basal proliferating cell layer (Belso et al., 2008) and down-regulated by expression of 
late differentiation markers like K10 (Paramio et al., 1999). Primary human oral 
squamous epithelial keratinocytes are immortalized by overexpression of Cyclin D1 
and p53 inactivation (Opitz et al., 2001). These studies demonstrate that Cyclin D1 is 
critical to control cell proliferation in keratinocytes. 
 
Moreover p21, a direct p53 target, is essential for the initiation of differentiation in 
keratinocytes and contributes to the differentiation-induced cell cycle arrest (Missero 
et al., 1996; Topley et al., 1999). On the other hand at later stages of differentiation 
p21 expression needs to be reduced to enable the cells to further proceed in 
differentiation (Di Cunto et al., 1998) indicating a negative feedback loop of p21 
expression during differentiation. This influence of p21 on differentiation is not 
limited to keratinocytes. For example differentiating osteoblasts show a similar 
expression pattern of p21 during differentiation with inhibitory effects of 
overexpressed p21 during later stages of differentiation (Bellosta et al., 2003). 
However during differentiation p21 seems to play an important role that is distinct 
from cell cycle control since p21 overexpression specifically increases MAPkinase 
signaling in keratinocytes and suppresses keratinocyte differentiation independently 
of the cell cycle (Devgan et al., 2006). In this case MAPkinase activation is mediated 
by the induction of IGF-1 expression by p21 leading to disturbed differentiation. This 
is consistent with the finding that overexpression of p21 in promyelocytic leukemia 
cells does not affect cell cycle progression but clearly differentiation processes 
(Casini and Pelicci, 1999). Furthermore deletion of the N-terminus of p21 that 
mediates the binding to Cyclin/CDK complexes and thus cell cycle exit, does not 
abrogate the inhibitory effects on cell differentiation (Di Cunto et al., 1998; Dotto, 
2000). To summarize this: in cell differentiation p21 has functions that can either 
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promote or inhibit differentiation and are distinct from its ability to control cell cycle 
progression.  
 
In addition p21 is an important factor in committing stem cell fate in keratinocytes. 
As mentioned in the introduction two populations of proliferating cells exist in the 
epidermis: self-renewing stem cells and transient amplifying cells that are committed 
to differentiation. In the absence of p21 the pool of keratinocytes with stem cell 
potential is markedly increased with an enhanced possibility of carcinogenesis in mice 
(Philipp et al., 1999; Topley et al., 1999; Weinberg et al., 1999) indicating that p21 
restricts the self-renewal potential of keratinocyte stem cells and promotes 
commitment for differentiation. In normal keratinocyte differentiation p21 activity is 
mainly controlled by Notch and p63 signaling in a p53 independent manner (Dotto, 
2008; Mack et al., 2005). 
 
Although the cell cycle inhibitory function of p16 is well described, information about 
its role in keratinocyte differentiation are rather limited. p16 deficiency in mice has no 
epidermal phenotype (like p21) but p16/p21 deficient mice show increased 
keratinocyte proliferation and defects in adult differentiation processes. Both seem to 
depend on alterations in Rb and p53 signaling (Paramio et al., 2001). Furthermore the 
limited proliferation potential and the exit from the cell cycle in keratinocytes (in 
contrast to several other cell types) potentially depends on p16, because 
immortalization of keratinocytes by hTERT fails as long as they express p16 (Dickson 
et al., 2000) and aging of keratinocytes in culture comes along with increased p16 
levels independent of telomere length (Darbro et al., 2005). In addition keratinocyte-
like cells derived from human embryonic stem cells undergo senescence associated 
with an increase of p16 expression (Dabelsteen et al., 2009) and normal human oral 
keratinocytes exhibit an extended life span when they are stimulated with retinoid 
acid which comes along with decreased p16 expression (You et al., 2000). p16 (like 
p21 and p27) expression is induced in keratinocytes that undergo differentiation by 
culturing them in suspension culture, accompanied by the induction of differentiation 
markers. In addition overexpression of p16 effects cell cycle progression but does not 
induce the expression of differentiation markers indicating that it is involved in 
differentiation-induced cell cycle exit but possibly does not play a role in other 
differentiation processes (Harvat et al., 1998). 
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p21 is a well-described p53 target with important functions in differentiation as 
described above. Although p53 is a JUN target and itself activates p21 transcription 
its function in keratinocyte differentiation is only poorly described. In fact p63, which 
belongs to the p53 protein family, is a very important factor in skin differentiation (as 
described in the introduction) while p53 seems to play only a minor role. Furthermore 
p21 regulation in differentiation mainly seems to be p53 independent. Nevertheless 
loss of p63 expression in keratinocytes by siRNA up-regulates p21 expression and 
results in cell cycle arrest (Truong et al., 2006). Simultaneous knock-out of p53 in this 
p63-/- background rescues the cell cycle arrest completely but a p21 knock-out only 
partially rescues this effect (Truong et al., 2006). This suggests that p21 is not the 
main mediator of p53 induced cell cycle arrest in keratinocytes. p63 is required for 
maintaining the proliferation potential of basal epidermal cells which seems to be 
depended on the inhibitory function of p63 on p53 expression (Truong and Khavari, 
2007) probably by competing for the same DNA binding sites (Truong and Khavari, 
2007; Yang et al., 1998). Thus the general opinion is that p63 and p53 counteract each 
another, one by maintaining cell cycle progression, the other inducing cell cycle arrest 
by inhibiting or promoting the expression of cell cycle regulators like p21, 14-3-3σ or 
IGFBP-3 (Truong and Khavari, 2007). At this point it is important to mention that 
p63/p53-dependent regulation of cell cycle progression in keratinocytes does not 
affect keratinocyte differentiation. Rescue of the p63 knock-out phenotype by a 
simultaneous p53 knock-out does not restore a p63 knock-out dependent loss of the 
differentiation potential of keratinocytes (Truong et al., 2006). This implies an only 
minor role for p53 in the differentiation program although it is important in the 
control of the cell cycle. In fact p63 dependent regulation of differentiation is only 
poorly understood but probably relies on a differential expression of p63 isoforms 
during differentiation and not on the counteracting functions of p63 and p53 (Wu et 
al., 2003).  
  
The studies presented in this thesis revealed a significant impact of IL-31 on the 
expression of major regulators in keratinocyte cell cycle arrest and differentiation, 
most notably JUNB and p21, in HaCaT-pSLIK-IL31RA monolayer culture and 
NHEK organotypic skin equivalents (Figs. 17-20). JUNB and p21 are induced after 
IL-31 stimulation while Cyclin D1, p53 and p16 expression is repressed. In case of 
p16 this repression on the mRNA level was not apparent on the protein level. These 
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data give first hints how IL-31 might be involved in regulating keratinocyte 
differentiation.  
 
The JUN/JUNB network in cell cycle control might be less relevant in keratinocyte 
differentiation since these proteins are differentially expressed in the epidermis 
suggesting that JUN and JUNB have distinct unique functions in differentiation that 
might not be affected directly by each other. The mRNA expression in IL-31 
stimulated HaCaT cells supports this hypothesis since JUNB up-regulation in many 
other cells would lead to p16 induction and Cyclin D1 repression. JUNB dependent 
inhibition of JUN induces p53 and subsequently p21 expression. In IL-31 stimulated 
HaCaT cells I observe a different pattern as it would be expected in a JUNB 
dependent regulation of the cell cycle and thus might be IL-31 regulated 
differentiation dependent.    
 
Repression of Cyclin D1 is in agreement with the observation that IL-31 stimulated 
HaCaT keratinocytes have a reduced proliferation rate in monolayer culture and 
organotypic skin equivalents and accumulate in G1 phase of the cell cycle (Fig. 10B, 
Fig. 13A and B, Fig. 14B). Also NHEKs arrest in the cell cycle, which was 
demonstrated by a reduced Ki67 nuclear staining in organotypic skin equivalents (Fig. 
6A). As described above down-regulation of Cyclin D1 is essential for the 
progression of keratinocyte differentiation at very early stages of the process and in 
intact epidermis it is preferentially expressed in the basal proliferating cell layer. 
Down-regulation of Cyclin D1 might be a direct consequence of IL-31-dependent 
induction of JUNB expression and is in common with the JUN/JUNB dependent cell 
cycle control network. 
 
IL-31 induced repression of p16 expression could only be observed in monolayer 
cultures of keratinocytes on the mRNA level and is probably not JUNB dependent 
since JUNB induces p16 in other cellular systems. It is most likely that p16 does not 
contribute to the IL-31 dependent phenotype because a p16 repression is connected in 
general with hyper-proliferation of cells and would maintain the proliferating state of 
keratinocytes which is not present in the observed differentiation models. In 
agreement with this hypothesis is the missing reduction on the protein level and the 
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missing regulation in the NHEK organotypic skin equivalents that might explain these 
missing known p16 effects. 
 
Down-regulation of p53 during differentiation has been observed before (Dazard et 
al., 2000) and seems to be connected to the transition from transient amplifying cells 
to terminal differentiating cells and is connected with an induction of the p53 
regulator MDM2. IL-31 stimulation also induces p53 repression in monolayer culture 
but could not be observed at the mRNA level in NHEK organotypic skin equivalents. 
Finally p21 induced expression is present in monolayer cultures of keratinocytes and 
NHEK organotypic skin equivalents. Since no direct regulation of p21 by JUNB has 
been reported yet and JUN negatively regulates p21 only indirectly by inhibition of 
p53, it is difficult to suggest how IL-31 or JUNB regulate p21. Nevertheless the 
constant overexpression of JUNB and p21 after IL-31 stimulation and the down-
regulation of p53 and Cyclin D1 connected to normal differentiation in monolayer 
keratinocyte cultures further supports the hypothesis that IL-31 might impair the 
transition of keratinocytes from an early differentiated stage to terminal differentiating 
cells. JUNB and p21 are candidates for mediating this phenotype. JUNB down-
regulation is essential in late differentiating cells. Furthermore JUNB/Fra-1 
heterodimers can induce β4-intergrin expression, which is in agreement with the 
increased distribution of β4-intergrin in the observed organotypic skin equivalents 
described above. But β4-integrin silencing is an essential step in the transition of cells 
from the basal layer to the stratum spinosum (see above). Also the down-regulation of 
p21 after a high expression in early differentiated steps is needed for proper 
differentiation and a constantly high p21 level contributes most likely to the induction 
of differentiation by committing amplifying cells for differentiation but impairs the 
final formation of the skin barrier and keeps the cells in an early differentiated state. 
 
If and how JUNB, Cyclin D1, p53, p21 and p16 contribute to the IL-31 phenotype is 
not proven yet. The described hypothesizes are based on the simple observation that 
these factors are induced after IL-31 stimulation in monolayer cultures and fully 
satisfying results from organotypic skin equivalents that also proof this regulation 
pattern in differentiating keratinocytes could not be observed. Monolayer cultures 
have the advantage of a consistent cellular state but in normal cell culture HaCaT 
keratinocytes do not differentiate. In contrast organotypic skin equivalents contain 
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feeder fibroblasts in combination with keratinocytes in different differentiation steps 
and thus with a potentially very different transcriptome. As displayed in Fig. 18D 
differences in JUNB expression could only be observed at day 2 after IL-31 
stimulation of a NHEK organotypic skin equivalent. p21 was constantly higher 
compared to the non-IL-31 stimulated model (except at day 5) and for p53 and p16 no 
differences between IL-31 stimulated and non- stimulated models were observed. In 
HaCaT derived skin equivalents that were all harvested after 7 or 14 days of IL-31 
stimulation, no differences in the mRNA expression were measured (data not shown). 
This is probably due to IL-31 induced transcriptional changes only in a minor subset 
of cells in a certain differentiation step that also affects later differentiation processes, 
which would concur with the observation that an IL-31 pulse stimulation of 24 hours 
is already sufficient to partially induce the IL-31 phenotype.  The large number of 
cells with different transcriptomes does not represent this minor subset of IL-31 
responsive cells that are present perhaps only in the basal layer and early spinous 
layer and thus IL-31 dependent changes are no longer measurable in 7 or 14 day old 
skin equivalents. To clarify this question, monolayer differentiation models (e.g. 
NHEK differentiation in monolayers can be induced by the increase of the Ca2+ 
concentration in the culture medium; HaCaT differentiation can be induced by 
prolonged detachment of the cells from a surface) are needed or the opportunity to 
investigate the transcriptome of certain cellular layers within an organotypic skin 
equivalent e.g. by single cell PCR and/or micro-dissection. 
 
3.5 Conclusions 
 
In conclusion several publications report that IL-31 is involved in the inflammatory 
processes in human skin diseases like AD and might have the capacity to enhance the 
inflammatory response by stimulating indirectly the recruitment of inflammatory 
cells. This thesis demonstrates for the first time that IL-31 can directly interfere with 
proper differentiation and skin barrier formation of keratinocytes. Impaired skin 
barrier formation is the most important symptom of AD as an increased penetration of 
the skin by allergens and pathogens leads to an aggravation of the inflammatory 
response. Filaggrin mutations are frequently associated with AD but the severity of 
AD does not correlate with the type of mutation, especially in heterozygouse 
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mutations. IL-31 has the ability to further weaken the skin barrier formation by 
inhibiting filaggrin expression. Thus IL-31 might be another important factor 
especially in patients suffering from a filaggrin mutation associated AD.  
 
Furthermore IL-20 and IL-24 are induced by IL-31 stimulation, contributing to the IL-
31 phenotype. They also might contribute to inflammatory processes in the skin since 
they have been shown to be tightly associated to psoriasis. 
 
IL-31 induces a phenotype that is closely related to the earliest steps of differentiation 
but seems to inhibit further progression in the differentiation process indicated by the 
exit of the cell cycle and the missing down-regulation of β4-integrin associated with 
the inhibition of terminal differentiation markers. This finding is supported by 
expressional changes in cell cycle and differention regulators associated with the 
JUN/JUNB network that would promote early differentiation but inhibit late 
differentiation.  
 
Thus I can conclude that IL-31 is an important regulator in skin differentiation and 
might highly contribute to inflammatory processes and differentiation in AD 
pathology. 
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4 Materials and Methods 
Materials and Methods are described according to standard protocols used in the 
Institute of Biochemistry and Molecular Biology, RWTH Aachen University, and 
modified regarding individual differences in experimental procedures. 
4.1 Consumables and reagents 
4.1.1 Consumables 
Consumables were purchased from: Amersham Biosciences, Ansell, Becton 
Dickinson, Biometra, Bio-Rad, Biosan, Biotron, Biozym, Brand, Braun, Cellstar, 
Costar, Eppendorf, eBioscience, Falcon, Fisher Scientific, Fuji, Gibco BRL, 
Heidolph, Hirschmann, Integra Biosciences, Komberley-Clark, Kojair, Millipore, 
Nalgene, Nerbe Plus, Omnilab, Rainin, Roth, Sanyo, Sarstedt, Sartorius, Schott 
Duran, Semper med, Siemens, TPP, VWR. 
4.1.2 Reagents 
Reagents met at least the criteria for the purity standard p.a and were purchased from: 
Amersham Pharmacia Biotech, AppliChem, Bayer, BD Biosciences, Bode, Biometra, 
Bio-Rad, Calbiochem, Chroma, Clontech, Eurogentec, Fermentas, Finnzymes, Fluka 
BioChemika, Gibco, Invitrogen, Invivogen, Merck, New England Biolabs, PAA, 
Pierce, Qiagen, Roche, Santa Cruz Biotechnology, Seromed, Serva, Sigma, Zymo 
Research. 
4.2 Oligonucleotides 
 
The following nucleotides were purchased from Eurofins-MWG-Operon, Sigma-
Aldrich, Qiagen or Applied Biosystems. 
Sequencing primers 	  	   	  	  
Primer name Sequence (5´-3´) Function 
M13 (-21) forward TGTAAAACGACGGCCAGT Sequencing of pEN221 inserts 
M13 reverse CAGGAAACAGCTATGACC Sequencing of pEN221 inserts 
IL-31RAORFseq_fw AAGTTCTGGAGTGACTGGAGCCAA Sequencing of IL31RA cDNA 
IL-31RAORFseq_rev TTTCCTGACCCGTTCTGGCTTCAT Sequencing of IL31RA cDNA 
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EGFP-N1_forward CAACGGGACTTTCCAAAATG Sequencing of pSFI express inserts 
EGFP-N1_rev CGGACACGCTGAACTTGTG Sequencing of pSFI express inserts 
pTRE_for TAAGCAGAGCTCGTTTAGTG Sequencing of  pEN_TGmirc3 inserts 
SeqL-B  Designed by Seqlab laboratories Sequencing of  pEN_TGmirc3 inserts 
 
PCR primers 	  	   	  	  
Primer name Sequence (5´-3´) Function 
IL31RAclon_fw  ATGTGCATCAGGCAACTCAAG amplification of IL31RA cDNA from pEN-IL31RA 
IL31RAclon_rev TTAGACTTCTCCCTTGGTGTG amplification of IL31RA cDNA from pEN-IL31RA 
IL-31RA-pSLIK_fw ATGATGTGGACCTGGGCACTG amplification of IL31RA-HA cDNA from pSFI-IL31RA-HA 
IL-31RA-pSLIK-
HA_rev TTAGGCATAATCTGGCACATCATA 
amplification of IL31RA-HA 
cDNA from pSFI-IL31RA-HA 
qRT-PCR primers and TaqMan® primer/probe sets	  	   	  	  
Target Sequence/cataloge number Company/reference 
OSMR_rev TCTGTGCTAATGACTGTGCTTGTGGT 	  Savarese et al., 2002)	  
OSMR_fw GTGTGGGTGCTTCTCCTGCTTCTGTA (Savarese et al., 2002) 
FAIM3 QT00011221 Qiagen 
PIGR QT00084651 Qiagen 
MAPKAPK2 QT01012508 Qiagen 
IL10 QT00041658 Qiagen 
IL24 QT00059059 Qiagen 
IL31RA QT00010794 Qiagen 
IL20 QT00044905 Qiagen 
IL19 QT00022015 Qiagen 
CCND1 QT00495285 Qiagen 
CDKN2A QT00089964 Qiagen 
TP53 QT00060235 Qiagen 
CDKN1A QT00062090 Qiagen 
IRF1 QT00494536 Qiagen 
JUNB QT00201341 Qiagen 
GADD45B QT00018480 Qiagen 
DUSP1 QT00036638 Qiagen 
EGR1 QT00999964 Qiagen 
FLG Hs00418578_m1 TaqMan® Applied Biosystems 
INV Hs00902520_m1 TaqMan®  Applied Biosystems 
KRT10 Hs00166289_m1 TaqMan® Applied Biosystems 
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ITGB4 Hs00236216_m1 TaqMan® Applied Biosystems 
HPRT_fw  TGACACTGGCAAAACAATGCA Lüscher Lab Pool  
HPRT_rev  GGTCCTTTTCACCAGCAAGCT Lüscher Lab Pool 
HPRT  Hs99999909_m1 TaqMan® Applied Biosystems 
4.3 Plasmids  
 
pENTR221-IL31RA 
The full open reading frame of IL-31RA was cloned into pENTR221. The clone was 
obtained from Imagenes (IOH34840, #ReqNo: 9801604). pENTR221 is an ORF 
expression vector expressing the gene of interest under the control of a T7 promoter. 
IL31RA was cloned in between attL sites for easy recombination within the 
Gateway® recombination system (Invitrogen). The vector harbors a kanamycin 
resistance gene for bacterial selection.  
pSFIexpress 
Sub-cloning vector for cloning into pRTS. Cloning of a gene of interest into an 
EcoRV restriction site adds the sequence for a C-terminal HA-tag to the cDNA and 
embeds the cDNA into SfiI restriction sites (Hölzel et al., 2007).  
pSFI-IL31RA-HA 
The cDNA of IL-31RA was cloned into pSFIexpress after PCR amplification from 
pENTR221-IL31RA. 
pRTS 
Episomal doxycycline controllable expression vector for the creation of stable cell 
clones (Hölzel et al., 2007). This vector is extensively described in the results section.   
pRTS-IL31RA-HA 
The IL31RA-HA cDNA was cloned via SfiI restriction sites from pSFI-IL31RA-HA 
into pRTS. 
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pRTS-IL31RA-HAΔGFP 
pRTS-IL31RA-HA has a bi-directional tetracycline-controllable promoter with the 
IL-31RA cDNA on the one side and a GFP cDNA on the other side. The GFP cDNA 
was removed by digestion of pRTS-IL31RA-HA with BglII and SwaI. 
pEN_TGmirc3 
Sub-cloning vector for insertion of a gene of interest into pSLIKneo via 
recombination (Shin et al., 2006). Cloning into pEN_TGmirc3 adds a tetracycline 
responsive element (TRE) in front of a cDNA and embeds this combination into attL 
sites for recombination.  
pEN-IL31RA-HA  
The IL-31RA-HA cDNA was PCR amplified from pSFI-IL31RA-HA and cloned into 
pEN_TGmirc3. 
pSLIKneo 
Tetracycline controllable expression vector that integrates into the target cell genome 
via lentiviral infection (Shin et al., 2006). The vector is extensively described in the 
results section 
pSLIK-IL31RA-HA 
The IL-31RA.HA cDNA was cloned into pSLIKneo via recombination with pEN-
IL31RA-HA 
4.4 Antibodies 
Target Company Catnr. Species Dilution 
primary antibodies   
Filaggrin Santa Cruz sc-66192 mouse 1:100 
Involucrin Sigma I-9018 mouse 1:2000 
Keratin 10 Dako M7002 mouse 1:500 
Keratin14 Chemicon CBL197 mouse 1:200 
β4-Integrin Millipore MAB2059 mouse 1:200 
Ki67 Dako M7240 mouse 1:100 
IL-31RA (biotinylated) R&D BAF2769 goat 1:200 
Hämagglutinin (HA)-tag 
E.Krämer 
(München) 3F10 (clone) mouse 1:1000 
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4.5 Inhibitors and cytokines 
 
Inhibitors 
Name Target Cataloge number Company final concentration 
JAK Inh. I JAK kinases 420099 Calbiochem 100nM 
SB202190 p38 559388 Calbiochem 20µM 
JNK Inh. II JNK kinases 420119 Calbiochem 20µM 
U0126 MEK1 (ERK) 662005 Calbiochem 20µM 
Wortmannin PI3-kinase 691675 Calbiochem 500nM 
 
recombinant human (rh) Cytokines 
Name  Catalog number Company final concentration 
rhIL-31  200-31 Peprotech 100ng/ml 
rhIFNγ  AF-300-02 Peprotech 20ng/ml 
rhIL-20  1102IL R&D 20ng/ml 
rhIL-24 1965IL R&D 20ng/ml 
α-Tubulin Sigma T-5168 mouse 1:2500 
Actin MP Biomedicals 69100 mouse 1:1000 
STAT3 Santa Cruz SC-482 rabbit 1:1000 
phospho-STAT3 (Tyr705) Cell Signaling #9131 rabbit 1:1000 
IL-22R R&D MAB2770 mouse 1:200 
IL-20Rβ Santa Cruz sc-47058 goat 1:200 
IL-20Rα R&D AF1176 goat 1:200 
JUNB Santa Cruz sc-73 rabbit 1:1000 
p53 Santa Cruz sc-126 mouse 1:1000 
p21 BD PharMingen 556431 mouse  1:1000 
p16 Santa Cruz SC-1661 mouse 1:1000 
  
secondary antibodies  
mouse IgG & IgM (H+L) HRP 
coupled 
Jackson Immuno 
Research 115-036-068 goat 1:5000 
rabbit IgG & IgM (H+L) HRP 
coupled 
Jackson Immuno 
Research 111-035-144 goat 1:5000 
rat IgG & IgM (H+L) HRP 
coupled 
Jackson Immuno 
Research 112-035-068 goat 1:5000 
goat IgG &IgM (H+L) HRP 
coupled Santa Cruz sc-2768 rabbit 1:5000 
goat IgG (H+L)-Alexa Fluor 
488 Invitrogen A11055 donkey 1:2000 
rabbit IgG (H+L)-Alexa Fluor 
555 Invitrogen A21428 goat 1:2000 
rabbit IgG (H+L)-Alexa Fluor 
488 Invitrogen A11034 goat 1:2000 
mouse IgG (H+L)-Alexa Fluor 
488 Invitrogen A11029 goat 1:2000 
mouse IgG (H+L)-Alexa Fluor 
555 Invitrogen A21422 goat 1:2000 
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4.6 Work with nucleic acids 
 
4.6.1 DNA preparation 
Plasmid DNA from prokaryotic cultures was extracted using the Nucleobond Xtra 
Maxi plus kit  (Macherey-Nagel) for large scale preparations and the Plasmid 
Miniprep Kit (Zymo Research) for small-scale preparations, according to the 
manufactures recommendations. 
4.6.2 Enzymatic Manipulation of Plasmid DNA 
For digestion, modification and ligation of Plasmid DNA restriction enzymes, calf 
intestine alkaline phosphatase, Klenow fragment and T4 DNA Ligase were purchased 
from Fermentas, Germany. Plasmid DNA digestions and double digestions were 
performed in a 20-50µl Volume for 1h to o/n with the appropriate buffers and 
temperatures according to the restriction enzyme specific recommendations. De-
phosphorylation of DNA 5´-ends was achieved by incubation with calf intestine 
alkaline phosphatase for 1h at 37°C. Refill of sticky-ends to blunt-ends was achieved 
by addition of deoxynucleotides and incubation with Klenow Fragment at 37°C for 
1h. Sticky end ligations were carried out for 1-2h at 37°C with T4 DNA ligase. For 
Blunt-end ligations 5% PEG2000 was added to the reaction and the time was 
extended to 2h-o/n. 
4.6.3 Agarose gel electrophoresis 
Gel Electrophoresis was performed in 0,8-3,0% low EEO agarose (Sigma-Aldrich) as 
described before (Sambrook, 1989). 
4.6.4 Gel extraction of DNA 
DNA from agarose gels was recovered using the Zippy Gel DNA Recovery Kit 
(Zymo Research) according to the manufactures recommendations. 
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4.6.5 Polymerase Chain Reaction (PCR) 
All PCR reactions were performed using the Phusion High Fidelity Polymerase Kit 
(Finnzymes) according to the manufactures recommendations. 
For a 50µl reaction volume: 
plasmid DNA     10ng 
10x Phusion HF buffer   10µl 
Primer      0,5µM 
dNTPs      200µM 
Phusion DNA polymerase   0,02 U/µl 
H2O PCR grade    added to 50 µl final reaction volume  
PCR program: 
All PCR reactions were performed using the peqSTAR 96 Universal Gradient 
Thermocycler (Peqlab). 
Initial denaturation    98°C 30 sec 
35 cycles: Denaturation  98°C 10 sec    
Annealing  60°C 20 sec 
Elongation  72°C 20 sec 
Final extension   72°C 5 min  
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4.7 Work with prokaryotic cells 
 
4.7.1 Bacterial strains: 
E.coli XL10-Gold  
(Stratagene)  
Tetr D(mcrA)183 D(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-  
1 recA1 gyrA96 relA1 lac Hte [F’ proAB lacIqZDM15 Tn10 (Tetr)  
Amy Camr]  
 
E.coli DH5α   
(Invitrogen)  
F- 80dlacZ M15 (lacZYA-argF) U169 recA1 endA1 hsdR17(rk-  
mk+) phoA supE44 - thi-1 gyrA96 relA1 
 
4.7.2 Materials 
 
LB-Medium:     1% (w/v) Tryptone (AppliChem) 
       0,5% (w/v) Yeast extract (AppliChem) 
       1% (w/v) NaCl 
       pH 7,0 
 
Agar-Plates:     LB-Medium 
       1,5% (w/v) Bacto-Agar (Difco) 
 
Antibiotics:     100µg/ml Ampicillin or 50µg/ml Kanamycin 
 
4.7.3 Bacterial Transformation and cultures for plasmid DNA preparation 
100µl chemically competent bacteria were thawed in a 1,5ml reaction tube and mixed 
with 100- 500ng plasmid DNA. The mixture was incubated on ice for 10-30min and 
heat-shocked for 45sec at 42°C and immediately placed back on ice. 1ml 37°C LB 
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medium was added to the bacteria and they were incubated at 37°C for 1h. The 
bacteria were pelleted by centrifugation, re-suspended in 100µl LB Medium and 
plated on LB agar plates containing the appropriate antibiotic for selection. The cells 
were incubated at 37°C until bacterial colonies could be selected. Single cell colonies 
were selected to seed o/n cultures for plasmid DNA preparation. For small-scale 
preparations 3ml LB-Medium and for large-scale preparations 300ml LB Medium, 
substituted with the plasmid specific selection antibiotic, were incubated in a shaker at 
37°C and 160rpm. 
 
4.8 Work with eukaryotic cells 
 
4.8.1 Primary cells 
 
HDFs 
 
Human dermal fibroblasts 
 
NHEKs 
 
Normal human epidermal keratinocytes 
 
Isolation of HDFs and NHEKs 
 
Normal human keratinocytes were isolated from skin biopsies of adult skin and 
foreskin (obtained from healthy volunteers after coutaneous surgery), rinsed with 70% 
ethanol and washed 3 times in PBS with antibiotics/ antimycotics, and cut into pieces 
of 1cm2. The epidermis was separated by incubation in 50 Caseinolytic units/ml 
Dispase (BD Bioscience) for 2h at 37ºC. After incubation in 0,25mg/ml 
trypsin/EDTA (Lonza) for 30minutes at 37ºC a single cell suspension of keratinocytes 
was released by gentle pipetting. After inactivation of the trypsin with Trypsin 
Neutralisation Solution TNS (Lonza) cells were cultured in KGM (Lonza) in 
100x20mm cell culture dishes (Sarstedt) at 37ºC in a humidified atmosphere at 5% 
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CO2. 
Keratinocytes were used at their first to second passage for organotypic skin 
equivalents or monolayer cultures. 
Normal human fibroblasts were isolated from the remaining dermis after incubation 
of skin in Dispase. The Dermis was digested in Collagenase 1A 100U/ml (Sigma) and 
cultivated in DMEM (Invitrogen) substituted with 10% Fetal Calf Serum (Biochrom) 
and penicillin (50U/ml)/streptomycin (50µg/ml) 
The Isolation of HDFs and NHEKs was performed by Yvonne Marquard 
(Dermatology Department, Medical School, RWTH Aachen University) with 
informed consent by the donor. 
4.8.2 Eukaryotic cell lines 
HaCaT 
HaCaT cells are a spontaneously transformed cell line derived from keratinocytes of 
histological normal skin of a 63 years old male (Boukamp et al., 1988) and were a 
generous gift of N. Fusenig. 
 
HEK 293 
Human epidermal kidney (HEK) cell line (ATCC CRL-1573) transformed with 
Adenovirus 5 DNA, integrated into chromosome 19q13.2.Obtained from ATCC. 
 
HEK 293T 
A cell line derived from HEK293 cells containing the large T-antigen from the Simian 
Virus 40 (ATCC CRL-11268). Obtained from ATCC. 
 
HaCaT pRTS-IL31RA 
HaCaT derived cell line containing a stably integrated episomal vector that leads to 
the expression of a HA-tagged IL-31RA upon doxycycline addition to the cell culture 
medium. The cell line was generated by Superfect (Qiagen) transfection of wt HaCaT 
cells with the vector pRTS-IL31RA-HAΔGFP. 
 
 
HaCaT pSLIK-IL31RA 
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HaCaT derived cell line containing a stably integrated cassette that leads to the 
expression of a HA-tagged IL-31RA upon doxycycline addition to the cell culture 
medium. The cell line was generated by lentiviral infection of wt HaCaT cells with 
the vector pSLIK-IL31RA-HA. 
4.8.3 Cell culture media, supplements, buffers and plastic materials 
DMEM (Gibco) with 4,5g/l Glycose and GlutaMax 
KGM® Keratinocyte Growth Medium (Lonza) 
 Supplements (Lonza):    Bovine pituitary extract (BPE) 
       hEGF 
       Insulin 
       Hydrocortisone 
 
PBS       140mM NaCl 
       2,6mM KCl 
       2mM Na2HPO4 
       1,45mM KH2PO4 
  
Trypsin/EDTA (Seromed)   0,5/0,02% (w/v) in PBS 
Trypsin/EDTA (Lonza)   0,25/0,01% (W/V) in PBS 
Trypsin Neutralizing Solution (Lonza) 
Hygromycin B solution (Roth)  50mg/ml 
G418-Solution (Roth)    50mg/ml 
Puromycine (Sigma-Aldrich)  1mg/ml 
Doxycycline (Sigma-Aldrich)  1mg/ml 
Penicillin/Streptomycin (Seromed) 10.000 Units/ml / 10.000 µg/ml 
FCS (Fetal calf serum, Gibco) 
Cell culture dishes (Sarstedt)   ∅ 6cm, 10cm, 15cm 
Cell culture plates (TPP)   6-well, 12-well, 24-well, 48-well, 96-well 
1ml cryotubes (Nalgene) 
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4.8.4 Culture conditions 
All cell lines were cultured in a humidified atmosphere of 5% CO2 at 37°C. NHEKs 
are cultured in KGM supplemented with BPM, hEGF, Insulin and Hydrocortisone. 
HDFs are cultured in DMEM supplemented with 10% FCS and 1% 
Penicillin/Streptomycin until they are seeded in co-culture with NHEKs. HaCaT, 
HEK293 and HEK293T cells were cultured in DMEM supplemented with 10% FCS 
and 1% Penicillin/Streptomycin. HaCaT pRTS-IL31RA cells were cultured by 
addition of 400µg/ml Hygromycin B to the normal HaCaT culture medium. To the 
culture medium of HaCaT pSLIK-IL31RA 800µg/ml G418 was added.  
 
4.8.5 Protocols for work with prokaryotic cells 
4.8.5.1 Cryoconservation 
For cryconservation 5-8x106 cells were pelleted by centrifugation and re-suspended in 
1ml 90%FCS/10%DMSO (v/v) and transferred to a cryotube. After incubation on ice 
for 30min the cells were wrapped in several layers of tissue paper and within 16-48h 
cooled down to -80°C in an isolated box. For long term storage the cryotubes were 
transferred to -150°C. 
 
4.8.5.2 Thawing of cells 
Cryotubes with frozen cells were thawed fast in a water bath at 37°C until all ice 
crystals were melted. The cells were immediately re-suspended in 37°C fresh culture 
medium, pelleted by centrifugation, taken up in 10ml culture medium and transferred 
to an appropriate culture dish. 
 
4.8.5.3 Seeding and passaging of cells 
To detach the cells from their surface, the culture medium was aspirated and the cells 
were washed once with PBS to remove bivalent ions that would inactivate trypsin. 
HaCaT cell lines were washed with PBS containing 10mg/ml EDTA to remove 
bivalent ions more efficiently. All cell lines were incubated in Trypsin/ EDTA 
(0,5%/0,02%, NHEKs: 0,25%/0,01%) until they detached from the plastic surface. By 
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addition of culture medium the trypsin was inactivated. The cell number/ml was 
determined by using the Casy Cell Counter (Innovatis) and the cells were seeded in 
the appropriate dilutions in new cell culture plates. 
 
4.8.5.4 Transient transfections 
Calcium-phosphate method 
 
2x Hebs buffer:    274mM NaCl 
      42mM HEPES 
      9,6mM KCl 
      1,4mM Na2HPO4 
      pH 7,1 
HEPES buffer:    142mM NaCl 
      10mM HEPES 
      6,7mM KCl 
      pH 7,3 
250mM CaCl2 
 
This transient transfection method is based on the fact that calcium-phosphate-DNA 
complexes form precipitates that can be taken up by adherent cells through 
endocytosis (Bousset et al., 1994; Chen and Okayama, 1988). This method was used 
to transfect HEK293 and HEK293T cells. 
The day before transfection approximately 106 cells (10cm dishes), 4x105 (6cm 
dishes) or 105 cells (6-well plates) were seeded in cell culture dishes. 20µg (10cm), 
7µg (6cm) or 3µg (6-Well) of total DNA was diluted in 1/20 culture medium volume 
of 250mM CaCl2. The same volume 2x HEBS was added drop wise under continuous 
mixing by agitation to the DNA-CaCl2 solution. The solution was incubated for 
15min at room temperature and afterwards added drop wise by pipetting to the cell 
monolayers. The cells were incubated approximately for 6 hours and residual 
precipitate was removed by washing the cells with HEPES buffer followed by 
addition of fresh medium. 
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Superfect (Qiagen) transfection of HaCaT cells 
SuperFect Reagent consists of activated-dendrimer molecules with a defined spherical 
architecture. Branches radiate from a central core and terminate at charged amino 
groups which can then interact with negatively charged phosphate groups of nucleic 
acids. SuperFect Reagent assembles DNA into compact structures that bind to the cell 
surface and are taken into the cell by nonspecific endocytosis. The reagent buffers the 
pH of the endosome, leading to pH inhibition of endosomal nucleases, which ensures 
stability of SuperFect–DNA complexes. Due to highly controlled chemical synthesis 
the activated-dendrimer molecules in SuperFect Reagent have a precise size and a 
defined shape. This ensures consistent transfection-complex formation and 
reproducible transfection results (from www.qiagen.com) (Tang et al., 1996) 
According to the manufactures recommendations the day before transfection 2x106 
cells were seeded in 10cm dishes. At the day of transfection 10µg pRTS-IL31RA-
HAΔGFP were diluted in 300µl serum- and antibiotic-free DMEM medium and 
mixed with 50µl Superfect reagent. The mixture was incubated at RT for 10 min. The 
cells were washed four times with PBS, 2,5 ml normal growth medium was added to 
the plasmid-Superfect mixture and applied to the cells. After 3 h of incubation under 
normal cell culture conditions the transfection medium was aspirated, the cells were 
washed once with PBS and normal growth medium was added. 
 
4.8.5.5 Lentiviral infection 
Lentiviruses belong to the family of Retroviruses. They harbor a single stranded RNA 
which is reverse transcribed into a cDNA and integrated into the genome via long 
terminal repeats (LTR). The most prominent member of this virus family is HIV. The 
system how HIV integrates its genomic information into the host genome can be used 
to deliver transgenes into the genome of target cells. In a first step HEK293T cells are 
used to produce virus particles that harbor a lentiviral expression vector that is 
capable to deliver the genetic information into the cells via infection. To enable 
HEK293T cells to produce viral particles, the cells are transfected with so called 
helper or packaging plasmids. These plasmids encode essential proteins needed for 
virus formation. The plasmid pLP1 codes for the viral genes gag/pol (core and 
structural proteins, protease and integrase), pLP2 encodes the reverse transcriptase rev 
and pLP/VSV-G encodes lentiviral envelope proteins needed for binding and 
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infection of the target cell. The HEK293T cells express all proteins and the virus 
particles are formed automatically and are released into the supernatant. For biosafety 
reasons the vectors for the gene of interest include only an expression cassette and no 
additional genes needed for viral reproduction to ensure that any infected cell cannot 
produce new viral particles. 
The day before transfection 2,4x106 HEK293T (passage ≤ 20) cells were seeded on 
10cm cell culture dishes. The cells were transfected with the calcium-phosphate-
method with a total DNA amount of 20µg (5µg of each plasmid pLP1, pLP2, 
pLP/VSV-G and the lentiviral expression vector). At day 3 the medium was replaced 
by 8ml fresh medium. The target cells were seeded in 10cm dishes in a density that 
reaches 10-50% confluency on the next day. At day 4 the virus particle containing 
supernatant of the HEK293T cells was sterile filtered with a 0,45µm PVDF 
membrane filter. In some instances the medium of the HEK293T cells was replaced 
by fresh medium for a second harvest of viral particles at day 5.Half of the target cell 
medium was replaced by the virus containing supernatant and 8µg/ml polybrene was 
added, which promotes the viral infection.  
After 6-9h of infection the medium of the target cells was replaced. At day 6 
successfully infected cells were selected by addition of the appropriate selection 
marker to the culture medium. 
 
4.9 Three dimensional organotypic skin equivalents 
 
4.9.1 NHEK skin equivalents: 
Keratinocytes and fibroblasts were prepared from sterile human skin samples and 
cultivated under regular cell culture conditions. Organotypic skin equivalents were 
constructed as described previously and cultured over a period of up to 14 days at the 
air liquid interphase (Neis et al., 2010). Skin equivalents were lifted at the air – liquid 
interphase and treated with the different cytokines as indicated in the figure legends. 
The reconstructs were harvested at the days indicated, cut into pieces and either fixed 
according to a standardized protocol for routine histology or embedded in Tissue Tec 
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(O.C.T.) (Sakura Finetek) compound for cryosectioning. Parts of the cultures were 
stored in RNA Later (Roche) for RNA isolation. 
4.9.2 HaCaT pRTS-IL31RA/ HaCaT pSLIK-IL31RA skin equvalents: 
For 3D organotypic cultures, primary dermal fibroblasts were isolated, cultured and 
seeded into collagen gels at a density of 5x105/ml. These dermal equivalents were 
covered with DMEM containing 10% FCS. The following day, HaCaT-IL31RA cells 
(8x105/cm2) were plated onto the fibroblast-collagen matrix. After two days of 
culturing, the skin equivalents were lifted to the air - liquid interphase. The day before 
lifting the models to the air liquid interphase, doxycyclin (1µg/ml) was added to 
cultures to induce IL-31RA expression. Once lifted to the air - liquid interphase, 
interleukins were added as described in the figure legends. Untreated models were 
maintained as negative controls. For the pulse experiments, rhIL-31 (100ng/ml) was 
added to the culture for 2h, 8h and 24h. Models were carefully washed and further 
cultured with medium at the air – liquid interphase. Organotypc skin equivalents were 
prepared by Yvonne Marquard (Dermatology Department, Medical School, RWTH 
Aachen University). 
4.9.3 Haematoxilin-eosin staining of three dimensional skin equivalents: 
4µm thin slices were cut from cryo-conserved parts of three dimensional skin 
equivalents and transferred onto microscope slips. Acidic structures (that are 
concentrated in the nucleus and ER) are stained by 5min incubation of the slides in 
haemalaun with subsequent 10min incubation in water that increases the pH of the 
samples leading to a blue staining. Basic structures (e.g. most cytoplasmic proteins) 
are stained by 3min incubation of the samples in 0,1% eosin in ddH2O. Eosin is 
removed by 2x 3 min washing in water. Water within the samples is removed by 2x 
3min washing in 70% ethanol followed by 2x 3min in 90% ethanol and 2x 3min in 
100% ethanol. Subsequently the slides are 3x 3min washed in Xylol and embedded 
under a cover slip with Vitro Clud® (Langenbrinck). 
4.9.4 Immunostainings of three dimensional skin equivalents: 
4µm thin slices were cut from cryo-conserved parts of three dimensional skin 
equivalents and transferred onto microscope slides. They were fixed for 10min in 4°C 
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aceton, air dried and washed with Ca2+ and Mg2+ free PBS. Afterwards they were  
incubated for 1hr with the appropriate dilution of the primary antibody in antibody 
diluent (Dako). The slides were washed 3 times with PBS and incubated 1 hr with the 
appropriate dilution of the secondary Alexa Fluor 488 labeled antibody in antibody 
diluent (Dako). After three PBS washing steps the slides were incubated 5min with a 
1:5000 dilution of Hoechst 33258 (10mg/ml), washed three times with PBS and 
embedded under a cover slip with fluorescent mounting medium (Dako). 
Immunostainings of organotypic skin equivalents were performed by Yvonne 
Marquard (Dermatology Department, Medical School, RWTH Aachen University).    
 
4.10 Work with proteins  
 
4.10.1 Preparation of cell lysates 
RIPA extracts   
 
RIPA-buffer:     10mM TrisCl, pH 7,4 
       0,15M NaCl 
       1% NP-40  
       0,1% SDS 
        1% Deoxycholate (DOC) 
 
100x ProteoBlock™ Protease:  100mM AEBSF HCl 
Inhibitor Cocktail (Fermentas)  80µM Aproptinin 
       5mM Bestatin 
       1,5mM E64 
       2mM Leupeptin 
       1mM Pepstatin A 
       0,5mM EDTA 
 
Phosphatase inhibitors:   20mM β- Glycerophosphat 
       1mM EGTA 
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       0,1mM Vanadate 
       50mM NaF 
       50mM Okadaic acid 
 
All steps were performed on ice. 250µl (150µl) RIPA-buffer, freshly substituted with 
the protease inhibitor cocktail (1:100) and phosphatase Inhibitors, was added to 6cm 
(6-well) cell culture dishes and incubated for 5min. The lysates were scraped off the 
plates and transferred to a 1,5ml reaction tube. The lysates were sonified in the 
Bioraptor (Diagenode) sonifier for 15min, 30sec cycles, max intensity, 4°C. Un-
dissolvable cell fragments were pelleted by centrifugation (13200rpm, 20min, 4°C) 
The supernatants were transferred to a new tube and stored at -20°C. 
 
4.10.2 Denaturing discontinues polyacrylamide gel electrophoresis (SDS-PAGE) 
2x  sample buffer:   160mM Tris-HCl, pH 6,8 
      20% (v/v) glycerol 
      10% (w/v) SDS 
      0,25% (w/v) BPB 
      100mM β-Mercaptoethanol 
 
Laemmli-buffer pH 6,8:  25mM Tris base 
      250mM glycine 
      0,1% (w/v) methanol 
 
Protein ladder:    Page Ruler™ Prestained Protein Ladder 
      10-180kDa (Fermentas) 
 
 
The denaturing SDS-PAGE separates complex protein mixtures according to the 
molecular size of the proteins. SDS quantitatively binds denatured proteins and leads 
to a large negative net charge that makes the natural protein charge, caused by the 
different amino acids, negligible. This ensures a separation towards the anode only 
influenced by the protein size. Discontinuous gels are composed of a large-pored 
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stacking gel and a small-pored separation gel. The large-pored gel leads to 
accumulation of the proteins at the small-pored border because of a change in pore 
size and the change in the pH of the gel (6,8 in the accumulation gel to 8,8 in the 
separation gel). 
The discontinuous SDS-PAGE was performed according to Laemmli (Laemmli, 
1970). RIPA-lysates were diluted 1:1 with 2x sample buffer, incubated 5 min at 95°C 
to denature the proteins, and loaded on a gel composed of a 5% stacking gel and a 
10/12/15 % separation gel (dependent on the size of the protein of interest). The 
proteins were separated at 200V using a Mini-PROTEAN electrophoresis system 
(BIO-RAD). 
 
4.10.3 Western Blot 
10x Semi-Dry-buffer:   250mM Tris-base 
      1,92M Glycin 
      pH 8,3-8,8 
1x Semi-Dry-buffer:   10% 10x Semi-Dry-buffer 
      20% Methanol 
Wash buffer :   PBS 
      0,05% (v/v) Tween-20 
Blocking buffer:    Wash buffer 
      5% (w/v) dry milk powder 
In a Western Blot proteins in a polyacryamide gel matrix are transferred vertically 
onto a nitrocellulose membrane via electrophoresis.  
In the semi-dry transfer of proteins, the gel is covered by a nitrocellulose membrane 
(Anode site). Gel and membrane are surrounded by Whatman papers soaked in semi-
dry buffer. This “sandwich” is placed in a blotting chamber between electrode plates. 
It is important to ensure that the size of each “sandwich” component is the same to 
ensure an optimal electrical flow through the “sandwich”. It is also important to 
remove every air bubble within the “sandwich”. The proteins are transferred onto the 
membrane by 1,2mA/cm2 of the membrane size for 1-1,5h. After blotting the 
membrane is washed 1-2 times in H2O. 
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4.10.4 Immunodetection of proteins 
PBS-T:     PBS 
      0,05% (v/v) Tween-20 
 
Blocking buffer:    PBS-T 
      5% (w/v) dry milk powder 
0,2% (w/v) Ponceau S in 1% (v/v) acetic acid 
 
ECL-Kit (Pierce) 
 
Femto ECL-Kit (Pierce) 
 
After Western blotting the membrane was stained 5 min in Ponceau S solution and 
washed with H2O to remove the background staining of the membrane to make the 
protein bands visible. This proves proper blotting of the proteins and facilitates the 
cutting of the Western blot in pieces according to the size of the protein of interest. 
Afterwards the membrane was blocked in blocking buffer for 30 min at room 
temperature to saturate all free protein binding sites at the nitrocellulose membrane. 
The membrane was washed twice with PBS-T. The primary antibody targeting the 
protein of interest was diluted in an appropriate amount of PBS-T and incubated with 
the membrane for at least 2h at room temperature or o/n at 4°C. The membrane was 
washed 3 times for at least 10 min in PBS-T to remove unbound primary antibody and 
incubated afterwards with an appropriate dilution of a horse radish peroxidase (HRP) 
coupled secondary antibody in PBS-T for 1-2h at room temperature. The secondary 
antibody is directed against the invariable part of the primary antibody. After washing 
the membranes at least 3 times for 10 min in PBS-T the detection was performed 
using the ECL-Kit or the Femto ECL-Kit according to the manufactures 
recommendations with a computer assisted camera (Las-3000, Fuji). The ECL-Kit 
contains a chemieluminescent substrate for the HRP enzyme. After being processed 
by HRP the substrate emits light which can be detected. 
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4.11 Analysis of gene expression using the Affymetrix GeneChip® 
Human Exon 1.0 ST array  
 
Probe preparation and GeneChip hybridization were performed using the 
GeneChip®Whole Transcript (WT) Sense Target Labelling Assay (Affymetrix) 
according to the manufactures recommendations using a protocol for 2µg total RNA. 
RNA and probe quality was analyzed using the Nanodrop ND-1000 spectrometer 
(Peqlab) and the Agilent 2100 Bioanalyzer (Agilent). Gene ChiP scanning was 
performed using the Affymetrix 428 scanner. Probe preparation was performed by 
Yvonne Marquard (Dermatology Department, Medical School, RWTH Aachen 
University). GeneChip hybridization and scanning were performed in the Chip core 
facility of the IZKF (Interdisziplinäres Zentrum für Klinische Forschung) Aachen. 
GeneChip data analysis was performed by Jens-Malte Baron (Dermatology 
Department, Medical School, RWTH Aachen University). The array for IL-31 
stimulated and the non-stimulated control was performed twice. 
  
4.12 Quantitative reverse transcriptase PCR (qRT-PCR) 
  
4.12.1 Total RNA preparation 
For preparation total RNA the RNeasy Mini Kit (Qiagen) was used according to the 
manufactures recommendations. The cell lysates were homogenized using the 
QIAShredder (Qiagen) columns. Remaining genomic DNA was digested on column 
using the RNase free DNase Set (Qiagen) for 15min at RT. The RNA concentration 
was determined using the Nanodrop 100 UV/VIS Spectrophotometer (Peqlab/Thermo 
Scientific). RNA was stored at -80°C and thawed on ice. 
4.12.2 cDNA synthesis 
Complementary (c)DNA was synthesized using the QuantiTect Reverse Transcription 
Kit (Qiagen) according to the manufactures recommendations. 500ng or 1µg RNA 
was used for cDNA synthesis depending on the total RNA concentration. 2µl genomic 
DNA wipe out buffer was added to 1µg total RNA and filled up to total 12µl reaction 
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volume with RNase free water (PCR grade) and incubated for 2min at 42°C. A 
mixture of 4µl RT-buffer, 1µl random hexamer/oligo-dT primer and 1µl Reverese 
Transcriptase was added and incubated for another 15 min at 42°C. The reaction was 
stopped after 3 min incubation at 96°C. The cDNA was stored at -20°C. 
4.12.3 Real-time PCR 
In the real-time PCR a fluorescent dye is added to the PCR reaction that emits light at 
a certain wavelength after excitation only when it is incorporated into double stranded 
DNA. The total fluorescence of the reaction is measured after every elongation step 
within a PCR cycle. By setting a certain threshold for a positive signal the measured 
Ct-value (cycle threshold) directly correlates with the amount of cDNA in the 
reaction. This allows conclusions about the initial amount of transcript (e.g. mRNA of 
a certain gene) in the samples and gives the opportunity for e.g. comparable gene 
expression analyses. Since PCR is an exponentially growing reaction tight controls 
are needed. The amount of total RNA used in the cDNA synthesis reaction is set to 
the same amount in every sample (500ng or 1µg) and the amount of cDNA used in 
every real-time PCR reaction has to be strictly the same (in this case 2µl of a 1:10 
dilution of a 1µg cDNA synthesis reactions, or a 1:5 dilution for 500ng cDNA 
synthesis reactions respectively, of a 20µl cDNA sample). To normalize for pipetting 
variances the Ct-value of the gene of interest (GOI) is normalized to the Ct-value of a 
so called house-keeping gene. The expression of this gene is not allowed to change 
under the performed treatments within the experiment and thus is the same in every 
sample. Since PCR is an exponential growing reaction the primer performance is 
another important aspect. Before performing a qRT-PCR experiment the primer 
specificity was verified by performing a melt curve and agarose gel electrophoresis to 
ensure the amplification of a single PCR product at the expected size. Finally the 
primer efficiency was determined by performing a standard curve with dilutions of a 
characterized template. 
 
All real-time PCR experiments were performed using the Rotor-Gene 6000 
(Corbett/Qiagen).         
Used PCR Mastermixes:   Universal Mastermix (Diagenode) 
     SensiMixTM Plus SYBR Kit (Quantace) 
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Both mixes use SYBR green as fluorescent dye 
Reaction:   5 µl Mastermix 
   2 µl template cDNA (1:10 or 1:5 diluted in RNase free water) 
    1 µl primer mix of forward and reverse primers:  
    QuantiTect primer assays 1:4 diluted in TE pH 8,0, 
    individually ordered oligonucleotides, 100nM, 1:40 diluted 
    2 µl RNase free water 
 
PCR programs:  
Universal Mastermix: 10 min 95°C 
    40 cycles 10 sec 95°C 
      60 sec 60°C 
      (fluorescence measurement) 
Melt curve: 60°C-95°C in 0,5°C steps, 5sec each step, 
fluorescence measurement after every step 
 
Sensimix:   10 min 95°C 
    40 cycles 15 sec 95°C 
      15 sec 60°C 
      30 sec 72°C 
      (fluorescence measurement) 
    Melt curve: 60°C-95°C in 0,5°C steps, 5 sec each step, 
    fluorescence measurement after every step  
 
4.13 Flow Cytometry 
 
4.13.1 Analysis of the cell cycle 
Propidium iodide (PI) is a fluorescent dye that incorporates into a DNA double strand. 
It has an absorption peak at 488 nm and an emission peak at 562-588 nm. DNA of 
fixed and permeabilized cells can be stained with PI and the emission of light can be 
measured in a FACS (fluorescence activated cell sorting) machine. The emitted light 
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directly correlates with the amount of DNA in the cell. The different cell cycle phases 
(G0/G1, S and G2/M phase) differ in the amount of DNA. From G0/G1 with a single 
set of chromosomes the amount of DNA increases in S phase until in G2/M phase a 
doubled set of chromosomes and thus a doubled fluorescence intensity is present. This 
can be used to analyze the stage in the cell cycle of single cells and allow conclusions 
about the influence of cell treatments on the cell cycle. 
 
Materials:    FACSCanto II (BD) 
     1-3 x 106 cells per sample 
     PBS/EDTA 
     Trypsin/EDTA 
     Culture Medium containing 10% FCS 
     PBS 
     100% Methanol (-20°C) 
     20mg/ml RNase A 
     PI solution (1mg/ml, Roth) 
 
HaCaT cells were washed with PBS/EDTA and detached from the surface by adding 
Trypsin/EDTA. Trypsin was inactivated by adding normal culture medium containing 
10% FCS. The cells were pelleted by centrifugation at 1500 rpm for 3 min and 
washed twice with PBS. The supernatant was aspirated and under continuous 
vortexing 3ml Methanol (-20°C) was added to fix and permeabilize the cells. The 
cells were incubated at -20°C for 20min. After pelleting the cells by centrifugation 
and 3 washing steps with PBS, 200µl 20µg/ml RNase A in PBS was added and 
incubated for 5min at RT. Subsequently 400µl of 1:20 PI solution diluted in PBS was 
added and the cells were incubated in the dark at RT for  at least 30min. The cellular 
fluorescence was analyzed with the FACSCanto II system. Analysis of the data was 
performed with the FLOWJO software (Tree Star). 
4.13.2 Analysis of the presents of cell surface proteins 
Flow cytometry can also be used to detect cellular surface markers. For this purpose 
the cells were fixed in paraformaldehyde to keep the cell surface intact and prevent 
antibody penetration to the inner parts of the cell. Subsequently the cells are incubated 
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with a primary antibody directed against the extracellular domain of cell surface 
markers. A species specific secondary antibody linked to a fluorescent dye stains the 
primary antibody and allows the detection in Flow Cytometry. 
         
Materials:    1x106 cells per sample 
     PBS/EDTA 
     Trypsin/EDTA 
     Culture medium with 10% FCS 
     3,7 % Paraformaldehyde (PFA) in PBS 
     PBS 
     PBS/1 % bovine serum albumin (BSA) 4°C 
     Primary antibody 
     Secondary Alexa Fluor coupled antibody 
 
HaCaT cells were washed with PBS/EDTA and detached from the surface by adding 
Trypsin/EDTA. Trypsin was inactivated by adding normal culture medium containing 
10% FCS. The cells were pelleted by centrifugation at 1500 rpm for 3min and washed 
twice with PBS. Under continuous vortexing 1ml 3,7% PFA was added the cells and 
they were incubated at RT for 20min. The cells were pelleted and washed 3 times 
with PBS/1% BSA and blocked 30min in PBS/1% BSA. The primary antibody was 
diluted in 200µl per sample PBS/1% BSA in the appropriate dilution, added to the 
cells and incubated for 1h at RT. The cells were washed twice with PBS/1% BSA and 
incubated with a 1:2000 dilution of the secondary antibody in PBS/1% BSA for 
20min in the dark. The cells were washed 3 times with PBS/1% BSA, resuspended in 
500µl PBS/1% BSA and analyzed for fluorescence in the FACSCanto II system. 
Analysis of the data was performed with the FLOWJO software (Tree Star). 
4.13.3 Analysis of apoptotic cells 
One of the first changes that occur when cells undergo apoptosis is the translocation 
of Annexin V from the cytosolic side of the plasma membrane to the cell surface. 
Annexin V is a surface marker that can be detected like described in the above 
section. In addition in late apoptosis the plasma membrane disintegrates. PI cannot 
pass an intact plasma membrane but it passes a disintegrated membrane and thus 
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binds to DNA in the nucleus. Apoptotic cells can be analyzed by a double staining of 
the cells with PI and for Annexin V on the cell surface to detect apoptotic cells and 
distinguish between early and late apoptotic cells. Early apoptotic cells are Annexin V 
positive and PI negative while late apoptotic cells are always PI and Annexin V 
positive because anti-Annexin V antibodies also pass a disintegrated membrane and 
bind to Annexin V at the cytosolic side of the plasma membrane.    
 
Materials:    see above 
     Annexin V-eFluor 450 Apoptosis detection kit 
(eBioscience) 
 
The cells were treated as described in the above section. The PFA fixed and PBS/1% 
BSA washed/blocked cells were washed once in 100µl Annexin V binding buffer and 
resuspended in 100µl Annexin V binding buffer. 5µl FITC labeled anti-Annexin V 
antibody was added and incubated 15min at RT in the dark. The cells were washed 
twice in PBS/1% BSA, resuspended in 500µl PBS/1% BSA and 5µl PI solution was 
added. The cellular fluorescence was analyzed with the FACSCanto II system. 
Analysis of the data was performed with the FLOWJO software (Tree Star). 
 
4.14 Immunocytochemistry 
 
Immunocytochemistry is used to fluorescently label cellular proteins for fluorescence 
microscopy or confocal laser microscopy to determine the expression and localization 
of these factors. Surface proteins can be stained by non-permeabilizing fixation of the 
cells. For cytosolic proteins or proteins in other cell compartments the cells can be 
permeabilized additional by adding a detergent. 
 
Materials:    Glass coverslips 
     PBS 
     3,7 % PFA in PBS 
     0,1 % Triton-X100 in PBS 
     PBS/1 % BSA 
     Hoechst 33258 10mg/ml 
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     Mowiol 4-88 
     Primary antibody 
     Secondary AlexaFluor labeled antibody  
 
Cells grown on cover slips were washed twice in PBS, fixed for 20min with 3,7% 
PFA and permeabilized for another 15min with 0,1% Triton-X100 as needed. 
Blocking of unspecific binding sites was achieved by washing and incubation of the 
cells with PBS/1% BSA. The primary antibody was diluted in PBS/1% BSA and 
incubated for 60min at RT. The cover slips were washed twice with PBS/1% BSA 
and incubated with a 1:2000 dilution of the secondary antibody in PBS/1% BSA for 
another 30-60min at RT in the dark. The cells were washed twice with PBS/1%BSA, 
once with PBS and incubated for 5min at RT with a 1:5000 dilution of Hoechst stain 
in ddH2O. After additional two washing with ddH2O the cover slips were embedded 
in Mowiol 4-88 and left at 4°C over night in the dark. The next day stained cells were 
evaluated by fluorescence microscopy on an Olympus IX50 microskope or by 
confocal laser microscopy on a Zeiss Axiovert LSM510. The images were processed 
with the ImageJ programm (National Institute of Health, USA). 
 
4.15 Proliferation assay 
 
To determine the proliferation rate of cells, 60000 cells were seeded in 6 well plates in 
triplicates and treated as indicated in the figure legends. For a period of 4 days, every 
day one triplicate sample was washed in PBS/EDTA and detached from the surface 
by adding exactly 400µl Trypsin/EDTA. To inactivate trypsin 600µl normal growth 
medium substituted with 10% FCS was added. The total cell number was determined 
in the Casy Cell counting system (Innovatis). 
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6 Appendix 
6.1 Abbreviations 
 
°C  degree Celsius 
µ  micro 
3D  three dimensional 
A  ampere 
A. dest  destilled water 
aa  amino acid 
AAM  alternatively activated macrophage 
Ab  antibody 
ACD  allergic contact dermatitis 
AD  atopic dermatitis 
ADA  adenosine deaminase 
AE  atopic eczema  
AKT  v-akt murine thymoma viral oncogene homolog 1 
Amp  ampicillin 
AP-1  activator protein 1 
Arf  p16, cyclin- dependent kinase inhibitor 2A 
ASK-1  apoptosis signal-regulating-kinase 1 
ATCC  American Type Culture Collection 
Bak  Bcl2-antagonist/killer 
Bcl  B-cell CCL/lymphoma2 
BFU-E  burst-forming unit erythroid 
bio  biotin 
bla  β-lactamase 
bp  base pair 
BSA  bovine serum albumin 
C/EBP  CCAAT enhancer binding protein 
ca.  circa 
CBD  cytokine binding domain 
CCL  CC chemokine receptor ligand 
CD  cluster of differentiation 
CD  Crohn´s disease 
Cdc2  CDK1, cyclin-dependent kinase 1 
CDK   cyclin dependent kinase 
CDK  cyclin-dependent kinase  
cDNA  copy DNA 
CE  cornified envelope 
CFU-GEEM colony-forming unit erythroid, granulocyte, macrophage, and megakaryocyte 
CFU-GM colony-forming unit granulocyte and macrophage 
CLA  cutaneous lymphocyte antigen 
CLC  cardiotrophin-like cytokine 
CLSP  calmodulin like skin protein 
CNTF  ciliary neurotrophic factor 
CRE  cAMP responsive elements 
CT  cardiotrophin 
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Ct  cycle threshold# 
CU  spontaneous urticarial 
CXCL  CXC chemokine receptor ligand 
Da  Dalton 
DC  dendritic cell  
Dex  dexamethasone 
DLK  dual leucine zipper-bearing kinase 
Dlx3  distal-less homeobox 3 
DMSO  dimethyl sulfoxide 
DNA  desoxyribo-nucleotide-acid 
dNTPs  desoxynucleotide-tri-phosphate 
dox  doxycycline 
DRR  distal regulatory region 
DTT  dithiothreitol 
DUSP  dual specific phosphatase 
E.coli  Escherichia coli 
EBI3  Epstein-Barr virus induced 3 
ECL  enhanced chemoluminescence 
EDC  epidermal differentiation cluster 
EDTA  Ethylenediaminetetraacetic acid 
EGF  epithelial growth factor   
EGR1  early growth response 1 
ErbB2  v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 
ERK  extracellular signal-regulated kinase 
EST  expressed sequence tag 
ET  essential thrombocythemia 
et.al.  et alii 
FACS  fluorescence activated cell sorting 
FAIM3  fas apoptotic inhibitory molecule 3 
FASN  fatty acid synthase 
FCS  fetal calf serum 
FL  fms-like tyrosine kinase ligand 
FLG  filaggrin 
FN III  fibronectin type III 
FOS  FBJ osteosarcoma oncogene 
FRA-1  FOS-like antigen 1 
g  gramm 
GADD45β growth arrest and DNA-damage-inducible, beta 
GCSF  granulocyte colony-stimulating factor 
GFP  green fluorescence protein 
GLMR  gp130-like monocyte receptor 
GM-CSF granulocyte macrophage colony-stimulating factor 
gp130  glycoprotein 130 
GPL  gp130-like receptor 
Grb2  growth factor receptor-bound protein 2 
GRO1  CXCL1, CXC chemokine ligand 1 
GTP  guanosinetriphosphate 
HA  haemaglutinin 
hBD  human β-defensins 
HBE  human bronchial epithelial (cell line) 
HE  haematoxylin-eosin 
HEK  human embryonic kidney 
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HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HGF  hepatocyte growth factor 
HPC  hematopoietic progenitor cell 
HPRT  hypoxanthine guanine phosphoribosyl transferase 
hr(s)  hour(s) 
HRP  horse radish peroxidase    
hyg  hygromycine 
i.e.  that is 
IBD  inflammatory bowel disease 
ICAM  intercellular adhesion molecule 
IF   immunofluorescence 
IFN  interferon 
Ig  immune globulin 
IGF  insulin like growth factor 
IL  Interleukin 
IL-31RA IL-31 receptor alpha 
Ink4a  p16, cyclin-dependent kinase inhibitor 2A 
INV  Involucrin 
IRES  internal ribosomal entry site 
IRF  interferon regulatory factor 
ITGB4  β4-integrin 
JAK  janus tyrosine kinase 
JNK  Jun N-terminal kinase 
JUN  c-JUN, jun proto-oncogene 
JUNB  Jun-B oncogene 
K  keratin 
k  kilo 
KGF  keratinocyte growth factor 
Ki67  antigen identified by monoclonal antibody Ki 67 
KO  knock out 
l  liter 
LB  luria broth 
LCE  late cornified envelope 
LDH  lactate dehydrogenáse  
LFA-1  ITGB2, integrin β2 
LIF  leukemia inhibitory factor 
LIFR  leukemia inhibitory factor receptor 
LPS  lipopolysaccharide 
LTR  long terminal repeat 
m  milli 
M  molar (Mol/l) 
MAPK  mitogen activated protein kinase 
MAPKAPK2 mitogenic activated protein kinase activated kinase 2 
max  maximum 
MB  mega bases 
MC  mast cell 
MCS  multiple cloning site 
MDA7  melanoma differentiation associated gene 7 
MDC  CCL22, CC chemokine ligand 22 
MDM2  Mdm2 p53 binding protein homolog (mouse) 
MEK  MAP2K, mitogen-activated protein kinase kinase 
MIF  macrophage migration inhibitory factor 
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min  minimum 
min  minutes 
MIP  major intrinsic protein of lens fiber 
MMP  matrix metallo- proteases 
MPN  myeloproliferative neoplasms 
mRNA  messenger RNA 
MSP  macrophage-stimulating protein 
mTICs  mouse tumor-initiating cells 
n  nano 
NCID  notch intracellular domain 
Neo  neomycin 
NFκ-B  nuclear factor kappa B 
NHEK  normal human epidermal keratinocyte 
NOD  ATN1, atrophin1 
NOD2  nucleotide binding oligomerization domain 
NP-40  Nonidet P-40 
ORF  open reading frame 
OSM  oncostatin M 
OSMR  oncostatin M receptor 
OVA  ovalbumin 
PAGE  polyacrylamide gel electrophoresis 
PBMC  peripheral blood mononuclear cell 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PEG  poly-ethylene glycol 
Ph-MPN  chromosome-negative myeloproliferative neoplasms 
PI3-K  Phosphoinositide-3-kinase 
PIGR  polymeric immunoglobulin receptor 
PKB/C  protein kinase B/C 
PKC  protein kinase C 
PLT  platelets 
PMF  primary myelofibrosis 
PRR  proximal regulator region 
PV  polycythemia vera 
RAS  rat sarcoma viral oncogene 
RBC  red blood cell 
RBP-Jk  recombination signal binding protein for Igκ J region 
Reg1  regenerating islet-derived 1 
rh  recombinant human 
RNA  ribonucleic acid 
ROS  reactive oxygen species 
rpm  rounds per minute 
RT-qPCR quantitative reverse transcriptase polymerase chain reaction 
SB  stratum basale 
SC  stem cells 
SC  stratum corneum 
Scarf  Calm4, calmodulin 4 
SCF  stem cell factor 
SDF  CXCR4, CXC chemokine receptor 4 
SDS  sodium dodecyl sulfate 
SEB  superantigen staphylococcal enterotoxin B 
SEMF  Human colonic subepithelial myofibroblast 
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SG  stratum granulosum 
Shc  Src homology 2 domain containing transforming protein 
SHP-2  PTPN11, protein tyrosine phosphatase, non-receptor type 11 
shRNA  small hairpin RNA 
SIN  self-inactivating 
SMAD  mothers against decapentaplegic homolog or SMAD family member 
SNP  single nucleotide polymorphisms 
SOCS  suppressor of cytokine signaling 
SOS  son of sevenless 
SP-1  specificity protein 1 
SPF  specific pathogen free 
SPR  small proline rich 
SS  stratum spinosum 
STAT  signal transducers and activators of transcription 
TAC  transient amplifying cells 
TARC  CCL17, CC chemokine ligand 17 
TE  Tris-EDTA 
TG  transglutaminase 
TGF  transforming growth factor 
TIMP-1  TIMP metallopeptidase inhibitor 1 
TLR  toll like receptor 
TNCB  2,4,6-trinitrochlorbenzene 
TNF  tumor necrosis factor 
TRE  tetracycline responsive element 
Tyr, Y  tyrosine 
U  unit 
Ubi-C  ubiquitin C 
UC  ulcerative colitis 
UV  ultra violet light 
v/v  volume per volume 
VEGF  vascular epithelial growth factor 
w/v  weight per volume 
WB  western blot 
WRE  woodchuck regulatory element 
WSX-1  IL27RA, IL-27 receptor alpha 
WT  wild type 
x  times/-fold 
β-ME  β-mercaptoethanol 
λ  wavelength of light 
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